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The transcriptional coactivator peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) 
is a potent inducer of mitochondrial biogenesis and oxidative metabolism. Highest expression levels of 
PGC-1α are found in tissues with high energy demands like brain, skeletal muscle, heart, brown 
adipose tissue and kidney. In these tissues, PGC-1α can be induced by metabolic stress, like cold in 
brown fat, exercise in skeletal muscle or fasting in liver. Once activated, PGC-1α regulates the activity 
of transcription factors and is thus capable of inducing entire biological programs like mitochondrial 
biogenesis, fatty acid oxidation, angiogenesis or gluconeogenesis. PGC-1α does not possess an 
intrinsic histone acetylase activity (HAT), but instead binds proteins with HAT activity and recruits 
them to the site of transcription. Similarly, PGC-1α binds the mediator and to the SWI/SNF complexes 
and thereby serves as a platform to connect the transcription factors with transcription initiation 
complex, chromatin remodelling complex and proteins with HAT activity. Therefore, PGC-1α senses 
extracellular stimuli and metabolic stress and connects these events with gene transcription. In skeletal 
muscle, basically all pathways triggered by exercise at some point converge at PGC-1α and change the 
expression of Ppargc1a transcripts or stabilize the PGC-1α protein through posttranslational 
modifications. When expressed in skeletal muscle, PGC-1α induces mitochondrial biogenesis, glucose 
uptake, promotes angiogenesis, protects skeletal muscle from atrophy and leads to a muscle fibre type 
switch towards more oxidative fibres. Thus, PGC-1α acts as a master regulator of exercise-induced 
adaptations in skeletal muscle.  
Some key transcription factors mediating these PGC-1α induced changes like ERRα, NRF-1 and 
MEF2C have been identified. However, a profound knowledge about the transcriptional network of 
transcription factors and other proteins mediating PGC-1α gene regulation is still missing. To reveal 
this transcriptional network and to be able to draw general conclusions about the role of PGC-1α as a 
coactivator, we have investigated the activity of PGC-1α on genome-wide scale. By combining ChIP-
Seq studies with expression arrays, we have identified all interactions of PGC-1α with the genome in 
cultured skeletal muscle cells and gained knowledge about how PGC-1α regulates gene expression. 
PGC-1α induced expression of genes involved in oxidative metabolism and suppressed the expression 
of inflammatory response genes. Surprisingly, the induction of gene expression by PGC-1α was not 
only directly by binding to transcription factors in promoters, but also indirectly, without the need for 
PGC-1α to be present at the promoters of some induced genes.  Inversely, the suppression of 
inflammatory genes was almost exclusively indirect because it did not require the recruitment of PGC-
1α to the promoters of suppressed genes, indicating that PGC-1α does not act as a corepressor in 
skeletal muscle cells. We identified ERRα as a major mediator of PGC-1α induced gene expression. 
By performing ChIP-sequencing of ERRα, we have found that ERRα can be transcriptionally active 
and regulate gene expression with and without PGC-1α. In addition to ERRα, we predict several other 
transcription factors to cooperate with PGC-1α and directly regulate gene expression. By knocking 
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down some of these transcription factors, we validated our predictions and showed that these 
transcription factors are involved in the transcription of a subset of PGC-1α target genes. These results 
suggest that PGC-1α coactivates the transcription factor complex AP-1 to regulate the expression of 
genes involved in the response to hypoxia. Last, even though the inhibition of phosphodiesterases 
PDE1 and PDE4 led to induction of Ppargc1a expression in cultured skeletal muscle cells, this effect 
could not be shown in vivo. Because the activation of β2-AR signaling strongly induced Ppargc1a 
expression in skeletal muscle in vivo, the involvement of cAMP in the regulation of Ppargc1a 
expression is very likely. Therefore the involvement of other cAMP-specific PDEs in this regulation 
cannot be excluded.  
In conclusion, in this thesis, we describe how the transcriptional coactivator PGC-1α controls gene 
expression in cultured skeletal muscle cells on a genome-wide scale. We identified and validated some 
key transcription factors as members of the PGC-1α transcriptional network. The large amount of data 




1 GENERAL INTRODUCTION 
1.1 PGC-1α, a powerful transcriptional coactivator 
The Ppargc1a gene is located on chromosome 5 in the mouse genome and encodes a protein consisting 
of 797 amino acids (797 in mouse, 798 in humans) termed peroxisome proliferator-activated receptor γ 
coactivator 1α or briefly PGC-1α. Together with PGC-1β and the PGC-related coactivator (PRC) it 
forms the PGC-1 family of coactivators. 
PGC-1α is a powerful transcriptional coactivator, capable to bind and coactivate numerous 
transcription factors including most members of the nuclear receptor superfamily of transcription 
factors (Puigserver and Spiegelman, 2003; Puigserver et al., 1998). Binding to the latter class of 
transcription factors is at least in part accomplished through the LLXXL and LXXLL motifs which are 
found close to the N terminus of the PGC-1α protein (Knutti et al., 2000; Puigserver et al., 1998). This 
motif is also found in other members of the PGC-1 family of coactivators as well as in other 
coregulators and was shown to serve for the interaction with nuclear receptors (Heery et al., 1997). 
The N terminus of PGC-1α itself is represented by an activation domain which interacts with proteins 
like cAMP response element binding protein-binding protein (CBP), p300 and the steroid receptor 
coactivator-1 (SRC-1) (Puigserver et al., 1999). Thus, although PGC-1α itself is not capable of 
acetylating histones, it binds to proteins with histone acetyltransferase (HAT) activity and brings them 
in the proximity of transcription factors and to the site of transcription. By modifying histones, these 
proteins make the chromatin accessible for the transcription factors and the transcription machinery. 
The C-terminal region of PGC-1α binds to the thyroid hormone receptor-associated protein/vitamin D 
receptor interacting protein (TRAP/DRIP) or simply mediator complex, allowing the interaction with 
the RNA polymerase and the transcription initiation machinery (Wallberg et al., 2003). The 
SWitch/Sucrose NonFermentable (SWI/SNF) chromatin remodelling complex was demonstrated to 
bind to PGC-1α through BAF60a, thus further increasing the PGC-1α coactivating capacity (Li et al., 
2008b). Furthermore, in the C-terminal region of the PGC-1α protein, there are a serine- and arginine-
rich domain and an RNA binding motif, linking PGC-1α to mRNA processing (Monsalve et al., 2000). 
Based on these findings, PGC-1α can be considered as a docking platform for proteins regulating gene 
transcription. PGC-1α binds to transcription factors and brings them together with the transcription 
initiation complex, proteins with HAT activity, chromatin remodelling complex and the proteins 
involved in mRNA processing.  
Initially, PGC-1α was discovered as a coactivator of PPAR-γ in brown adipose tissue and therefore 
was termed PPAR-γ coactivator-1α (PGC-1α) (Puigserver et al., 1998). This and later studies revealed 
that PGC-1α coactivates other transcription factors as well and that it is not only present in brown fat, 
but in many tissues with high energy demands like skeletal muscle, heart, brown adipose tissue, 
kidney and brain (Lin et al., 2005; Puigserver et al., 1998). Generally, PGC-1α is a strong inducer of 
mitochondrial biogenesis and regulates many genes involved in energy metabolism (Lehman et al., 
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2000; Lin et al., 2005; Mootha et al., 2004; Puigserver et al., 1998). In some of these tissues, the 
expression of PGC-1α can be induced by external stimuli. In liver, PGC-1α is strongly induced by 
fasting and boosts the expression of genes involved in hepatic gluconeogenesis and fatty acid 
oxidation (Herzig et al., 2001; Yoon et al., 2001). In brown adipose tissue, PGC-1α is induced by cold 
and regulates cold-induced thermogenesis by inducing biogenesis of mitochondria, increasing fatty 
acid oxidation and uncoupling of oxidative phosphorylation (Puigserver et al., 1998). PGC-1α mRNA 
is also found in skeletal muscle, especially in slow twitch muscle fibres, and its expression in this 
tissue can be induced by exercise training (Baar et al., 2002; Pilegaard et al., 2003; Russell et al., 
2003).  
To explore the function of PGC-1α in vivo, transgenic mice overexpressing PGC-1α as well as PGC-
1α knockout mice have been generated and the role of PGC-1α in different tissues was studied (Leone 
et al., 2005; Lin et al., 2002; Lin et al., 2004). Mice lacking PGC-1α are viable, but a half of the pups 
die in the early postnatal period (Lin et al., 2004). These mice cannot maintain their body temperature 
when exposed to cold, show only a slight hypoglycaemia when fasted, have brain lesions and are 
hyperactive. Surprisingly, the PGC-1α-/- mice are lean and resistant to diet induced obesity (Lin et al., 
2004). In another study however, PGC-1α-/- mice show an increased body fat with age (Leone et al., 
2005). In contrast, transgenic PGC-1α expression in skeletal muscle induces mitochondrial biogenesis 
and drives a fibre type conversion in fast twitch muscle fibres towards a more oxidative, slow twitch 
phenotype (Lin et al., 2002). The muscles of these mice are redder in color, rich in mitochondria and 
resistant to contraction induced fatigue (Lin et al., 2002). 
 
1.2 Upstream of PGC-1α - the regulation of PGC-1α expression and activity 
1.2.1 Regulation of expression, protein stability and activity 
Every living cell has to manage its energy needs, more precisely the cell needs to sense the current 
nutritional status and subsequently run biological programs which will allow the cell to keep a balance 
between energy intake, storage and expenditure. PGC-1α is thought to be such a metabolic sensor. The 
image of a coactivator which is constitutively expressed and passively recruited by transcription 
factors is wrong in the case of PGC-1α. The coactivator itself senses environmental changes and is an 
inducible regulator of energy metabolism. The expression and the activity of PGC-1α are regulated by 
external stimuli or nutritional status. 
 
Liver 
In liver, fasting strongly induces PGC-1α mRNA expression (Herzig et al., 2001; Yoon et al., 2001). 
The liver plays an important role in maintaining plasma glucose levels in fasting animals. It does so by 
breaking down glycogen (glycogenolysis) and by generating glucose from precursors 
(gluconeogenesis). In this way, the liver can replenish the glucose which was removed from the blood 
by the peripheral tissue. PGC-1α is central in regulating the hepatic fasting response (Handschin et al., 
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2005; Herzig et al., 2001; Rhee et al., 2006; Yoon et al., 2001). The increased expression of PGC-1α 
mRNA following fasting is initiated by elevated blood glucagon levels and subsequently regulated by 
elevated cAMP levels (Herzig et al., 2001). This induction involves the binding of the cAMP response 
element binding protein (CREB) to the promoter of the Ppargc1a gene (Herzig et al., 2001). In this 
context, it was also shown that the activation of the p38 mitogen-activated protein kinase (MAPK) 
leads to a phosphorylation of PGC-1α and increases fasting induced PGC-1α expression (Figure 1) 
(Cao et al., 2005). In addition to hormonal regulation, the expression of the gluconeogenic gene 
program can be induced by free fatty acids. p38 and CREB are upstream of PGC-1α and regulate its 
expression which is important for the free fatty acid-induced gluconeogenesis in hepatocytes (Collins 
et al., 2006).  
 
 
Figure 1. Posttranslational modifications of PGC-1α. Figure adapted from (Fernandez-Marcos and 
Auwerx, 2011). 
 
In contrast to glucagon signalling, insulin triggers phosphorylation of PGC-1α by the protein kinase 
Akt2/protein kinase B (PKB)-β in the liver (Figure 1) (Li et al., 2007). This phosphorylation inhibits 
PGC-1α and thus attenuates the PGC-1α regulated gluconeogenesis and fatty acid oxidation in the 
liver (Li et al., 2007). Furthermore, another protein kinase Cdc2-like kinase 2 (Clk2) is regulated 
through the insulin/Akt pathway and phosphorylates PGC-1α to inhibit its cotranscriptional activity 
(Figure 1) (Rodgers et al., 2010). In addition to PGC-1α phosphorylation by Akt, this represents 
another mechanism by which insulin represses hepatic gluconeogenesis and glucose output through 
posttranslational modification of PGC-1α (Rodgers et al., 2010).  
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Acetylation represents yet another way to repress PGC-1α cotranscriptional activity in liver. The 
acetylation of PGC-1α by the acetyltransferase GCN5 leads to a translocation of PGC-1α to nuclear 
foci and prevents PGC-1α regulated expression of gluconeogenic genes and secretion of glucose 
(Figure 1) (Lerin et al., 2006). In contrast, the NAD+-dependent deacetylase SIRT1 deacetylates PGC-
1α in response to fasting to control the gluconeogenic genes and thus represents a way to control PGC-
1α activity by nutrient availability (Rodgers et al., 2005). Interestingly, SIRT1 is the mammalian 
homologue of Sir2 from Saccharomyces cerevisiae and Caenorhabditis elegans, which extends the 
lifespan in these organisms upon caloric restriction (Kaeberlein et al., 1999; Tissenbaum and 
Guarente, 2001). It is thus tempting to speculate that this link between metabolism and longevity 
might be functional in humans and extend the human lifespan as a result of caloric restriction. 
Besides, the PGC-1α protein can be bound and modified by the O-lnked β-N-acetylglucosamine (O-
GlcNAc) transerase (OGT) (Figure 1). This GlcNAcylation and interaction result in the targeting of 
OGT to FoxO1 to regulate its activity (Housley et al., 2009). 
 
Brown fat 
PGC-1α was discovered in brown fat and the brown fat was the first tissue in which the regulation of 
PGC-1α in response to environmental triggers was demonstrated. Cold-induced PGC-1α stimulates the 
expression of the uncoupling protein-1 (UCP1) in order to regulate thermogenesis by uncoupling the 
oxidative metabolism from ATP production, leading to dissipation of the proton gradient and thus heat 
generation (Puigserver et al., 1998). The expression of PGC-1α in brown fat is induced by cAMP, 
which is produced following cold exposure. Similarly, treating brown fat cells with β-adrenergic 
receptor agonists and thus mimicking cold exposure also leads to increased expression of PGC-1α 
mRNA (Puigserver et al., 1998). Similar to the regulation in the liver, p38 MAPK is involved in the 
regulation of PGC-1α expression and activity in the brown fat as well. P38 MAPK phosphorylates 
PGC-1α together with activating transcription factor-2 (ATF-2) to drive the expression of UCP1 
(Figure 1). ATF-2 on the other hand induces the expression of PGC-1α. Thus in brown fat, p38 MAPK 
regulates PGC-1α by both phosphorylation and induction of mRNA expression (Cao et al., 2004). 
Besides, nitric oxide (NO) signalling induces mitochondrial biogenesis in brown adipose tissue by 
increasing expression of PGC-1α mRNA (Nisoli et al., 2003). Moreover, the mitochondrial biogenesis 
induced by cold in this tissue requires at least to some extent NO signalling, because the observed 
mitochondrial biogenesis is reduced when in absence of the endothelial nitric oxide synthase (eNOS) 
(Nisoli et al., 2003). 
The transcriptional activity of PGC-1α is at least in part attenuated by direct interaction with the 
corepressor receptor-interacting protein 140 (RIP140) (Hallberg et al., 2008). RIP140 is a coregulator 
involved in energy homeostasis and interestingly, it represses the expression of genes which are 
typically induced by PGC-1α (Fritah et al., 2010). Whether this inhibition also affect all tissues in 





Based on these observations that cold and fasting regulate PGC-1α in the brown fat and liver 
respectively, it becomes evident that PGC-1α is regulated by stress situations in metabolically active 
tissues. This is also true for the skeletal muscle because in this tissue, exercise training represents a 
stress situation. A working muscle uses up its energy stores and increases its needs for blood and 
oxygen supply to burn fuels. Accordingly, exercise training induces PGC-1α expression in skeletal 
muscle of rodents and humans (Baar et al., 2002; Pilegaard et al., 2003; Russell et al., 2003). This 
induction is transient but regular activity like in endurance exercise training results in higher basal 
PGC-1α transcription and a switch towards more oxidative muscle fibres (Pilegaard et al., 2003; 
Russell et al., 2003). In contrast, physical inactivity leads to lower PGC-1α expression and renders the 
muscle prone to atrophy (Sandri et al., 2006). Besides that fact, it is astonishing that nearly all 
signalling events which usually happen in an exercising muscle, at some step lead to modification of 
PGC-1α transcription or activity. Intracellular calcium levels are increased during exercise and 
important calcium effector proteins like the calcium /calmodulin-dependent protein kinase IV 
(CaMKIV) and calcineurin A (CnA) are upstream of PGC-1α and regulate its expression (Handschin 
et al., 2003; Olson and Williams, 2000). Analogous to the regulation in liver and brown fat, the PGC-
1α regulation by CaMKIV and CnA in skeletal muscle involves cAMP signalling because CREB binds 
to the promoter of PGC-1α and regulates its transcription (Handschin et al., 2003). Furthermore, the 
members of the myocyte enhancer factor family of transcription factors (MEFs) bind to the PGC-1α 
promoter and are coactivated by PGC1α itself to regulate the expression at the PGC-1α promoter. This 
creates a positive autoregulatory loop and further increases PGC-1α expression (Handschin et al., 
2003). Moreover, the activation of β2-adrenergic receptor (β2-AR) signalling triggers PGC-1α 
expression in skeletal muscle, again confirming the involvement of cAMP signalling in the regulation 
of PGC-1α expression (Miura et al., 2007). In muscle cell nuclei which are in the proximity of a 
neuromuscular junction (NMJ), PGC-1α is regulated through neuregulin boosted phosphorylation of 
PGC-1α and subsequent coactivation of the GA – binding protein (GABP) to control the expression of 
NMJ genes (Handschin et al., 2007).  
The AMP activated protein kinase (AMPK) is an important intracellular metabolic sensor and 
becomes active after sensing the demand for ATP in a working muscle (Hardie and Hawley, 2001). 
Activated AMPK subsequently phosphorylates PGC-1α to activate the protein as well as increasing 
gene expression (Figure 1) (Jager et al., 2007). In addition to changing the AMP/ATP ratio, the 
increased energy demand in contracting muscle fibres also changes the ratio of the oxidized and 
reduced form of nicotinamide adenine dinucleotide (NAD+ / NADH). This ratio determines the 
activity of SIRT1, so that SIRT1 becomes active in an exercising muscle and deacetylates PGC-1α at 
several residues along the entire length of the PGC-1α protein (Figure 1) (Gerhart-Hines et al., 2007; 
Houtkooper et al., 2010). The deacetylation by SIRT1 increases the PGC-1α activity whereas the 
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acetylation of PGC-1α by GCN5 has the opposite effect and reduces the expression of PGC-1α target 
genes (Gerhart-Hines et al., 2007). Because NAD+ is a substrate for SIRT1 and active AMPK 
increases intracellular NAD+ levels, this AMP activity enhances the deacetylase activity of SIRT1 
(Canto et al., 2009). Thus AMPK not only regulates PGC-1α by direct phosphorylation and induction 
of expression, but also through stimulation of deacetylation of PGC-1α by SIRT1. Moreover, the 
phosphorylation of PGC-1α by AMPK appears to be required for the subsequent deacetylation by 
SIRT1 (Figure 2) (Canto et al., 2009). It is possible that this phosphorylation induces conformational 
changes of PGC-1α protein which allow deacetylation by SIRT1. These observations reveal a 
coordinated regulation of PGC-1α activity by the two upstream enzymes SIRT1 and AMPK. 
 
 
Figure 2. Schematic illustration of coordinated actions of AMPK and SIRT1 on PGC-1α. Figure 
adapted from (Canto et al., 2009). 
 
An exercising muscle experiences a mechanical contraction stress which is sensed by the stress kinase 
p38 mitogen-activated protein kinase (MAPK) and results in the phosphorylation and stabilization of 
the PGC-1α protein which normally is susceptible to degradation (Puigserver et al., 2001). This 
stabilization of PGC-1α protein in exercising muscle appears to happen before the mRNA of PGC-1α 
is expressed, thus offering a fast way to provide the cell with active PGC-1α protein in the initial phase 
(Wright et al., 2007). However, the stabilization of the protein alone does not account for the observed 
increase in coregulatory activity. PGC-1α phosphorylation by p38 MAPK leads to the detachment of 
p160 myb binding protein (p160MBP), a repressor which binds to the negative regulatory domain of 
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PGC-1α and represses its activity (Fan et al., 2004). This release of p160MBP further contributes to 
regulation of PGC-1α activity by p38 MAPK. 
Another stress which is encountered in metabolically active tissues like the working skeletal muscle is 
the generation of reactive oxygen species (ROS) in active mitochondria which also has been shown to 
induce the expression of PGC-1α (St-Pierre et al., 2006). 
In addition to an increased demand for nutrients, an exercising muscle increases its needs for oxygen, 
which are caused by the high metabolic activity and increased compression of the muscle during 
exercise, so that the muscle faces a transient hypoxia (Wagner, 2011). This hypoxic condition induces 
the expression of PGC-1α (Arany et al., 2008).  
Similar to the regulation of PGC-1α by insulin and Akt/PKB signalling in liver, insulin represses 
expression of PGC-1α in skeletal muscles of healthy individuals but not of patients with type 2 
diabetes (Southgate et al., 2005).  
Last, the PGC-1α protein is phosphorylated by the glycogen synthase kinase 3β (GSK3β) and targeted 
to proteasomal degradation (Anderson et al., 2008). The physiological purpose of this regulation is not 
fully understood, but it is possible that this degradation of PGC-1α would limit the activation of PGC-
1α by SIRT1 during oxidative stress (Fernandez-Marcos and Auwerx, 2011). 
These observations together reveal that nearly all signalling pathways triggered by exercising muscle 
at some point converge on PGC-1α, and therefore suggest a role for PGC-1α in skeletal muscle as a 
sensor of changes induced by exercise in this tissue. 
 
1.2.2 PGC-1α regulation in other tissues and by other mechanisms 
Cardiac PGC-1α is strongly induced directly after birth after short term fasting (Lehman et al., 2000). 
This is when the neonatal heart changes the generation of its energy by shifting from glycolysis to 
fatty acid oxidation in mitochondria (Lehman et al., 2000). Thus, PGC-1α serves as a regulator of 
mitochondrial biogenesis and a molecular switch for the change in fuel usage in the heart. 
The highest level of PGC-1α expression in rodent brain is reached two weeks after birth in different 
brain regions, especially in γ-aminobutyric acid (GABA)-positive neurons in the cortex, hippocampus 
and cerebellum (Cowell et al., 2007; Handschin, 2009). Because oxidative stress and mitochondrial 
dysfunction are associated with neurodegeneration, PGC-1α has been linked to disorders like 
Huntington, Parkinson or Alzheimer (Handschin, 2009). Indeed, the expression of PGC-1α appears to 
be reduced in brains of Alzheimer disease patients (Qin et al., 2009). PGC-1α also plays a role in the 
development of Parkinson disease. A transcriptional repressor termed parkin interacting substrate 
(PARIS) binds to the promoter of PGC-1α and inhibits its expression (Shin et al., 2011). It is 
suggested that in Parkinson disease, the reduction of parkin levels leads to higher availability of 
PARIS and thus suppression of PGC-1α expression and as a consequence reduced expression of PGC-
1α target genes (Shin et al., 2011). 
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In mouse melanocytes, PGC-1α expression is regulated by ultraviolet (UV) light radiation (Shoag et 
al., 2013). When the skin cells experience damage by UV radiation, the keratinocytes start producing 
and releasing a peptide termed α-melanocyte stimulating hormone (α-MSH) and this hormone leads to 
induction of PGC-1α expression in melanocytes (Shoag et al., 2013). Nitric oxide (NO) modulates the 
expression of PGC-1α in endothelial cells (Borniquel et al., 2006). Short-term exposure to NO 
supresses PGC-1α expression, whereas long-term NO exposure up-regulates PGC-1α mRNA 
(Borniquel et al., 2006). 
In addition to the previously mentioned posttranslational modifications, the PGC-1α protein is also 
subject to ubiquitinylation, methylation and SUMOylation (Olson et al., 2008; Rytinki and Palvimo, 
2009; Teyssier et al., 2005). The ubiquitinylation of PGC-1α is performed by a member of the 
Skp1/Cullin/F-box (SCF) class of E3 ubiquitin ligases termed SCFCdc4 (Olson et al., 2008). Cdc4 
stands for cell division control protein 4 and represents the F-box component of the SCFCdc4 complex. 
The ubiquitinylation targets PGC-1α for degradation and phosphorylation of PGC-1α by p38 and 
GSK3β might promote ubiquitinylation by SCFCdc4 (Olson et al., 2008). Another E3 ubiquitin ligase 
known to modify PGC-1α and promote its degradation in brown adipose tissue is Ring-finger-
containing protein 34 (RNF34) (Wei et al., 2012). Cold exposure however supresses RNF34 
expression in brown fat, thereby allowing PGC-1α induction (Wei et al., 2012). Protein arginine 
methyltransferase 1 (PRMT1) methylates PGC-1α at three arginine residues and this modification is 
thought to promote the coactivator activity of PGC-1α (Teyssier et al., 2005). 
PGC-1α can be SUMOylated at the lysine residue 183 and this is the same residue that can be 
acetylated by GCN5 (Rodgers et al., 2005; Rytinki and Palvimo, 2009). SUMOylation supresses the 
coactivator activity of PGC-1α and can be reversed by Sentrin/SUMO-specific protease 1 (SENP1) to 
promote PGC-1α activity and regulate mitochondrial biogenesis (Cai et al., 2012; Rytinki and 
Palvimo, 2009). Interestingly, SUMOylation does not attenuate PGC-1α by changing the stability of 
the protein, but promotes the interaction of PGC-1α with its repressor RIP140 (Fritah et al., 2010; 
Rytinki and Palvimo, 2009). The repressor RIP140 itself can also be SUMOylated, resulting in 
dislocation from small nuclear foci to a more dispersed distribution in the nucleus, allowing RIP140 to 
interact with other proteins and suppress their activity (Fritah et al., 2010; Rytinki and Palvimo, 2008). 
Different isoforms of PGC-1α have been described and therefore, its activity and specificity for 
choosing its binding partners and regulating gene expression might also be regulated by alternative 
splicing (Baar et al., 2002; Tadaishi et al., 2011). Such an isoform is the truncated form of PGC-1α, 
termed NT-PGC-1α because it is contains the N terminus of the classical PGC-1α protein and harbours 
the transactivation and nuclear receptor interaction domain (Zhang et al., 2009). In contrast to the 
classical isoform, NT-PGC-1α is a relatively stable protein, which can localize in the cytoplasm. The 
export of NT-PGC-1α from nucleus to cytoplasm can be inhibited by protein kinase A (PKA) 
phosphorylation (Chang et al., 2010). Last, expression of PGC-1α shows a circadian rhythm and PGC-
1α itself regulates mammalian clock genes (Liu et al., 2007). 
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These different modes of regulation prove that PGC-1α is not a constitutively expressed coactivator 
which is passively recruited by the transcriptional machinery. It is rather a tightly regulated sensor of 
environmental changes and connects these changes with transcription. Moreover, the multitude of 
possibilities to change its activity and expression indicates that PGC-1α is not only turned off or on, 
but can receive inputs through signals from different signalling pathways and initiate cellular changes 
which are adequate for the current environmental or metabolic conditions. It is also evident that some 
modifications of PGC-1α drastically change its activity or availability, whereas others can be seen as 
fine-tuning the current status of PGC-1α activity. 
 
1.3 cAMP and cyclic nucleotide phosphodiesterases in the regulation of PGC-1α 
expression and activity  
Generally, PGC-1α can be considered as a strong promoter of mitochondrial biogenesis (Wu et al., 
1999). Nevertheless, PGC-1α also possesses tissue-specific functions like regulating hepatic response 
to fasting, inducing thermogenesis in brown adipose tissue or controlling a fibre type switch in skeletal 
muscle (Lin et al., 2002; Puigserver et al., 1998; Yoon et al., 2001). Therefore, it is not surprising that 
PGC-1α expression or activity was linked to different medical conditions in these tissues (Handschin, 
2009). PGC-1α protects neural cells from oxidative stress and neurodegeneration (St-Pierre et al., 
2006). Increased expression of PGC-1α in the bone might be beneficial for the treatment of 
osteoporosis (Nervina et al., 2006). Higher PGC-1α levels in skeletal muscle protect against atrophy 
and ameliorate Duchenne muscular dystrophy by up-regulating utrophin (Handschin et al., 2007; 
Sandri et al., 2006). Also, perturbations in PGC-1α expression have been linked to different 
pathological conditions. Reduced expression of PGC-1α is observed in the subcutaneous fat of 
morbidly obese people or in muscles of type 2 diabetes patients (Semple et al., 2004). Therefore, 
controlling PGC-1α levels by drug treatment might be beneficial for the treatment of these illnesses 
and the therapeutic potential of PGC-1α for different medical conditions is being investigated 
(Handschin, 2009). 
Considering the different modes of regulation, which are described in chapter 1.2, it is clear that 
cAMP signalling or generally cyclic nucleotide signalling is involved in the regulation of PGC-1α 
expression and activity. This is based on the fact that molecules like CREB, PKA or β2-AR either bind 
to the PGC-1α promoter to induce its expression or phosphorylate either PGC-1α itself or proteins 
regulating PGC-1α. These proteins are either upstream or downstream of cAMP. β2-AR signalling 
promotes production of cAMP whereas CREB and PKA are directly regulated by cAMP (Omori and 
Kotera, 2007).  
Cyclic adenosine monophosphate (cAMP) was discovered more than 50 years ago by Sutherland and 
colleagues and was found to be synthesized from ATP through adenylate cyclases (ACs) (Rall and 
Sutherland, 1958, 1962; Sutherland and Rall, 1958; Sutherland et al., 1962). cAMP is a second 
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messenger, meaning that extracellular signals which are received at the plasma membrane are 
transduced to generate a second, intracellular signal. In this way extracellular events can be 
communicated to intracellular structure. More precisely, hormones like epinephrine can activate 
membrane-resident G-protein coupled receptors (GPCRs) which in turn lead to activation of adenylate 
cyclase and subsequent synthesis of cAMP from ATP (Cooper, 2003; Sassone-Corsi, 2012). There are 
ten ACs in mammalian cells, nine of which are membrane-bound and a soluble AC which is not 
activated by GPCR signalling (Cooper, 2003). In 1971 Sutherland won a nobel prize in 
physiology/medicine for his work in this field and last year (2012), two other scientists, Robert 
Lefkowitz and Brian Kobilka, were awarded a nobel prize in chemistry for their work on GPCRs, 
reflecting the importance of this signalling pathway in biology (www.nobelprize.org).  
Once generated, cAMP can disperse throughout the cell and control the activity of its effector proteins. 
These include cAMP gated ion channels, PKA and cAMP-regulated guanine nucleotide exchange 
factors (cAMP-GEFs) called exchange proteins activated by cAMP (Epac) (Omori and Kotera, 2007; 
Sassone-Corsi, 2012). After the second messenger has elicited cellular processes, the intracellular 
cAMP levels need to be lowered to the basal levels and thereby allow a new round of signalling events 
in future. Indeed, cyclic nucleotide phosphodiesterases (PDEs) have been described shortly after the 
discovery of cAMP (Butcher and Sutherland, 1962). PDEs play an important role by hydrolysing 
cAMP to AMP and thereby extinguishing the previously generated signal (Sassone-Corsi, 2012). The 
mammalian genome encodes 21 phosphodiesterase genes, which are subdivided into 11 gene families 
(Bender and Beavo, 2006). However, there are many more than 21 gene products. Due to expression 
from alternative promoters and alternative splicing there are estimates of 100 – 200 or more gene 
products (Bender and Beavo, 2006; Bingham et al., 2006). The nomenclature follows certain rules. In 
the name of the phosphodiesterase HsPDE1C2, “Hs” stands for Homo sapiens, “PDE1” indicates the 
gene family, followed by the letter “C” for the family member and finally with number “2” to specify 
the splice isoform. The members of the 11 PDE families share a conserved catalytic domain near the C 
terminus, but the amino acid sequences outside the catalytic domain show a high variation. This is 
seen when comparing the regulatory domains near the N terminus (Figure 3) (Francis et al., 2011).  
PDE4, PDE7, PDE8 and are cAMP specific, PDE5, PDE6 and PDE9 are cGMP specific whereas 
PDE1, PDE2, PDE3, PDE10 and PDE11 hydrolyse both cAMP and cGMP (Francis et al., 2011; 
Omori and Kotera, 2007). However, PDEs show a tissue specific expression pattern and have tissue 
specific functions, thus the majority of the cAMP or cGMP activity depends on the most abundant 
PDE family in that specific tissue (Bingham et al., 2006; Omori and Kotera, 2007). PDE1C2 for 
example can be found in olfactory sensory neurons, PDE 6 plays an important role in vision and is 
therefore highly expressed in the retina and PDE4 has a more ubiquitous expression (Burns and 
Arshavsky, 2005; Houslay and Adams, 2003; Yan et al., 1995). This thesis focuses on skeletal muscle 
and the members of the PDE4, PDE5, PDE7A, PDE7B and PDE11 are highly expressed in the skeletal 
muscle tissue (Bender and Beavo, 2006). PDE1B is weakly expressed in skeletal muscle (Omori and 
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Kotera, 2007). PDE9 members show a wide tissue distribution and therefore, their expression in 
skeletal muscle tissue can be expected (Bender and Beavo, 2006).  
 
 
Figure 3. 11 phosphodiesterase families. Figure taken from (Francis et al., 2001). 
 
This tissue specific distribution and the involvement in many important biological processes are only 
some of many reasons why PDEs are considered as important drug targets. 
A selective PDE inhibitor would influence only those tissues in which the inhibited phosphodiesterase 
is expressed, thereby reducing the probability of side effects. Other reasons are the basic 
pharmacological principle that inhibiting degradation of a second messenger results often in a faster 
change than promoting the synthesis or that PDEs appear to have a higher maximal reaction rate 
(Vmax) than ACs (Bender and Beavo, 2006). A variety of selective and nonselective PDE inhibitors 
have been developed and are used to treat different medical conditions like asthma, depression or most 
prominently erectile dysfunction (Table 1) (Bender and Beavo, 2006; Coward and Carson, 2008; 





Table 1. Specific PDE inhibitors. Table taken from (Bender and Beavo, 2006). 
 
Because the activation of the PKA by forskolin and binding of CREB to the promoter of PGC-1α 
induces expression of the PGC-1α promoter in skeletal muscle cells, it might be expected that the 
inhibition of PDEs would also promote the expression of PGC-1α (Handschin et al., 2003). Moreover, 
because the induced expression of PGC-1α in skeletal muscle by triggers like exercise is transient, a 
successful regulation of PGC-1α by PDE combined with expression induction might delay the drop of 
PGC-1α expression. This would result in a long-lasting PGC-1α up-regulation and possibly a 




1.4 Downstream of PGC-1α - biological pathways regulated by PGC-1α 
As described above, external stimuli or metabolic changes trigger numerous signalling pathways 
which converge on PGC-1α. Typically, these events result in induced expression or protein 
modification of PGC-1α which can lead to either activation of PGC-1α or its degradation. Once PGC-
1α is active, it binds to its transcriptional partners and regulates the expression of tissue-specific gene 
programs.  
In response to fasting, PGC-1α coactivates Forkhead box protein O1 FoxO1, glucocorticoid receptor 
(GR) and hepatocyte nuclear factor 4 α (HNF4α) to promote the expression of gluconeogenic genes 
like phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (Puigserver et al., 
2003; Yoon et al., 2001). Even though the requirement of the interaction of PGC-1α with FoxO1 has 
been disputed, PGC-1α cannot regulate hepatic gluconeogenesis without FoxO1. In addition to control 
gluconeogenesis, PGC-1α participates in the regulation of fatty acid β-oxidation, ketogenesis and bile-
acid homeostasis in liver by coactivating several transcription factors like PPARα, FXR and LXR 
(Koo et al., 2004; Leone et al., 1999; Lin et al., 2005; Oberkofler et al., 2003; Shin et al., 2003; Zhang 
et al., 2004). Which transcription factors are involved in the regulation of oxidative phosphorylation 
genes in liver is not precisely known, but nuclear respiratory factor-1 (NRF-1) and estrogen-related 
receptor α (ERRα) are possible candidates (Schmidt and Mandrup, 2011). In heart, PGC-1α is induced 
after birth and following fasting and both events lead to increased utilization of fatty acids as major 
energy source. To induces genes which regulate mitochondrial respiratory function and fatty acid 
oxidation PGC-1α coactivates PPARα and ERRα (Finck and Kelly, 2006; Rowe et al., 2010). When 
expressed in heart cells, PGC-1α promotes mitochondrial biogenesis (Lehman et al., 2000). In neural 
cells, PGC-1α is induced by oxidative stress and increases the expression of ROS detoxifying enzymes 
superoxide dismutase 2 (SOD2) and glutathione peroxidase 1 (GPx1) thereby protecting these cells 
against oxidative stressors (St-Pierre et al., 2006). In mouse embryonic development, PGC-1α binds to 
SRY-related high mobility group-Box gene 9 (Sox9) enhancing its activity on the expression of 
chondrogenic genes in the embryonic limb buds (Kawakami et al., 2005).  
Soon after the discovery that PGC-1α coactivates PPARγ in brown adipose tissue to run the 
thermogenic program, PGC-1α was found to induce the expression of the nuclear respiratory factors 
NRF-1 and NRF-2 and coactivate them (Wu et al., 1999). By coactivating NRF-1 in muscle cells, 
PGC-1α induces the expression of mitochondrial transcription factor A (mtTFA), which is an 
important regulator of mitochondrial DNA replication and transcription (Wu et al., 1999). In skeletal 
muscle, ERRα and GA repeat-binding protein α (Gabpa or NRF-2) are essential transcriptional 
partners and together with PGC-1α they regulate the expression of the entire genetic program for 
oxidative phosphorylation and mitochondrial biogenesis (Mootha et al., 2004; Schreiber et al., 2004). 
In addition to coactivating these transcription factors, PGC-1α also induces their expression (Mootha 
et al., 2004). The transcriptional complex consisting of ERRα and PGC-1α induces the expression of 
vascular endothelial growth factor (VEGF) to regulate angiogenesis in skeletal muscle (Arany et al., 
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2008). Triggered by motor nerve activity, NRF-2 and PGC-1α together run the expression of the 
neuromuscular junction (NMJ) gene program (Handschin et al., 2007). By coactivating myocyte 
enhancer factor 2C (MEF2C), PGC-1α increases the expression of the insulin-sensitive glucose 
transporter (GLUT4), thus regulating glucose uptake in muscle (Michael et al., 2001). Therefore, by 
binding to chosen transcription factors and enhancing their expression, PGC-1α regulates nearly all 
adaptations of skeletal muscle to exercise. Likewise,  as a result to stress situations in other tissues, 
PGC-1α can becomes active and regulate the expression of those gene programs which are necessary 
in that specific situation and help the cell to deal with that stress.  
Based on these observations, PGC-1α can be considered as a master regulator, which responds to 
external stimuli and coactivates different transcription factors to induce entire gene programs. 
Although PGC-1α has been shown to coactivate numerous transcription factors, it is not likely that 
PGC-1α always coactivates all putative transcription factors. First, always inducing all potential target 
genes would be very inefficient, unspecific and a waste of energy and resources. Only inducing these 
genes that are required not only saves energy but also protects the cell from undesired consequences. 
The expression of a gene at wrong time or in wrong situation might even be deleterious for the cells.  
Second, different tissues express a different set of transcription factors, which subsequently become 
available for PGC-1α to bind to them. Third, some transcription factors are only available under 
specific conditions. Environmental stimuli or metabolic changes might result in increased expression 
of the mRNA for a certain transcription factor, its protein stabilization or translocation to nucleus, 
where it can interact with PGC-1α. Likewise, PGC-1α itself is target for numerous modes of regulation 
including regulated expression, protein stability, alternative splicing and posttranslational 
modifications. It can be assumed that these changes influence the preference of PGC-1α for its binding 
partners and modify its efficacy in performing its role as a coactivator (Figure 4). Indeed, an example 
of such a regulation mode can be observed in liver. The central role played by PGC-1α in hepatic 
fasting response is described in detail in previous chapters. Researchers have shown that S6 kinase 
becomes active in liver after feeding and subsequently phosphorylates PGC-1α (Lustig et al., 2011). 
Thereupon, PGC-1α is not anymore able to induce gluconeogenesis while the regulation of 
mitochondrial and fatty acid genes remains unchanged. This is because the S6 kinase phosphorylation 
blocks the interaction of PGC-1α with the gluconeogenesis regulator HN4α, whereas the interaction 
with mitochondrial biogenesis and fatty acid oxidation regulators ERRα and PPARα is not affected 
(Lustig et al., 2011). In this case, S6 kinase phosphorylation inhibits only one segment of the wide 
range of possible PGC-1α actions. It is very probable, that other posttranslational modifications, 
splicing or inhibition of PGC-1α by proteins like RIP140 or p160MBP operate in a similar way. 
Different posttranslational modifications derive from different signalling pathways and possibly 
influence the activity of PGC-1α in a unique way.  
Considering that different modes of PGC-1α regulation can occur at the same time and theoretically 
can be combined in numerous ways, the combination of these events would allow an immense 
19 
General Introduction 
combinatorial complexity. In such a model, the posttranslational modification status of PGC-1α can be 
considered as a “coactivator code”, similar to the “phosphocode” suggested for the regulation of 
nuclear receptors (Wu et al., 2005). This coactivator code would direct and specify the PGC-1α 
activity (Figure 4).  
 
 
Figure 4. The regulation of PGC-1α specificity by posttranslational modifications or alternative 
splicing of PGC-1α. Figure adapted from (Handschin and Spiegelman, 2006). 
 
Although the coactivator code regulation is possible, it is not proven yet that this regulation is really 
true. Nevertheless, it is clear that PGC-1α at any given time will coregulate several transcription 
factors and change the expression of many genes. Therefore, fully understanding the network of 
proteins which together with PGC-1α induce biological programs cannot be achieved by studying 
PGC-1α on individual gene promoters. Many studies focus their analysis on one promoter or a subset 
of promoters. Such approaches are not suitable to draw general conclusions, about how a transcription 
factor or coactivator regulates transcription. To understand the complex network and to get a global 
picture of the entire PGC-1α mediated gene regulation, a genome-wide approach is required. This 
approach should allow that the interaction of PGC-1α with the entire genome can be studied and this 
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knowledge should be used to understand genome-wide changes in gene expression induced by PGC-
1α. 
 
1.5 ChIP-Sequencing - detecting the interaction of PGC-1α with chromatin 
The first step to study how a factor regulates gene expression is to investigate its interaction with the 
genome. Probably the best way to do so is by performing chromatin immunoprecipitation (ChIP) 
(Figure 5). In this approach, the cells or tissue are treated with formaldehyde to crosslink the protein of 
interest with the chromatin. In the next step the chromatin is sheared by sonication or digestion and the 
protein of interest is precipitated together with the DNA fragment bound to it by a specific antibody. 
The remaining chromatin is washed away, leaving only those chromatin pieces which were occupied 
by the protein of interest. Next, the crosslinking is reversed, protein and RNA are digested and the 
remaining DNA is precipitated. In this way, a DNA library is created which consist of only those parts 
of DNA which were initially bound by the protein of interest. This means that by identifying these 
DNA fragments, the researchers can deduce all parts of the genome that have been occupied by the 
protein of interest in the initial experiment. There are two common methods to identify all DNA 
fragment in the library generated by ChIP experiments (Euskirchen et al., 2007; Park, 2009). In one 
method, the goal is to hybridize DNA to tiling arrays which cover all promoters and thus detect all 
promoters bound by the protein of interest. Because this method combines chromatin 
immunoprecipitation with arrays (chip), it was termed ChIP-on-chip (Figure 5) (Blat and Kleckner, 
1999; Ren et al., 2000). The other method utilizes ultrahigh-throughput DNA sequencing to identify 
the DNA fragments in the library and is therefore called ChIP-Sequencing or briefly ChIP-Seq (Figure 
5) (Johnson et al., 2007; Robertson et al., 2007).  
The coactivator PGC-1α does not bind DNA directly, but is rather recruited to DNA by transcription 
factors. Therefore the DNA library generated by chromatin immunoprecipitation of PGC-1α will 
contain DNA fragments which were bound by different transcription factors which were coactivated 
by PGC-1α. 
ChIP-Seq has some advantages over ChIP-on-chip (Park, 2009). ChIP-Seq has a much greater 
resolution which is in best case a single nucleotide. In ChIP-on-chip the resolution is array-specific, 
but definitely lower. ChIP-on-chip only covers promoter regions whereas the coverage in ChIP-seq is 
basically not limited. Furthermore, arrays are only available for some organisms. The only restriction 
is limitations in alignability due to repeats, but with increasing DNA sequence fragment (read) length 
even repeat regions can be covered. The cost of ChIP-Seq is rapidly decreasing and the required 
amount of DNA for the library is much smaller. The disadvantage of ChIP-Seq is the complexity of 
data analysis and the lack of suitable analysis programs. In the last years, many ChIP-Seq analysis 
tools have been published, but most require profound skills in bioinformatics and the files generated 
by these tools often cannot be directly further analysed with other analysis tools without a time 
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consuming reformatting of the file (Furey, 2012). For our experiments, we decided to go with ChIP-
Seq because of the numerous advantages of ChIP-Seq over ChIP-on-chip. 
 
Figure 5. Schematic illustration of the methods ChIP-chip (ChIP-on-chip) and ChIP-Seq. Figure 
adapted from (Farnham, 2009). 
 
The sequencing of the DNA library is performed by powerful genome analysers, which combine DNA 
amplification with scanning after every round of amplification. Because the DNA fragments are 
immobilised on the slides the obtained scan pictures can be used to retrieve sequences of millions of 
DNA fragments (Fields, 2007; Johnson et al., 2007; Park, 2009). The image processing and base 
calling depends on the sequencing platform and can introduce errors (Park, 2009). Another challenge 
is data management, because the files generated in ChIP-Seq experiments require big memory 
capacities (Park, 2009). The sequenced DNA fragments are also called reads and in a typical ChIP-Seq 
experiment many millions of reads are obtained. 
The sequencing depth is rapidly increasing. In our first ChIP-Seq experiments, the number of reads 
obtained for one ChIP-Seq experiment was approximately 5-10 millions. A few years later, this 
number was ten times higher. To map the reads to a reference genome, several freely available tools 
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have been developed and are still being optimized (Furey, 2012). In the early years of ChIP-Seq 
however, there were very few alignment programs and other analysis tools available. This presented a 
major bottleneck in the ChIP-Seq analysis, because the researchers would relatively rapidly obtain the 
sequences, but did not have the proper programs or the computing capacities to run the analysis. 
Furthermore, many researchers were biologists and thus simply not qualified to develop new programs 
or analysis tool and were stuck with their data. One of the early aligners, ELAND, was developed by 
the company Illumina and was the standard aligner on their genome analysers (illumina.com).  
Researchers later developed freely available aligners like MAQ or Bowtie, just to mention a couple 
(Langmead et al., 2009; Li et al., 2008a). In general, the aligners are always a trade-off between 
accuracy on the one side and speed and memory usage on the other side (Park, 2009). Once the reads 
are mapped, the data can be visualized in a genome browser like the popular genome browser of the 
University of California at Santa Cruz (UCSC) (Meyer et al., 2013). The genome browser allows a 
visualisation of the data at individual sites in the genome and serves mainly to verify that the 
experiment has worked or to test the enrichment at individual sites. For an in-depth systemic analysis 
of enrichment, the reads are usually analysed with called peak finders. The programs like MACS or 
PeakSeq scan the data along the genome and identify areas of local read enrichment called peaks 
(Rozowsky et al., 2009; Zhang et al., 2008). Peaks are considered as genomic locations which were 
occupied by the protein of interest in the initial experiment. Alternatively, in ChIP-Seq experiments, 
which do not investigate the interaction of transcription factors with DNA but rather epigenetic 
modifications of the chromatin, a peak is considered as an area with histone modification. The width 
of a peak and its sharpness strongly depend on the experimental design and the phenomenon that is 
studied. In protein-DNA binding experiments the resulting peaks are mostly sharp and have a narrow 
range of peak width changes. In histone modification experiments, the peak width can vary (Park, 
2009). Therefore, there cannot be one superior peak caller for all experiments.  
By combining peaks with gene expression arrays, researcher can assign changes in gene expression to 
binding events (peaks) and thus verify if the binding of the protein of interest changes gene expression. 
If so, the protein of interest would directly regulate the expression of that specific gene by binding to 
its promoter or other adjacent regions. In the case of PGC-1α, this would mean that PGC-1α together 
with a transcription factor directly drives the expression of that gene. Conversely, a gene that is 
changing expression upon deletion or introduction of the protein of interest, but is not located in the 
proximity of a peak, would be indirectly regulated by the protein of interest. In addition, a gene 
ontology (GO) analysis can be applied on the induced and suppressed genes to reveal which biological 
pathways are directly and indirectly regulated by PGC-1α. 
The genomic regions covered by the peaks can be searched for known transcription factor motifs or 
undergo a de novo motif search analysis. Motif search programs like MotEvo and PhyloGibbs 
developed by Arnold and colleagues or Siddharthan and colleagues respectively were used for the 
analysis of the data in this thesis (Arnold et al., 2012; Siddharthan et al., 2005). As mentioned 
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previously, PGC-1α does not bind DNA directly. Consequently, the motifs that could be found in 
PGC-1α occupation sites (peaks) would not represent the binding of PGC-1α to DNA, but the binding 
of transcription factors which are coactivated by PGC-1α. Therefore by identifying motifs in PGC-1α 
peaks, predictions about transcriptional partners of PGC-1α can be made. Moreover, gene ontology 
results might be combined with the findings from motif search. This would allow making predictions, 
which transcription factors are involved in the regulation of each biological pathway, that is regulated 
by PGC-1α.  
Together these findings would provide an insight into the complex regulatory network of PGC-1α 
regulated gene programs. The described analysis procedure could also be applied after a 
posttranslational modification PGC-1α has been introduced. This would offer a possibility to identify 
which PGC-1α regulated gene programs are affected by each posttranslational modification of PGC-
1α.  
The question is, if a bioinformatics analysis would be sufficient to analyse the regulation of 
transcription by a protein of interest. First, the occurrence of a motif alone does not necessarily mean 
that the transcription factor bind in vivo to that site. In the case of PGC-1α there is no binding motif 
known, because it does not bind DNA directly. It is also not probable that all putative binding sites are 
occupied in all tissues and in under any condition. Conversely, transcription factors have been found to 
bind or to be active at sites which do not have a consensus motif for this transcription factor (Farnham, 
2009). One possible explanation is that the factor binds at a distal site, which contains the motif and 
then loops to the site in question to interact with the transcriptional machinery (Farnham, 2009). 
Second, it is very likely that epigenetic modifications influence the binding of a transcription factor to 
DNA (Farnham, 2009). Third, it is not known if all binding events are really functional. It is 
imaginable that a transcription factor binds to a consensus motif in all tissues, but regulates the 
expression in only one (Farnham, 2009). Therefore, to obtain accurate studies of transcription, a 
prediction based on bioinformatics analysis alone is not sufficient. The physical interaction of the 
protein of interest with the chromatin has to be verified by biological experiments. Incidentally, much 
of the knowledge how transcription works and how the genomic information translates to gene 
expression has been gained from genome-wide studies (Birney et al., 2007). 
 
1.6 PGC-1α in genome-wide studies 
PGC-1α was discovered in 1998 and its role as a coactivator and a potent inducer of mitochondrial 
biogenesis, oxidative phosphorylation, gluconeogenesis and thermogenesis has been described in 
numerous studies (Handschin and Spiegelman, 2006; Puigserver et al., 1998). Nevertheless, only few 
studies investigated the activity of PGC-1α on genome-wide scale. In a study published in 2004, 
Mootha, Handschin and colleagues analysed PGC-1α induced genome-wide expression in cultured 
skeletal muscle cells (Mootha et al., 2004). They developed motifADE, a motif analysis tool, and 
applied it to analyse the expression array. MotifADE first ranks differentially expressed genes and 
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searches then in the promoters of the ranked genes for known transcription factor motifs. MotifADE 
then tests whether the genes containing a motif tend to rank higher or not. If a motif is found in 
promoters of genes, which rank high, it can be assumed that the corresponding transcription factor 
regulates the expression of this subset of PGC-1α induced genes (Mootha et al., 2004). In this study 
they identified the motifs for ERRα and NRF-2 as top scoring transcription factors motifs, suggesting 
that these two transcription factors are major binding partners for PGC-1α induced genes in skeletal 
muscle cells (Mootha et al., 2004). When the interaction of PGC-1α with ERRα was inhibited with the 
synthetic inverse agonist XCT790, the induction of PGC-1α induced genes with an ERRα binding site 
in the promoter was diminished. Conversely, PGC-1α genes without ERRα binding site in the 
promoter were not affected by the inhibitor treatment (Mootha et al., 2004). Schreiber and colleagues 
demonstrated in another study that PGC-1α requires ERRα expression to induce mitochondrial genes 
and to increase the content of mitochondrial DNA (Schreiber et al., 2004). A constitutively active form 
of ERRα induced these pathways even without PGC-1α. These studies suggest that PGC-1α requires 
ERRα to regulate at least a subset of its target genes. However, it is not precisely known which genes 
PGC-1α and ERRα regulate together and which independently. It is also not known which PGC-1α 
target genes are regulated by the direct recruitment of the coactivator to the promoter and which genes 
are regulated in an indirect manner. The latter issue also concerns the ERRα target genes. The 
occurrence of an ERRα motif in the promoter does not necessarily mean that ERRα really binds there. 
This promoter might serve for the regulation of that gene by ERRα but in another tissue or eventually 
only under certain conditions. 
Charest-Marcotte studied the gene regulation by the PGC-1α/ERRα complex in liver and cultured liver 
cells (Charest-Marcotte et al., 2010). The identified a transcription factor called prospero-related 
homeobox 1 (Prox1) as a negative regulator of the PGC-1α/ERRα regulated transcription. Prox1 
appears to attach to ERRα and repress its transcriptional activity. To study the interaction of these 
proteins on a genome-wide scale they conducted ChIP-on-chip studies with ERRα and Prox1, but not 
with PGC-1α (Charest-Marcotte et al., 2010). Therefore the role of PGC-1α on a genome-wide scale 
cannot be completely delineated from the finding in this study. 
The only genome-wide analysis of PGC-1α recruitment to DNA was conducted in cultured liver cells 
(Charos et al., 2012). ChIP-Seq was performed in human liver carcinoma cells (HepG2), which were 
treated with forskolin, an activator of PKA, to induce PGC-1α expression. They identified 1886 
genomic sites which were occupied by PGC-1α using a false discovery rate (FDR) of 1%. However, 
this number varies strongly if the value for FDR changes, thus the number of peaks with FDR=5% 
goes up to 9366 (Charos et al., 2012). Therefore it is hard to estimate which peaks represent real 
binding events. The motif search of top 250 PGC-1α peaks discovered only three motifs with 
statistical significance. Top scoring motif was the one for heat shock factor 1 (HSF1), followed by 
ERRα and CCAAT/enhancer-binding protein beta (CEBPB). However the role of the coactivation of 
HSF1 by PGC-1α is not clear, because it is not known which biological pathways are regulated by the 
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two factors together. It is also not known, if the induction of a subset of PGC-1α target gene is 
diminished if HSF1 is absent. Therefore the role of HSF1 for the regulation of PGC-1α induced genes 
in liver needs to be further investigated. It is surprising that the motif for HNF4α was not detected in 
PGC-1α peaks, considering that this factor is important for the PGC-1α regulated hepatic fasting 
response (Charos et al., 2012; Yoon et al., 2001). When the expression of genes in HepG2 cells was 
compared PGC-1α peak occurrence, PGC-1α was detected in the proximity of up-regulated and down-
regulated genes. It appears that recruitment of PGC-1α to repressed genes is even stronger than to 
induced genes (Charos et al., 2012). This is surprising, because PGC-1α is mainly known as a 
coactivator and less as a repressor.  
Together, these genome-wide approaches indicate that ERRα appears to be a very important effector 
of PGC-1α regulated gene expression. But it is not to which extent the PGC-1α regulated gene 
expression requires ERRα. Other transcription factors like HSF1 might be novel transcriptional 
partners, but this interaction might be tissue-specific. Are there transcription factors which are active 
with PGC-1α in all tissues? Which PGC-1α partners are tissue-specific?  To answer these questions, 




1.7 Aims of the thesis 
The work in this thesis focuses on the role of PGC-1α in skeletal muscle. As described above, different 
signalling events in skeletal muscle converge at some time point on PGC-1α and affect its expression 
or lead to its posttranslational modification. In this way, extracellular events, activity and metabolic 
changes influence the availability and activity of PGC-1α in skeletal muscle cells. The combination of 
these events allows an immense combinatorial complexity of PGC-1α regulation. Following 
activation, PGC-1α masters the expression of entire gene programs by coactivating key transcription 
factors. Therefore PGC-1α represents a junction between environmental changes and transcription. 
Therefore, to fully understand how PGC-1α regulates gene expression in response to metabolic 
changes, pathways upstream and downstream of PGC-1α have to be studied.  
 
The aims of this thesis can be summarized as follows: 
 
- Upstream: Because cAMP regulates PGC-1α gene expression, we want to discover if the 
manipulation of intracellular cAMP levels by cyclic nucleotide phosphodiesterase inhibition 
changes PGC- 1α gene expression or protein levels. If so, which precise phosphodiesterase is 
involved in this regulation? Does the combined activation of cAMP synthesis together with 
suppressed hydrolysis by PDE inhibition lead to a long lasting PGC-1α expression in skeletal 
muscle? 
 
- Downstream: We want to get a global picture of the PGC-1α mediated regulation of gene 
expression in skeletal muscle cells. To which and to how many genomic locations is PGC-1α 
recruited? Is this recruitment in the proximity of genes and is it functional? Which biological 
pathways are regulated by PGC-1α in skeletal muscle cells? Which are the key transcription 
factors that act together with PGC-1α to regulate this expression changes? Does PGC-1α 
regulate gene expression directly by binding transcription factors in promoters of these genes 
or indirectly, or both? Can PGC-1α act as a corepressor? 
 
- Downstream: Based on studies described previously, ERRα appears to be the major effector of 
PGC-1α induced gene expression. Is that true on a genome-wide scale? To which extent is 
ERRα required for PGC-1α mediated gene expression changes? In other words, which genes 
require ERRα to be regulated by PGC-1α? Which biological pathways do these genes 
regulate? Does ERRα suppress gene expression? Which biological pathways does PGC-1α 
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Skeletal muscle tissue shows an extraordinary cellular plasticity, but the underlying molecular 
mechanisms are still poorly understood. Here we use a combination of experimental and 
computational approaches to unravel the complex transcriptional network of muscle cell plasticity 
centered on the peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α), a regulatory 
nexus in endurance training adaptation. By integrating data on genome-wide binding of PGC-1α and 
gene expression upon PGC-1α over-expression with comprehensive computational prediction of 
transcription factor binding sites (TFBSs), we uncover a hitherto underestimated number of 
transcription factor partners involved in mediating PGC-1α action. In particular, principal component 
analysis of TFBSs at PGC-1α binding regions predicts that, besides the well-known role of the 
estrogen-related receptor α (ERRα), the activator protein-1 complex (AP-1) plays a major role in 
regulating the PGC-1α-controlled gene program of hypoxia response. Our findings thus reveal the 
complex transcriptional network of muscle cell plasticity controlled by PGC-1α. 
 
Significance statement 
PGC-1α coordinates the adaptations of skeletal muscle to endurance exercise by regulating the 
transcription of the entire gene program required for this enormous cellular remodeling. By acting as a 
transcriptional coactivator, PGC-1α modulates the activity of numerous transcription factors. In the 
present study, we identified the genomic locations to which PGC-1α is recruited in skeletal muscle 
cells. Moreover, we linked the recruitment data with functional outcome in terms of gene expression 
as well as prediction and validation of transcription factor binding partners involved in the genome-
wide control of PGC-1α-regulated muscle gene expression. In doing so, we identified AP-1 as a novel 




A sedentary life style can lead to an imbalance between energy intake and expenditure and favors the 
development of a number of chronic diseases like obesity and type 2 diabetes. Regular exercise on the 
other hand is an effective way to reduce the risk for these lifestyle-related pathologies (1). The health 
benefits of exercise are at least in part induced by changes in skeletal muscle tissue. Muscle cells 
exhibit a high plasticity and thus a remarkably complex adaptation to increased contractile activity. 
For example, endurance training induces mitochondrial biogenesis, increases capillary density and 
improves insulin sensitivity (1, 2). To achieve such a complex plastic response, a number of different 
signaling pathways are activated in an exercising muscle, for example p38 MAPK-mediated protein 
phosphorylation events, increased intracellular calcium levels or the activation of the metabolic 
sensors AMP-dependent protein kinase (AMPK) and sirtuin-1 (SIRT1) (3). While the temporal 
coordination of the numerous inputs is not clear, all of the major signaling pathways converge on the 
peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) to either induce Ppargc1a gene 
expression, promote post-translational modifications of the PGC-1α protein, or by doing both (4, 5). 
Upon activation, PGC-1α mediates the muscular adaptations to endurance exercise by coactivating 
various transcription factors (TFs) involved in the regulation of diverse biological programs such as 
mitochondrial biogenesis, angiogenesis, ROS detoxification or glucose uptake (3). Accordingly, 
transgenic expression of PGC-1α in mouse skeletal muscle at physiological levels not only induces 
mitochondrial biogenesis but also drives a fiber type conversion towards a more oxidative, slow-twitch 
phenotype (6) while muscle-specific Ppargc1a knockout animals exhibit several symptoms of 
pathological inactivity (7, 8). 
Coregulators are part of multicomponent regulatory protein complexes that are well suited to translate 
external stimuli into changes in promoter and enhancer activities by combining various enzymatic 
activities to modulate histones and chromatin structure, and recruit other TFs (9). Thus, dynamic 
assembly of distinct coregulator complexes enables the integration of many different signaling 
pathways leading to a coordinated and specific regulation of entire biological programs by multiple 
TFs (10, 11). For example, PGC-1α not only recruits histone acetylases (12), the 
TRAP/DRIP/Mediator (13) as well as the SWI/SNF protein complexes (14), but also binds to and 
coactivates a myriad of different transcription factors, even though a systematic inventory of TF 
binding partners has not been compiled yet (15). Thus, the specific control exerted by the PGC-1α-
dependent transcriptional network might provide an explanation for the dynamic and coordinated 
muscle adaptation to exercise. Since PGC-1α in skeletal muscle not only confers a trained phenotype, 
but also ameliorates several different muscle diseases (16), the unraveling of the PGC-1α-controlled 
transcriptional network in skeletal muscle would be of great interest to identify putative therapeutic 
targets within this pathway. 
Therefore, we aimed at obtaining a global picture of the co-regulatory activity of PGC-1α in skeletal 
muscle cells. More precisely, by combining data on the genome-wide binding locations of PGC-1α 
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and the gene expression profiles in response to PGC-1α over-expression with comprehensive 
computational prediction of transcription factor binding site (TFBS) occurrence, we sought to unveil 
the biological processes that are regulated by PGC-1α, to identify the transcription factors that partner 
with PGC-1α, and to determine the mechanistic details of PGC-1α-regulated transcription. We not 
only mapped the locations on the DNA where PGC-1α was bound, but also delineated the target genes 
whose expression is either directly or indirectly affected by PGC-1α and identified novel putative 
transcription factor partners that mediated PGC-1α’s action. In particular, our results strongly suggest 
that the activator protein-1 (AP-1) complex is a major regulatory partner of PGC-1α, with AP-1 and 






2.3.1 Broad recruitment of PGC-1α to the mouse genome 
PGC-1α-dependent gene transcription has been studied in many different experimental contexts. In 
isolation, gene expression arrays however are unable to distinguish direct from indirect targets, or to 
reveal the genomic sites where PGC-1α is recruited to enhancer and promoter elements, i.e. by 
coactivating TFs that directly bind to the DNA. Thus, we first performed chromatin 
immunoprecipitation followed by deep sequencing (ChIP-Seq) of PGC-1α in differentiated C2C12 
mouse myotubes to identify the locations where PGC-1α is bound to the genome. To identify genomic 
regions that are significantly enriched in the ChIP, we slid a 200 bp window across the genome 
comparing the local ChIP read density with the read density from a background whole cell extract 
sample. We selected all regions with a Z-statistic larger than 4.5 as significantly enriched (FDR 0.6%, 
Suppl. Fig. S1A). Using this stringent cutoff, we identified 7512 binding regions for PGC-1α via 
interaction with a TF genome-wide, which include binding regions in the promoters of known PGC-1α 
target genes (Fig. 1A) such as medium-chain specific acyl-CoA dehydrogenase (Acadm) and 
cytochrome c (Cycs) (17, 18). The enrichment of immunoprecipitated DNA fragments from the ChIP-
Seq was validated for these and other PGC-1α target genes by semiquantitative real-time PCR (Fig. 
1B). In absolute terms, the distribution of the ChIP-Seq peaks revealed that PGC-1α is mostly 
recruited at distal sites from the assigned targets and, to a lesser extent, to proximal regions of the gene 
or within an intronic sequence (Fig. 1C). However, when compared to randomly selected DNA 
regions of equal size and number, PGC-1α binding peaks occur twice as often within 10 kb upstream 
of the transcription start site (TSS). 
In parallel to the ChIP-Seq experiment, we furthermore analyzed gene expression patterns in 
differentiated muscle cells both in control condition and under PGC-1α over-expression. Using a 
reference set of mouse promoters (19) and associating microarray probes to promoters by mapping to 
known transcripts, we found 1566 promoters (corresponding to 984 genes) to be significantly up-
regulated (log2 fold change >= 1; Z score >= 3) and 1165 promoters (corresponding to 727 genes) to 
be significantly down-regulated (log2 fold change <= -1; Z score <= -3). Thus, similar to previous 
reports, PGC-1α induced and repressed the transcription of almost the same number of genes, 
respectively, indicating that the physiological function of PGC-1α includes both the activation and 
inhibition of substantial numbers of genes. 
To combine the DNA binding results from the ChIP-Seq with the data of the gene expression arrays, 
we then assigned ChIP-Seq peaks to the closest promoter (and the associated gene) within a maximum 
distance of 10 kb. In this way, about 30% of all peaks (2295 of 7512) could be associated with a target 
promoter. Inversely, for about 35% of all significantly up-regulated genes (341 of 984), a PGC-1α 
binding peak is found within 10 kb of the promoter. Since some of the up-regulated promoters may be 








Figure 1. Genome-wide DNA recruitment of PGC-1α in mouse muscle cells. 
(A) PGC-1α ChIP-Seq binding peaks (read densities) around the TSS of the genes Acadm and Cycs obtained 
from the UCSC Genome Browser. 
(B) Real-time PCR validation of the ChIP enrichment measured at the promoter of a set of PGC-1α target genes. 
Bars represent fold enrichment over that of the Tbp intron, error bars represent SEM. *p < 0.05; **p < 0.01; 
***p < 0.001. 
(C) Mapping ChIP-Seq PGC-1α peaks across the genome. Transcription Start Site (TSS) and Transcription End 
Site (TES) are relative to mm9 RefSeq transcripts. “Intergenic”: ≥ 10 kb from the nearest transcript; “Upstream 
of TSS”: -10 to 0 kb from the TSS; “Downstream of TES”: 0 to 10 kb from the TES. Numbers between brackets 
indicate, for each category, the ratio between the percentage of PGC-1α peaks and the percentage of the same 
number of randomly distributed peaks. 
(D) Histogram illustrating the number of direct and indirect genes either up- or down-regulated by over-
expression of PGC-1α in muscle cells. Direct genes are those associated to promoters found within ±10 kb 
relative to the nearest peak. 
(E) Distribution of the distances of 532 peaks from their associated up-regulated gene promoters. 
(F) Distribution of the distances of 43 peaks from their associated down-regulated gene promoters. 
(G-H) Subset of the top significantly enriched GO Biological Process terms identified for directly and indirectly 
up-regulated (G) and down-regulated (H) PGC-1α target genes. 
 
In stark contrast, only about 5% of all repressed genes harbor one or more PGC-1α DNA recruitment 
peaks in their vicinity (36 of 727) opposed to 95% indirectly down-regulated PGC-1α target genes 
(691 genes) (Fig. 1D). Moreover, the distribution of the distances between PGC-1α peaks and their 
associated promoters revealed a tight cluster of 532 peaks close to promoter regions for up-regulated, 
direct PGC-1α target genes (Fig. 1E) whereas the distribution of the 43 peaks associated to down-
regulated genes was much wider, raising the possibility that the association of peaks to 
transcriptionally repressed genes might be spurious (Fig. 1F). In summary, the strong enrichment of 
binding peaks near up-regulated genes and the almost complete absence of binding peaks near down-
regulated genes suggest that direct regulation of transcription by PGC-1α is almost exclusively 
activating. We note that there is a large fraction of binding peaks (75%) that are associated to target 
genes that do not significantly alter their expression. These peaks may have been wrongly assigned, 
their functionality may be dependent on additional factors not active in these cells, or they may simply 
be spurious binding events that are not functional.  
We next used this stratification of peaks and genes to study whether direct (i.e. with an associated 
binding peak) and indirect PGC-1α target genes exert different biological function and identified Gene 
Ontology (GO) terms that were over-represented in any of the four categories. First, we observed that 
the most significantly enriched functional categories for directly and indirectly up-regulated genes 
were those related to mitochondria, oxidative phosphorylation and energy production (Fig. 1G and 
Suppl. Fig. S1B). In contrast, GO analysis of indirectly down-regulated PGC-1α target genes revealed 
a high prevalence of terms related to inflammation and immune response (Fig. 1H and Suppl. Fig. 
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S1C). Assuming that the assignment of peaks to repressed genes is not spurious, the few directly 
repressed PGC-1α targets exhibit an enrichment in functions related to muscle contraction, in 
particular for genes that are linked to contractile and metabolic properties of glycolytic, fast-twitch 
muscle fibers (Fig. 1H and Suppl. Fig. S1D), as would be expected from the observed shift from 
glycolytic to oxidative fibers mediated by PGC-1α in muscle (6). 
 
2.3.2 Modeling the direct and indirect gene regulatory effects of PGC-1α  
As a next step, we rigorously modeled the effects of PGC-1α on its target genes in terms of the 
occurrence of TFBSs for a large collection of mammalian regulatory motifs. We previously introduced 
a general framework, called Motif Activity Response Analysis (MARA) (20), for modeling the gene 
expression profiles as a linear function of the TFBSs occurring in the promoters and unknown 
regulatory “activities” of each of the regulators. As detailed in the Methods, we here extended MARA 
to incorporate information from the PGC-1α ChIP-Seq data, with the aim of identifying which other 
TFs are involved in mediating both the direct and indirect regulatory effects of PGC-1α. Specifically, 
for all “direct target” promoters that were associated with a PGC-1α binding peak, we modeled the 
expression of the promoter in terms of the predicted TFBSs in the neighborhood of the binding peak, 
while for “indirect target” promoters we modeled the promoter’s expression in terms of the predicted 
TFBSs in the proximal promoter region, according to the conventional MARA approach (Fig. 2A and 
2B). 
First, further supporting our analysis above, direct target promoters were almost exclusively up-
regulated and only in a few exceptional cases reached statistical significance for PGC-1α-repressed 
transcripts (Fig. 2C). Among the direct motif activities, the ESRRA position weight matrix was the top 
ranking motif with a Z score of 6.04 (Suppl. Fig. 2). The corresponding TF estrogen-related receptor α 
(ERRα), an orphan nuclear receptor, has been extensively studied as a central binding partner for 
PGC-1α in the regulation of mitochondrial gene expression (17, 18, 21). To stratify the different 
motifs according to their predicted function, we then divided all motifs into groups according to the 
behavior of both their direct and indirect activity changes. Strikingly, all motifs exhibited one of only 
four different motif activity patterns. First, 6 TFs (Suppl. Fig. S2) were predicted to positively regulate 
PGC-1α target genes only in the presence of PGC-1α (Fig. 2D). Second, we found 6 motifs (Suppl. 
Fig. S2) with significantly up-regulated direct and indirect motif activities upon PGC-1α over-
expression (Fig. 2E). To our surprise, ERRα was predicted to regulate PGC-1α target genes in this 
manner, even though in previous reports gene regulation by ERRα in the context of activated PGC-1α 
was suggested to be dependent on PGC-1α coactivation (17, 18, 21). Third, we found 13 motifs 
(Suppl. Fig. S2) that were predicted to regulate PGC-1α target genes, however only in the absence of 
PGC-1α (Fig. 2F). Fourth, there was a group of 28 motifs (Suppl. Fig. S2) that showed a significant 
decrease of indirect motif activity upon PGC-1α over-expression, but no significant change of their 
direct motif activity, including NFκB (Fig. 2G), a central regulator of inflammation which is indirectly 
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repressed by PGC-1α (22). Intriguingly however, no motif was found that showed significant direct 
repression of target genes, reinforcing the hypothesis that PGC-1α-dependent gene repression is an 
indirect event. 
 
Figure 2. Three distinct mechanistic modes of action for gene expression regulated by PGC-1α 
and TF partners. 
(A) Classification of direct and indirect target genes in MARA (see Methods) 
(B) Distribution of peak distance from the closest promoter and phastCons conservation score of the peak. 
(C) Distribution of log2 expression values for all mouse promoters. Expression values were averaged across the 
3 GFP and the 3 PGC-1α samples. Direct targets are depicted in red, indirect targets in grey. 
(D-G) Activity plot of the motifs SP1 (D), ESRRA (E), REST (F) and NFKB1_REL_RELA (G) as predicted by 
MARA (Motif Activity Response Analysis). Red: direct targets; green: indirect targets. 
 
2.3.3 Nuclear receptors and activator protein-1-like leucine zipper proteins are the main 
functional partners of PGC-1α in muscle cells 
As a next step, we analyzed the occurrence of TF DNA-binding motifs in the PGC-1α peaks identified 
by ChIP-Seq. We first performed de novo motif prediction on the top 200 peaks, using PhyloGibbs 
(23). As shown in Figure 3A, the motif that PhyloGibbs identified matches significantly (E-value = 
7.7834e-10, as calculated by STAMP (24)) the canonical ESRRA motif. In addition to the de novo 
prediction, we also used the same collection of 190 mammalian regulatory motifs used by MARA (19) 
to check which known TF DNA-binding motifs were significantly over-represented in the PGC-1α 
peaks relative to a set of background regions. Many of the most significantly enriched motifs represent 
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variations of nuclear receptor binding sequences that are based on the “AGT/GTCA” core hexamer and 
occur either alone or in direct, inverted or everted repeats with variable spacing (Fig. 3B). Of these, the 
most significantly enriched motif was ESRRA, which is present in ~20% of all peaks. Moreover, 
among all genes with at least one associated binding peak within 10Kb, ~28% are associated with a 
peak containing a predicted ERRα site. Interestingly, besides the nuclear receptor motifs, we also 
found the DNA-binding element of the insulator protein CCCTC-binding factor (CTCF), and a set of 
highly similar DNA elements sharing the FOS-JUN-like recognition sequence “TGAG/CTCA” bound 
by the TFs BACH2, FOS, FOSB, FOSL1, JUN, JUNB, JUND, FOSL2, NFE2, and NFE2L2 among 
the top 15 motifs enriched in PGC-1α peaks (Fig. 3B). 
The identity of the exact nuclear receptor binding partner that is bound at each peak is difficult to 
deduce from DNA-binding motifs, since considerable promiscuity exists between receptors and DNA-
binding elements in different configurations of hexameric repeats (25). Moreover, non-nuclear 
receptor-like TFs are less well studied in the context of PGC-1α-controlled gene expression. Thus, to 
identify which regulatory motifs are most over-represented among peaks that do not contain nuclear 
receptor-like sites, we first manually grouped all of the motifs with a sequence logo very similar to 
that of ESRRA. Next, we discarded all peaks that had one or more predicted TFBSs for any of the 
motifs in this set. With the remaining 3856 DNA sequences (51.33% of the peaks), we then again 
assessed the over-representation of each of the 190 mammalian regulatory motifs. In this analysis, 
"TGAG/CTCA” recognition elements, hence FOS-JUN-like motifs, were the most significantly 
enriched among these peaks (Suppl. Fig. S3A). This result suggests that PGC-1α peaks naturally fall 
into two classes: those containing ESRRA-like sites, and those containing sites for FOS-JUN-like 
motifs. 
We then constructed a matrix N, whose elements Npm contain the number of predicted TFBSs for each 
motif m in each peak region p. We then performed principal component analysis (PCA) on this site-
count matrix to identify linear combinations of regulatory motifs that explain most of the variation in 
site-counts across the PGC-1α peaks. The first two components (out of 190 in total) clearly proved to 
be the most relevant ones, accounting for 10% and 9.6 % of the total variation in our dataset, 
respectively (Fig. 3C). Figure 3D shows the projection of all motifs on these first two principal 
components, with the names of the motifs with the largest projection indicated in the figure. Whereas 
most motifs have projections close to zero along the first component, there is one group of motifs with 
strong negative projections (ESRRA, NR1H4, NR5A1,2, NR6A1) and one group of motifs with strong 
positive projections (BACH2, FOS_FOS(B,L1)_JUN(B,D), FOSL2, NFE2, NFE2L1, NFE2L2). 
These two sets of sites correspond precisely to the two classes of motifs identified above, confirming 
that the most significant variation in TFBSs across PGC-1α peaks is caused by the occurrence of either 
ESRRA-like motifs, or FOS-JUN-like motifs. Most interestingly, these two clusters of motifs reflect 
structurally distinct classes of TFs; the negatively scoring eigenmotifs are characterized by binding of 
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nuclear receptor-type zinc finger domains, while the eigenmotifs with a positive score correspond to 
activator protein-1 (AP-1)-like leucine zipper domains. 
The second principal component corresponds to the strength of the binding signal for these 10 motifs, 
as confirmed by the robust negative correlation (r=-0.92) between the TFBSs posterior sum per peak 
and the peak’s projection along the second principal component (Suppl. Fig. S3B). 
 
 
Figure 3. PCA reveals FOS-JUN-like leucine zippers as a new class of putative functional PGC-
1α partners. 
(A) Sequence logo of the top position weight matrix discovered de novo by PhyloGibbs in the top 200 scoring 
peaks and of the corresponding canonical motif of ERRα as predicted by STAMP. 
(B) Top scoring results of motif search performed on all 7512 PGC-1α peaks with MotEvo. Motifs depicted in 
red and blue correspond to the clusters identified by PCA in panel D. 
(C) Fraction of explained variance of the top 10 PCA components. 
(D) PCA analysis of the 7512 PGC-1α peaks. Eigenmotif scores across Principal Component 1 (PC1) and 
Principal Component 2 (PC2) are shown. Red and blue ellipses highlight motif clusters, as identified by PC1, of 




2.3.4 Validation of top scoring motifs reveals novel functional partners of PGC-1α 
Our analysis identified a number of so-far uncharacterized TFs as potentially functional partners for 
PGC-1α-controlled gene expression in skeletal muscle cells. In order to experimentally validate some 
of these candidates, we sorted all TFs by a number of criteria including TFBS over-representation in 
binding peaks, MARA activity upon PGC-1α over-expression, and the expression pattern of the TFs 
themselves. Table 1 shows the top 15 ranked TFs according to this selection. As expected, the well-
known PGC-1α partner ERRα was identified as the most important factor. For our validation 
experiments, we chose the next two motifs (FOS_FOS(B,L1)_JUN(B,D) and ZNF143, which is also 
known as ZFP143) as well as three motifs from further down the list of the top 15 motifs (GTF2I, 
NFE2L2 and NFYC).  
FOS, the most up-regulated TF (log2 fold change = 1.78) among the TFs associated with the motif 
FOS_FOS(B,L1)_JUN(B,D), is a basic leucine zipper transcription factor known to heterodimerize 
with other leucine zipper proteins in order to form the AP-1 complex (26). The AP-1 complex 
furthermore contains JUN as well as ATF proteins. Thus, to dissect the function of the AP-1 protein 
complex, we also included JUN and ATF3, the most highly expressed isoforms of their respective 
protein families in muscle cells. 
For each of these 7 TFs (ATF3, FOS, GTF2I, JUN, NFE2L2, NFYC and ZFP143), we selected a 
dozen target genes based on the Chi2 score of the MARA prediction, presence of a PGC-1α binding 
peak with at least one predicted binding site for the factor of interest, and at least a 2-fold induction 
upon over-expression of PGC-1α. As summarized in Fig. 4 and Suppl. Fig. S4, siRNA-based 
knockdown of all TFs resulted in a robust reduction of the target mRNAs from -40% to -75%. With 
the exception of NFYC and JUN, we found that the large majority of predicted target genes were 
down-regulated upon knockdown of the factor, confirming our predictions (Fig. 4). The most 
consistent effects were observed for FOS and ZFP143 (all targets down-regulated), followed by 
GTF2I (11 out of 12 down-regulated) and NFE2L2 and ATF3 (10 out of 12 down-regulated). 
Interestingly, distinct target genes of the AP-1 complex showed differential responsiveness to 
knockdown of the three AP-1 complex components FOS, JUN and ATF3 (Fig. 4B, Fig. 4C and Fig. 
4D). Similarly, PGC-1α-mediated induction of a majority of the predicted target genes for NFE2L2 
(Fig. 4E), ZFP143 (Fig. 4F) and GTF2I (Fig. 4G) was reduced upon knockdown of the respective TF 
when compared to the expression in cells with overexpressed PGC-1α and a scrambled siRNA control. 
Surprisingly, only 1 of the 11 predicted target genes for NFYC that have been chosen for validation 
was significantly repressed by siRNA-induced reduction of this TF (Fig. 4H), suggesting that other 








Figure 4. Validation of TFs associated with top scoring motifs reveals novel functional PGC-1α 
partners. 
(A) siRNA-mediated knock-down efficiency for FOS. Bars represent fold induction over GFP/siCtrl value, error 
bars represent SEM. *p < 0.05; **p < 0.01; ***p < 0.001. See also Figure S4. 
(B-H) qRT-PCR analysis of PGC-1α target genes whose associated peak contains at least one binding site for the 
motif: FOS_FOS(B,L1)_JUN(B,D) (B-D), NFE2L2 (E), ZNF143 (F), GTF2I (G), NFY(A,B,C) (H). Bars 
represent % change compared to PGC-1α/siCtrl values. Error bars represent SEM. *p < 0.05; **p < 0.01; ***p < 
0.001. 
2.3.5 Functional interaction between PGC-1α and different compositions of the AP-1 protein 
complex 
Our targeted validation strategy revealed that PGC-1α target genes predicted to be regulated by the 
FOS-JUN-like motif react in distinct manners to siRNA-mediated knockdown of individual 
components of the AP-1 transcription factor protein complex. For example, some genes only reacted 
to reduction of FOS (Fig. 5A), while others were responsive to the knock-down of two (Fig. 5B) or 
even all three AP-1 protein partners (Fig. 5C) that we have tested using the siRNA-based approach. To 
further dissect the responsiveness of PGC-1α target genes to different AP-1 protein complexes, we 
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performed global gene expression arrays upon knockdown of each of the three TF components of the 
AP-1 complex. Fig. 5D depicts the number of genes that were induced by PGC-1α and that were, at 
the same time, down-regulated by the siRNA knockdown of any of the three AP-1 complex members. 
Amongst a total of 477 genes, 89% responded to FOS knockdown, 52% to ATF3 knockdown, and 
31% to JUN knockdown. Moreover, while 37% of all targets responded exclusively to FOS, the 
fraction of targets responding exclusively to either JUN or ATF3 was at most 5%. This analysis shows 
that, whereas different target genes respond differently to the knock-down of distinct AP-1 
components, FOS is the dominant factor in determining AP-1 function in these conditions. 
As shown in Fig. 3B, 341 genes were associated to a PGC-1α binding peak containing a predicted site 
for the FOS-JUN-like motif bound by the AP-1 complex. Of these genes, the expression of 55 was 
significantly induced by PGC-1α over-expression in muscle cells. In our siRNA-based validation 
experiment, we found that 47 out of these 55 PGC-1α-induced/AP-1 predicted targets were 
significantly down-regulated by knockdown of the AP-1 complex components and we called these 
genes “direct PGC-1α/AP-1 targets”. The remaining 430 genes out of 477 (Fig. 5D) were defined 
accordingly as “indirect PGC-1α/AP-1 targets” that lack a PGC-1α peak containing a FOS-JUN-like 
motif, but still are regulated by PGC-1α and the AP-1 protein components (Fig. 5E). To reveal 
whether these gene categories exert distinct functions, GO and KEGG enrichment analyses were 
performed. Surprisingly, the 47 direct PGC-1α/AP-1 target genes showed a distinct and significant 
over-representation of the terms “response to hypoxia” (GO ID: 0001666; adjusted p-value: 
0.0247542) and “mTOR signaling pathway” (KEGG ID: mmu04150; adjusted p-value: 0.030674) that 
were absent in the GO analysis of the remaining PGC-1α/AP-1 targets (Fig. 5F). These results suggest 
that AP-1, when coactivated by PGC-1α, drives a synergic effect of response to hypoxia; on the other 
hand, when AP-1 and PGC-1α act separately, and furthermore through downstream intermediate TFs, 
they regulate the expression of genes involved in mitochondrial organization and energy metabolism 







Figure 5. PGC-1α controls the hypoxia gene program via a functional interaction with different 
configurations of the AP-1 protein complex. 
(A-C) qRT-PCR analysis of Cdk15, Nppb and Slc6a19 mRNA levels in response to PGC-1α over-expression and 
either siFos, siJun or siAtf3 knock-down. Data are normalized to mRNA levels in GFP infected cells. Error bars 
represent ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001. 
(D) Venn diagram illustrating the overlap in number of genes up-regulated by PGC-1α and down-regulated by 
either FOS, JUN or ATF3 knock-down. 
(E) Histogram illustrating the number of direct and indirect PGC-1α/AP-1 target genes. 
(F) Subset of the top significantly enriched Gene Ontology and KEGG terms identified for the two gene groups 
illustrated in panel (E). 
(G) Schematic representation highlighting the functional link between PGC-1α and AP-1 in terms of directly and 
indirectly regulated signaling pathways. Dashed lines indicate that the protein might or might not be present at 
the site. 
(H) Schematic representation depicting the downstream effects of the functional interaction between PGC-1α 
and the AP-1 complex in the context of the hypoxia gene program. Direct targets of PGC-1α and AP-1 are 




Exercise-induced skeletal muscle cell plasticity is a highly complex biological program that involves 
the remodeling of a number of fundamental cellular properties. Since PGC-1α function has been 
strongly linked to the induction of an endurance-trained muscle phenotype, we here dissected the 
PGC-1α-controlled transcriptional network in muscle cells. First, our results reveal a broad recruitment 
of PGC-1α to many different sites in the mouse genome (7512 peaks), the majority of which were 
either not located within 10 kb distance of a TSS or close to a gene that was not regulated by PGC-1α 
over-expression at the time of harvest of the cells, as has analogously been observed in many other 
ChIP-Seq experiments (e.g. see (19)). Apart from the fact that PGC-1α could mediate long-range 
enhancer effects that were excluded in our peak-gene assignment, it is conceivable that PGC-1α 
recruitment is transcriptionally silent in some binding peaks because it requires the recruitment of 
additional cofactors for activation, which are not present in the conditions or cell type in which our 
experiments were performed. In addition, it is possible that a large fraction of PGC-1α binding peaks 
may be “neutral” in the sense of not having any direct role in regulating gene expression. 
Second, while an almost equally strong effect of PGC-1α on gene induction and repression has been 
reported (18), our analysis now indicates that direct PGC-1α-mediated gene expression is restricted 
almost exclusively to positively regulated PGC-1α target genes, whereas the vast majority of gene 
repression is indirect, i.e. not associated with PGC-1α recruitment within a 10 kb distance to their 
promoters. Thus, the fact that almost 95% of all repressed genes were not linked to PGC-1α 
recruitment strongly implies that this coregulator primarily acts as a coactivator, and not as a 
corepressor as suggested by the data of some studies (27-29). Importantly, indirect repression of PGC-
1α target genes was also supported by the MARA prediction. The strong indirect inhibition of genes, 
many of which are involved in inflammatory processes, is predicted by MARA to be mediated by TFs 
such as NFκB and IRF factors. Such an indirect inhibition of NFκB and pro-inflammatory genes by 
PGC-1α in muscle cells has been reported previously (22). 
One of the main functions of PGC-1α in all cells and organs is to boost mitochondrial gene 
transcription and oxidative metabolism. Accordingly, we observed that Gene Ontology terms related 
to these pathways were highly enriched when analyzing positively regulated PGC-1α target genes in 
muscle cells. Based on previous studies, the regulation of this core function could have been assigned 
to the direct interaction of PGC-1α and ERRα binding to regulatory elements of these genes (18, 21). 
Surprisingly, our data indicate that many of the genes that are involved in oxidative metabolic 
pathways are indirectly controlled by PGC-1α and, hence, do not require PGC-1α recruitment to 
enhancer and promoter elements. Likewise unexpectedly, the MARA analysis implies ERRα action on 
direct and indirect PGC-1α-induced target genes, i.e. in the presence or absence of PGC-1α 
coactivation. Thus, while these observations might obviously reflect a temporally distinct control of 
different PGC-1α target genes that is not represented in our simultaneous analysis of DNA binding and 
gene expression at one time point, it is conceivable that PGC-1α acts primarily as an upstream 
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regulator of other factors that are subsequently controlling more downstream PGC-1α target genes 
without direct involvement of PGC-1α itself. 
In skeletal muscle, PGC-1α has been reported to interact with ERRs, PPARs and other nuclear 
receptors, as well as myocyte enhancer and nuclear respiratory factors to mediate transcriptional 
regulation (3). Accordingly, ERRα and other nuclear receptor binding motifs were amongst the most 
highly significant binding elements in our present report. Importantly however, we also predict a 
number of so-far unknown TFs to functionally interact with PGC-1α and thereby contribute to PGC-
1α-controlled gene expression in skeletal muscle. Since a complete functional validation of all new 
putative TF partners is beyond the scope of this manuscript, we combined the high-throughput results 
with several computational analyses (see Table 1) to select and test some of the potentially most 
important factors together with predicted target genes. Notably, in siRNA-based knockdown 
experiments, we could show that depletion of FOS and its putative AP-1 multimerization partners JUN 
and ATF3 as well as NFE2L2, ZFP143 and GTF2I in muscle cells reduced the ability of PGC-1α to 
positively regulate target genes, confirming a functional interaction between these TFs and PGC-1α. 
Thus, our results indicate that the coactivation repertoire of PGC-1α in muscle exceeds the prediction 
of previous studies by far. For example, even in our list of the top 15 motifs, several predicted TFs 
have not yet been investigated in the context of PGC-1α-controlled gene expression, including BPTF, 
FOSL2, REST or RREB1. Future studies will aim at a more detailed dissection of the global 
functional consequences of PGC-1α coactivation of these TFs in muscle cells. 
Curiously, almost all of our analyses, and in particular the principal component analysis, highlighted 
the relevance of FOS-JUN-like motifs. In fact, the largest amount of variation in TFBS occurrence 
within PGC-1α binding peaks results from either ESRRA-like or FOS-JUN-like motifs. The FOS-
JUN-like motif, in particular, embodies the main binding elements of the AP-1 complex, which 
consists of different configurations of FOS, JUN, ATF and MAF proteins (26, 30). Our data 
comparing gene expression in cells with reduced FOS, JUN and ATF3 levels indicate that PGC-1α 
functionally interacts with the AP-1 complex in different configurations in the regulation of specific 
genes. The differential requirement observed for distinct AP-1 components might provide an 
additional layer of control for specific PGC-1α target gene regulation. 
AP-1 function itself is regulated by a variety of stimuli, including cytokines, growth factors and stress, 
and subsequently controls a number of cellular processes including apoptosis, cell proliferation and 
differentiation, stress response and hypoxia (30, 31). Mechanistically, we classified PGC-1α-
induced/AP-1-knocked-down targets in either direct or indirect genes. Most interestingly, functional 
analysis of these two groups of genes revealed that when AP-1 and PGC-1α act disjointedly, they are 
involved in the regulation of mitochondrial and other metabolic genes while, when coactivated by 
PGC-1α, AP-1 distinctly alters the expression of genes that are enriched in the ontology terms 
“response to hypoxia” and “mTOR signaling” (Fig. 5G). Intriguingly, a closer analysis of all 47 direct 
AP-1/PGC-1α target genes revealed 24 genes that are induced by hypoxia, are effectors of hypoxia or 
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attenuate the detrimental consequences of hypoxia (Fig. 5H). For example, several inhibitors of the 
mTOR signaling pathways are included in this group of genes and hypoxia has been described as a 
suppressor of mTORC1 activity (32). Another group of genes contributes to the reduction of cellular 
stress, detrimental metabolites, reactive oxygen species and increase in cellular survival to reduce 
potential harmful consequences of prolonged hypoxia (33). Furthermore, several genes promote 
endothelial regeneration, vascular remodeling and vascularization (34). In this context, PGC-1α has 
previously been shown to promote vascular endothelial growth factor (VEGF)-induced angiogenesis 
in skeletal muscle in a hypoxia-inducible factor 1α (HIF-1α)-independent, ERRα-dependent manner 
(35). Similarly, PGC-1α regulates the hypoxic response of brown fat (36), neuronal and endothelial 
cells (37) even though the mechanisms of cellular protection exerted by PGC-1α in these experimental 
contexts have not been elucidated. Our findings now indicate that, to ensure adequate oxygen and 
nutrient supplies for oxidative metabolism in skeletal muscle cells, PGC-1α might coordinate 
metabolic needs through ERRα-induced Vegf expression with a broad, stress-induced AP-1-dependent 
hypoxia program. 
In summary, our data provide a first insight into the transcriptional network controlled by PGC-1α in 
muscle cells. While one other study of global DNA recruitment of PGC-1α has been performed in the 
human hepatoma cell line HepG2 (38), our results highlight the importance of combining ChIP-Seq 
experiment, transcriptional data together with a comprehensive computational modeling approach and 
experimental validation of predicted key regulators, in order to be able to discover mechanistic as well 
as functional outcomes of such a network. Combined with the knowledge of transcriptional regulation, 
posttranslational modifications, alternative splicing and recruitment of different chromatin remodeling 
protein complexes, a scenario can thus be conceived in which PGC-1α is able to control and integrate 
different signaling pathways using a multitude of different transcription factor binding partners (10, 
11). A better understanding of such regulatory networks will eventually allow the targeting of whole 




Cell culture and siRNA transfection 
C2C12 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% 
fetal bovine serum (FBS), 100 Units/ml penicillin and 100ug/ml streptomycin. To obtain myotubes, 
the C2C12 myoblasts were allowed to reach 90% confluence and the medium was changed to DMEM 
supplemented with 2% horse serum (differentiation medium) for 72 hours. 
The siRNAs for the knock-down of NFE2L2, FOS, JUN, ATF3, NFYC, ZFP143, GTF2I, the non-
targeting siRNA pool and the DharmaFECT1 transfection reagent were purchased from Dharmacon 
(Fisher Scientific) and the siRNA transfection was performed according to the Thermo Scientific 
DharmaFECT Transfection Reagents siRNA Transfection Protocol. Briefly, after three days of 
differentiation, the respective siRNAs (50nM final concentration) was added to the medium. 24h after 
siRNA transfection, the cells were infected with either the PGC-1α or GFP adenovirus. Then, 48h after 
adenoviral infection, the cells were harvested. 
 
ChIP and ChIP Sequencing 
ChIP was performed according to the Agilent Mammalian ChIP-on-chip Protocol version 10.0. For 
detailed protocol see Supplemental Information. 
 
Identification of bound regions 
To identify regions that were significantly enriched in the ChIP, we passed a 200 bps long sliding 
window along the genome, sliding by 25 bps between consecutive windows, and estimated the fraction 
of all ChIP reads fIP that fall within the window, as well as the fraction fWCE of reads from the whole 
cell extract that fall in the same window (which we estimate from a 2000 bps long window centered on 
the same genomic location). A Z-score quantifying the enrichment in the ChIP of each window was 
computed as: 
𝑍 = 𝑓𝐼𝑃 −  𝑓𝑊𝐶𝐸
�𝜎2𝐼𝑃 + 𝜎2𝑊𝐶𝐸 
where 𝜎2𝐼𝑃 and 𝜎
2
𝑊𝐶𝐸 are the variances of the IP and WCE read frequencies, which are given by: 
𝜎2𝐼𝑃 =  𝑓𝐼𝑃∗ (1− 𝑓𝐼𝑃)𝑁𝐼𝑃  and 𝜎2𝑊𝐶𝐸 =  𝑓𝑊𝐶𝐸 ∗ (1 − 𝑓𝑊𝐶𝐸)𝑁𝑊𝐶𝐸  
respectively. 
The enrichments were reproducible across biological replicates. Using only the first sequencing 
dataset, we called peaks at a Z cutoff of 4.5; we then compared these with the Z scores from the 
corresponding regions of the second dataset and the Pearson correlation coefficient was found to be 
0.778. Similarly, we called peaks at a Z cutoff of 4.5 using only the second sequencing dataset; when 
we compared these peaks with the Z scores of the corresponding regions from the first dataset, the 
Pearson correlation coefficient was found to be 0.782. 
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To obtain a final set of binding peaks, we combined the reads from the two biological replicates 
computing the Z score of each window was computed as:  
𝑍 =  𝑓𝐼𝑃1+ 𝑓𝐼𝑃2− 𝑓𝑊𝐶𝐸1− 𝑓𝑊𝐶𝐸2
�𝜎2𝐼𝑃1+ 𝜎2𝐼𝑃2+ 𝜎2𝑊𝐶𝐸1+ 𝜎2𝑊𝐶𝐸2. 
We conservatively considered all windows with a Z-score larger than 4.5 as were considered 
significantly enriched (False Discovery Rate 0.6%). The final binding peaks were obtained by merging 
consecutive windows that all passed the cut-off and by considering the “peak” to correspond to the top 
scoring window, i.e. corresponding to the summit of the ChIP-Seq signal. To determine the PGC-1α 
distribution genome-wide, peaks were annotated according in relation to their closest Mus musculus 
RefSeq transcripts. We defined peaks as: “Intronic” (peak center lying inside an intron); “Exonic” 
(peak center lying inside an exon); “Upstream of TSS” (peak center lying within -10 to 0 kb from the 
closest TSS); “Downstream of TES” (peak center lying within 0 to 10 kb from the closest TES); 
“Intergenic” (peak center located farer than 10 kb from the nearest transcript). Moreover, we 
computed the ratio between observed and expected peak location distributions, obtained by generating 
100 peak sets composed of 7512 random peaks each. 
 
Motif finding and TFBSs over-representation 
The binding peak regions were aligned to orthologous regions from other 6 mammalian species – 
human (hg18), rhesus macaque (rheMac2), dog (canFam2), horse (equCab1), cow (bosTau3) and 
opossum (monDom4) – using T-Coffee (39). A collection of 190 mammalian regulatory motifs 
(position weight matrices or WMs) representing the binding specificities of approximate 350 mouse 
TFs (in many cases, sequence specificities of multiple closely-related TFs were represented with the 
same WM) were downloaded from the SwissRegulon website (19). TFBSs for all known motifs were 
predicted using the MotEvo algorithm (40) on the alignments of all the 7512 peak sequences. Only 
binding sites with a posterior probability >= 0.1 were considered for the further steps of the analysis. 
In order to create a background set of regions to assess the overrepresentation of binding sites within 
our regions, we created randomized alignments by shuffling the multiple alignment columns, 
maintaining both the gap patterns and the conservation patterns of the original alignments. TFBSs 
were predicted on the shuffled alignments using the same MotEvo settings as for the original peak 
alignments. Over-representation of motifs in the PGC-1α binding peaks was calculated by comparing 
total predicted TFBS occurrence within binding peaks with the predicted TFBS occurrence in the 
shuffled alignments. We evaluated the enrichment of TFBSs for each motif x by collecting the sum 𝑛𝑥 
of the posterior probabilities of its predicted sites in the peak alignments as well as the corresponding 
sum 𝑛′𝑥 in the shuffled alignments, and computed a Z-score: 
𝑍 =  𝑓𝑥 −  𝑓′𝑥
�𝑓𝑥 ∗
(1 −  𝑓𝑥)
𝐿𝑥





where 𝐿𝑥 and 𝐿′𝑥 are the total lengths of the original and shuffled alignments, respectively, while 𝑓𝑥 
and 𝑓′𝑥 are given by the equations: 
𝑛𝑥 ∗  𝑙𝑥 =  𝑓𝑥 ∗  𝐿𝑥  and 𝑛′𝑥 ∗  𝑙𝑥 =  𝑓′𝑥 ∗  𝐿′𝑥 
with 𝑙𝑥 the length of motif x. 
 
Principal Component Analysis of TFBS occurrence in binding peaks 
The input matrix N for the Principal Component Analysis (PCA) contained the total number of 
predicted binding sites Npm in each of the 7512 binding peaks p (rows) for each of the 190 mammalian 
regulatory motifs m (columns). After mean centering the columns of this matrix, 𝑁�𝑝𝑚 = 𝑁𝑝𝑚 − 〈𝑁𝑚〉, 
i.e. subtracting the average site count for each motif), Singular Value Decomposition (SVD) was used 
to factorize this matrix: 𝑁� = 𝑈 ∙ 𝑆 ∙  𝑉𝑇, where 𝑈 is an 𝑃 × 𝑀 matrix whose columns are the left 
singular vectors of 𝑁� ; 𝑆 is a 𝑀 × 𝑀 diagonal matrix containing the singular values, and 𝑉𝑇 (the 
transpose of 𝑉) is an 𝑀 × 𝑀 matrix whose rows are the right singular vectors, with P the number of 
peaks, and M the number of motifs. The SVD was performed using the “svd” package of the “R” 
programming language. 
 
Gene expression arrays 
Whole-gene expression after 48 hours of transfection with adenovirus was measured in C2C12 cells 
with Affymetrix GeneChip® Mouse Gene 1.0 ST microarrays at the Life Science Training core 
facility of the University of Basel. Raw probe intensities were corrected for background and unspecific 
binding using the Bioconductor package “affy” (41). Subsequently, probes were classified as 
expressed or non-expressed by using the “Mclust” R package (42) and, after removal of non-expressed 
probes, the intensity values were quantile normalized across all samples. Using mapping of the probes 
to the UCSC collection of mouse mRNAs, probes were then associated to a comprehensive collection 
of mouse promoters available from the SwissRegulon database (19). The log2 expression level of a 
given promoter was calculated as the weighted average of the expression levels of all probes 
associated to it. Log2 expression levels were then compared between over-expressed PGC-1α and the 
control GFP sample; for each promoter, the change in expression level across the two conditions was 
measured by log2 fold change (log2FC), computed as the difference between the mean of the log2 
values in PGC-1α and the mean of the log2 values in GFP. The significance of the expression change 
was assessed by a Z score, which was computed as: 




𝑛 +  𝜎2𝐺𝐹𝑃𝑛  
where 𝑛 = 3 was the number of replicate samples, 𝐸�𝑃𝐺𝐶1𝛼 is the mean log2 expression across the 





are the variances of log2 expression levels across the replicates for the PGC-1α and control samples, 
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respectively. Promoters were considered significantly up-regulated when log2FC >= 1 and Z >= 3, and 
significantly down-regulated when log2FC <= -1 and Z <= -3. 
Peaks were assigned to promoters by proximity. To assign each peak to a promoter, we calculated the 
distance from the center of the peak to the center of neighboring promoters; whenever the peak was 
closer than 10 kb from at least one promoter, it was assigned to the nearest promoter and, thus, to its 
associated gene. 
 
Gene Ontology enrichment analysis 
Gene IDs were extracted from differentially regulated promoters and divided in four groups: up-
regulated promoters with an assigned binding peak, up-regulated promoters without an assigned 
binding peak, down-regulated promoters with an assigned peak, and down-regulated promoters 
without an assigned peak. These four gene sets were used as input for the functional analysis tool 
FatiGO (43) to identify significantly over-represented Gene Ontology (GO) categories compared to all 
Mus musculus genes. Only GO terms having an FDR-adjusted p-value <= 0.05 were considered 
significant. 
 
Motif activity at direct and indirect targets of PGC-1α 
To integrate the information from the PGC-1α binding peaks, we extended MARA (20) to model the 
direct and indirect regulatory effects of PGC-1α. Given the input expression data and the 
computationally predicted binding sites, MARA infers, for each of 190 regulatory motifs m, the 
activity Ams of the motif in each sample s when the motif occurs outside of a region of PGC-1α, and 
the activities A*ms of the motifs when they occur within a PGC-1α binding peak. That is, changes in the 
motif activities Ams upon over-expression of PGC-1α indicate indirect regulatory effects of PGC-1α on 
each motif m, whereas changes in the motif activities A*ms reflect direct regulatory effects of PGC-1α 
as mediated by each motif m. For each promoter p that was not associated with any PGC-1α binding 
peak (which we denote indirect targets), we modeled its log-expression in sample s, eps, in terms of the 
predicted number of TFBSs Npm that occur in the proximal promoter region (running from -500 to 
+500 relative to TSS) for each regulatory motif m. That is, MARA assumes the linear model: 
𝑒𝑝𝑠 = 𝑐𝑝 + ?̃?𝑠 + � 𝑁𝑝𝑚𝐴𝑚𝑠
𝑚
 
where cp is the basal expression of promoter p, ?̃?𝑠 is a sample-dependent normalization constant, and 
𝐴𝑚𝑠 is the regulatory activity of motif m in sample s, which is inferred by the model. Formally, 𝐴𝑚𝑠 
quantifies amount by which the expression of promoter p in sample s would be reduced if a binding 
site for motif m were to be deleted from the promoter.  
For each “direct target” promoter p that has that has an associated PGC-1α binding peak, which we 
defined as promoters with a peak within 1 kb or with a peak within 100 kb that was highly conserved 
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according to PhastCons score of the region (44), we model its expression in terms of the predicted 
TFBSs in the binding peak, i.e.: 




∗  is the number of predicted TFBSs for motif m in the peak associated with promoter p, and 
𝐴𝑚𝑠
∗  is the motif activity of regulator m in sample s when this motif occurs in the context of PGC-1α 
binding. That is, the inferred motif activities 𝐴𝑚𝑠 quantify the activities of regulatory motifs when 
they occur independent of PGC-1α binding, and the motif activities 𝐴𝑚𝑠
∗  quantify the activities of 
motifs when they occur in a PGC-1α binding peak, i.e. the latter activities reflect direct effects of a 
PGC-1α while the former reflect indirect effects.  
MARA predicts activities for 190 different mammalian regulatory motifs, associated with roughly 350 
mouse TFs. Besides motif activities MARA also calculates error-bars 𝛿𝑚𝑠 for each motif m in each 
sample s. Using these, MARA calculates, for each motif m, an overall significance measure for the 
variation in motif activities across the samples analogous to a z-statistic: 
𝑧𝑚 = �1𝑆� (𝐴𝑚𝑠)2𝑚  
For each motif we calculate both a z-score 𝑧𝑚 associated with its indirect activity changes, and a z-
score 𝑧𝑚
∗  associated with its direct activity changes. MARA also ranks the confidence on predicted 
target promoters of each motif by a Bayesian procedure that quantifies the contribution of that factor 
to explaining the promoter’s expression variation by a Chi-squared value (for details, see (20)). The 
parameters used for motif stratification were: (i) the Z score 𝑧𝑚
∗  for direct activity changes, (ii) the Z 
score 𝑧𝑚 for indirect motif activity changes, (iii) the Z score 𝑧?̅?
∗  for direct motif activity changes, 
computed by averaging the sample replicates and (iv) the Z score 𝑧?̅? for indirect motif activity 
changes, computed by averaging the sample replicates. The latter two measures were used to show 
which direction the motif activity changes when over-expressing PGC-1α with respect to the control 
condition. All motifs m for which either the direct or indirect motif activities were changing 
significantly (𝑧 ≥ 2) were subsequently selected. 
 
De novo motif finding 
PhyloGibbs (23) was used to identify de novo motifs across the 200 top enriched PGC-1α peaks. The 
parameters used were -D 1 -z 1 -y 200 -m 10, corresponding to searching on multiple alignments for a 
single motif of length 10 with a total of 200 sites. The resulting motif was scanned for similarity to the 
other known motifs from our dataset using STAMP (24), with settings: Pearson Correlation 
Coefficient for column comparison metric, Smith-Waterman for the alignment method, penalty of 0.5 




Real-time PCR and target gene validation 
Putative target genes of distinct transcription factor-PGC-1α combinations were chosen according to 
three criteria: first, positive transcriptional regulation by PGC-1α by more than 2 fold, second, 
presence of a PGC-1α binding peak within a 10 kb distance from the TSS and third, prediction of 
targeting by MARA with a positive Chi-squared score. The sequences of the primers used in real-time 
PCR experiments are depicted in Suppl. Table 1. The values are presented as the mean +/- SEM. A 
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2.7 Supplemental Methods 
ChIP and ChIP Sequencing 
For each immunoprecipitation, approximately 1x108 C2C12 cells were differentiated into myotubes 
and infected with Ad-flag-PGC-1α. For cross-linking protein complexes to DNA binding elements, the 
cells were incubated in a 1% formaldehyde solution for 10 minutes, followed by the addition of 
glycine to a final concentration of 125mM to quench the effect of the formaldehyde. The cells were 
rinsed in 1xPBS, harvested in ice-cold 1xPBS using a silicone scraper and pelleted by centrifugation. 
The pelleted cells were either used immediately or flash frozen and stored for later. The cells were 
then lysed at 4°C using two lysis buffers containing 0.5% NP-40/0.25% Triton X-100 and 0.1% Na-
deoxycholate/0.5% N-lauroylsarcosine, respectively. The chromatin was then sheared by sonication to 
obtain DNA fragments of about 100-600bp in length. 50μl of the sonicated lysate was saved as input 
DNA. The immunoprecipitation was performed overnight at 4°C using magnetic beads (Dynabeads® 
Protein G, Invitrogen), which were previously coated with monoclonal anti-flag antibodies 
(Monoclonal ANTI-FLAG® M2 Antibody, Sigma). The beads carrying the precipitate were washed 
six times with RIPA buffer and once with TE that contained 50mM NaCl to eliminate unspecific 
binding of DNA to the beads. For elution, the beads were resuspended in elution buffer containing 1% 
SDS, placed in 65°C water bath for 15 minutes and vortexed every 2 minutes. To reverse the cross-
links, the samples were incubated at 65°C overnight. The following day, the RNA and the cellular 
proteins were digested using RNase A and proteinase K. The DNA was precipitated and used for 
sequencing after success of the chromatin immunoprecipitation was validated by semiquantitative real-
time PCR. 
The ChIP-Seq experiment of over-expressed PGC-1α in C2C12 cells was performed in biological 
duplicates. At the joint Quantitative Genomics core facility of the University of Basel and the 
Department of Biosystems Science and Engineering (D-BSSE) of the ETH Zurich in Basel, DNA 
libraries were prepared using the standard Illumina ChIP-Seq protocol, as described by the 
manufacturer, and the immunoprecipitated samples sequenced on the Genome Analyzer II. 
In order to keep only high quality data, the sequenced reads were filtered based on the quality score of 
each read and its alignments. Read were retained when Phred score >= 20, read length >= 25 bps and 
number of wrongly called nucleotides (Ns) <= 2. Those reads that passed the filter, (6’711’717 for the 
first immunoprecipitated sample (IP), 36’580’431 for the second IP, 17’899’074 for the first Whole 
Cell Extract (WCE), and 35’525’221 for the second WCE), were aligned to the mouse genome, UCSC 
mm9 assembly, using Bowtie version 0.12.7 (1) using parameters --best --strata -a --m 100. The 
number of aligned reads equaled 5’699’648 for the first IP sample, 16’053’370 for the first WCE, 




2.8 Supplemental Figures and Tables 
Suppl. Fig. S1. Peak Z score distribution and KEGG functional analysis. Related to Figure 1. 
(A) Distribution of the Z scores for all sliding windows considered by the peak-finding algorithm along the 
mouse genome. The chosen cutoff for peak calling is depicted by the dotted line. 
(B) Subset of the top significantly enriched KEGG terms identified for direct and indirect up-regulated PGC-1α 
target genes. 
(C) Subset of the top significantly enriched KEGG terms identified for direct and indirect down-regulated PGC-
1α target genes. 
(D) ChIP-Seq signal around the promoter region of the five directly down-regulated genes (Cacna1s, Mybph, 
Myh1, Myh4, Pfkfb3) involved in regulating the contractile properties of fast-twitch muscle fibers. 
 
Suppl. Fig. S2. Motif activities clustered by Z score in direct/indirect activation/repression. 
Related to Figure 2. 
(A) Motifs showing different types of regulation (1=yes, 0=not). 
 
Suppl. Fig. S3. PC2 interpretation and enriched motifs in “non ESRRA-like” peaks. Related to 
Figure 3. 
(A) Top scoring results of motif search performed on the 3656 “non ESRRA-like” peaks with MotEvo. 
(B) Correlation between Principal Component 2 scores and binding site posterior sum for each peak relative to 
the top 10 PCA motifs. “r” refers to the Pearson correlation coefficient. 
 
Suppl. Fig. S4. siRNA knock-down efficiency for the putative PGC-1α partner TFs. Related to 
Figure 4. 
(A-F) siRNA knock-down efficiency for ATF3 (A), GTF2I (B), JUN (C), NFE2L2 (D), NFYC (E) and ZFP143 
(F) knock-down. Bars represent fold change over GFP/siCtrl levels. Error bars represent SEM. *p < 0.05; **p < 
0.01; ***p < 0.001. 
 


























Real-time PCR primers used for testing the efficiency of the ChIP 
gene promoter or intron forward primer reverse primer 
Tbp intron TGTGAGCTCCTTGGCTTTTT ATAGTTGCCCAGCAATCAGG 
promoter of Aco2 CACCGATAGTTGCTTTCCAGATAC AACCATCTGACAGGCATAGTCAAT 
promoter of Cycs AAGGGCGCCCTCTGGGCACATC  ATCCCCGTCGCGCGCTCACCG 
promoter of Acadm CCTTGCCCGAGCCTAAAC GTCTGGCTGCGCCCTCT 
promoter of Atp5b CTGGAAACTTCCACCCTCACTA GAGAGGTTTTTGGCGGAACTA 
promoter of Idh3a GGACGGCGTCAAGGTCAAG GCCTAGGTGGCCTGTCTGTG 
   Real-time PCR primers used for testing the knock-down efficiency by siRNAs 
gene forward primer reverse primer 
Rn18s AGTCCCTGCCCTTTGTACACA CGATCCGAGGGCCTCACTA 
Fos TACTACCATTCCCCAGCCGA GCTGTCACCGTGGGGATAAA 
Jun TGGGCACATCACCACTACAC TCTGGCTATGCAGTTCAGCC 
Atf3 TCTGCGCTGGAGTCAGTTAC CCGCCTCCTTTTCCTCTCAT 
Gtf2i TTCGAAGGCTTTGCAAGGAAG TTCGGGGTCCTCACTGGTTT 
Nfe2l2 AGTGGATCCGCCAGCTACTC ATGGGAATGTCTCTGCCAAA 
Nfyc CCACCAGTTCTACGACCACC GGCCTGTACAATCTGCACCT 
Zfp143 GTGGTCGGTCCTTTACCACA AAATGCCCTCCCACATCCAG 
   Real-time primers used for target gene validation   
gene forward primer reverse primer 
Aim1l CCTGTTGCGTCCATAAGGGT GCTCTGAGTTCCACATCCCC 
Atp1b1 GCTACGAGGCCTACGTGCTA TGCCACAGTCCTCGAAAATC 
Atp5g1 CAGAGGCCCCATCTAAGCAG TGTCCCGGGAAATGACACTG 
Cdk15 ATGCAGTTGCTACCACCGTT CCGTGGAACTGGATGCTTCT 
Cdr2l GGAACAGGAAAACGAACGGC ACCACCGTGTACTCACGTTC 
Dot1l TGACCTCAGATGAGGAGCCA TGTCTTCGGGGGAGATTTGC 
Eef1a2 CAAGATGGACTCCACGGAAC CTGGGTTGTAGCCGATCTTC 
Eif2b4 ACGGCAAGACCCAATCAGAG AAGTTCTGCCTTACTCCGGC 
Fa2h GTGGACTGGCAGAAACCTCT TCTGAGTGGAAGAGGCGAAT 
Fabp3 CATGTGCAGAAGTGGAACGG CTCACCACACTGCCATGAGT 
Fam131c CTGGCTACGTCATCCCTTGT TCCAGCCTTTCCACTCGAT 
Gabpa GTCGAGGTGGTCATCGATCC GTAATGTGCTTGGTGCCGTC 
Gdf15 CACGCATGCGCAGATCAAAG TGTGCATAAGAACCACCGGG 
Gtpbp2 TGGAAACCTCAAAGCTCGGG GTACGGAGGGTTGTTGGCTT 
Il1a TGCAAGCTATGGCTCACTTC GATACTGTCACCCGGCTCTC 
Inpp5j ACAAGGGCGGAGTAAGTGTG TGAAAGTTATCCTTGCGCTGT 
Jam2 GTATTACTGCGAAGCCCGGA CAACCGTTGCTATGATGCCG 
Ldhb GACTCCGAAAATTGTGGCCG TTCTCTGCACCAGGTTGAGC 
Lpin1 CGGCCCTCAACACCAAAAAG AATTCACCCCACAGCCAGAG 
Lrrc2 GTGGAAGGAGCTGCCTGATT AACAGCTCGATGTACGTGGG 
Met GCTGAGAAACTCTTCCGGCT AGCCGGCCCATGAATAAGTC 
Ndufa9 TTCTGTGGCTCATCCCATCG TGTAGCCCCAAACACAGTGG 
Nmnat1 GGTCGGTGATGCGTACAAGA CCACGTATCCACTTCCACCC 
Nppb GGCCTCACAAAAGAACACCC TGCCCAAAGCAGCTTGAGAT 
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Nr0b2 CCTCTTCAACCCAGATGTGC GGGCTCCAAGACTTCACACA 
Osbpl1a TCCCCCAATCAGTGCATTCC GCTTCTACACTCTTGCCCCA 
Qrsl1 GTTGGATCAGGGTGCCCTAC GGGGTTTCTAACTGGCCCAA 
Rasl10b AGACCTGGAAGTGCGGCTAC GGCAGCGTGCACGTGTTT 
Rrm2 TTGCAGCGAGTGATGGCATA CCATGGCAATTTGGAAGCCA 
Samm50 TTTTGATGGACTTGGGCGGA TGAGATCGCCGCATTACCTC 
Slc25a4 GGTACTTCCCCACTCAAGCC AGCAAAGTAGCGCCAGAACT 
Slc25a35 TAGTCGTGGCAATGACACCC TCCAAGATCCCCCGGTACAT 
Slc6a19 TCCACTCAACCAGAACCAGAC TGAGTCACTGATGGAAGTGGAG 
Srxn1 CCAGGGTGGCGACTACTACT AGGTCTGAAAGGGTGGACCTC 
Stard7 CTCTACGGCCGCCTGTATTC CGCCATCAAAACAGAGGCAT 
Stk19 GTCCTCACTGTCCGAGATGC CACCATGCTCAGTACAGCCT 
Syt7 ACTGGGCAAACGCTACAAGA TGCAGGCAACTTGATGGCTT 
Tbrg4 AACGACAGCCGTACATTGGT AGCTCCAGGCACTTGTCTTC 
Tfam GAGCGTGCTAAAAGCACTGG GCTACCCATGCTGGAAAAACA 
Tinagl1 TTCTTGTACCAGCGTGGCAT CCCCACCCAGTGATCTTGAC 
Tomm5 CGGAGGAGATGAAGCGGAAG TATGGAGTGACTCGCAGCAG 
Trak2 GCTGAAGAGACGTTCCGCTA ATCTCGATCCCTCTCTGCCA 
Trmt61a GCTCCTTCTCTCCGTGCATT TGCGCACATTGTAGACCTGT 
Trp53inp2 TACCCCTCCCGCCTGTTTTA CTGCCGGTGACATAAACGGA 
Ttc7b TGCTCCCCACGATCAAGAAC ATCTCCCGACTCCTCTCGTC 
Tusc2 GCAGTGCCTCCCTTCGTATT CTGCCCATTCTTGGTGACGA 
Twf2 TGCTACCTCCTCTTCCGACT ATAGCATCTTCAGCCGCACC 
Wnt7b TTTCTCTGCTTTGGCGTCCT GGCCAGGAATCTTGTTGCAG 
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Skeletal muscle tissue reacts to exercise training by inducing changes, which allow the muscle to adapt 
to increased physical activity. The transcriptional coactivator PGC-1α is induced by exercise and 
subsequently mediates all exercise-induced adaptations of skeletal muscle by coordinating the activity 
of key transcription factors like the ERRα. Although ERRα is established as an effector of PGC-1α 
transcriptional activity, it is not clear to which extent PGC-1α requires ERRα to induce its target genes 
and how precisely this transcriptional network regulates gene expression. By performing genome-wide 
chromatin occupation studies we mapped the recruitment of PGC-1α and ERRα to DNA and thereby 
identified which subset of PGC-1α target genes is regulated by direct binding of PGC-1α, ERRα or 
both factors together. Surprisingly, we revealed that ERRα can occupy promoters of PGC-1α target 
genes and regulate their expression without being coactivated by PGC-1α. These ERRα binding sites 
are enriched for the Sp1 motif and therefore we suggest that these two transcription factors might 
interact to regulate gene expression. This study provides a global analysis of the gene transcription 
regulation by ERRα and PGC-1α in skeletal muscle cells and predicts additional transcription factors 





The expression and activity of the transcriptional coactivator peroxisome proliferator-activated 
receptor γ coactivator 1α (PGC-1α) can be induced and modulated by physiological stimuli, which 
require metabolic changes like cold exposure, fasting or exercise (Handschin and Spiegelman, 2006). 
PGC-1α integrates these signals and subsequently enhances the activity of transcription factors that are 
key regulators of metabolic processes. These transcription factors include most members of the 
nuclear receptor superfamily but also other transcription factors (Puigserver and Spiegelman, 2003). 
Therefore, PGC-1α has emerged as a major controller of mitochondrial biogenesis and oxidative 
phosphorylation (OXPHOS) across different tissues (Puigserver and Spiegelman, 2003). The potency 
of PGC-1α as a coactivator can in part be explained by its capability to bind to proteins with histone 
acetylase activity or to the mediator and SWI/SNF complexes and to bring them in the proximity of 
transcription factors (Liu and Lin, 2011; Puigserver and Spiegelman, 2003). In skeletal muscle, most 
signaling pathways typically induced by exercise at some point converge on PGC-1α and modify its 
expression or activity (Handschin, 2010). PGC-1α in turn then participates in the regulation of the 
expression of genes, which are induced in skeletal muscle in response to exercise (Handschin, 2010). 
In addition to inducing the entire genetic program for oxidative phosphorylation and mitochondrial 
biogenesis in skeletal muscle, PGC-1α also regulates the expression of genes which are important for 
angiogenesis, neuromuscular junction, glucose uptake and fiber type switch (Handschin, 2010).  
The orphan nuclear receptor ERRα, NRF-1 and NRF-2 are induced and subsequently coactivated by 
PGC-1α in order to drive the expression of some PGC-1α target genes in skeletal muscle cells 
(Mootha et al., 2004; Wu et al., 1999). Recently, we have identified ERRα as the major mediator of 
PGC-1α induced gene expression in cultured skeletal muscle cells (Baresic et al., 2013). However, to 
which extent the induction of PGC-1α target genes requires ERRα is not known. In other words, it is 
not fully clear which genes are induced by PGC-1α and ERRα cooperatively and which in absence of 
PGC-1α or which transcription factors cooperate with PGC-1α to regulate the expression of these 
ERRα independent PGC-1α target genes. Besides, most work investigating how PGC-1α regulates 
gene expression focuses on direct coactivation of transcription factors by PGC-1α in the promoters of 
target genes (Michael et al., 2001; Mootha et al., 2004; Schreiber et al., 2004; Wu et al., 1999). 
However, it is as well possible that many PGC-1α target genes are regulated by transcription factors 
which are induced but not coactivated by PGC-1α.  
By comparing genomic locations occupied by ERRα with those occupied by PGC-1α on a genome-
wide scale, we show that ERRα and PGC-1α co-localize in promoter regions of their target genes and 
identify which genes are cooperatively transcribed by these two factors. Surprisingly, we find that 
even though PGC-1α induces ERRα, it does not coactivate ERRα on all of its target genes. Thus, 
ERRα binds to promoters of some of its target genes and transcribes them without being coactivated 
by PGC-1α. Furthermore, the motif for specificity protein 1 (Sp1) is enriched in ERRα binding sites 
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that do not overlap with PGC-1α binding sites, suggesting that ERRα and Sp1 might cooperatively 
regulate transcription. 




3.3.1 ERRα is able to regulate transcription independently from PGC-1α 
The capability of ERRα to control the transcription of its downstream target genes has been postulated 
to be strictly dependent on the coactivation of PGC-1α, to the extent that this co-regulator – more 
precisely its homolog PGC-1β – has been proposed to act as a “protein ligand” for ERRα (Kamei et 
al., 2003). To verify this assumption and to identify all regions genome-wide that are bound by this 
transcription factor in skeletal muscle, we performed a chromatin immunoprecipitation experiment 
followed by high-throughput sequencing (ChIP-Seq) of ERRα in differentiated C2C12 murine 
myotubes. These ERRα binding sites were then compared to a previously sequenced set of PGC-1α 
recruitment regions (Baresic et al., 2013) obtained within the same context of adenovirus-induced 
PGC-1α over-expression. 
In order to identify all genomic locations significantly enriched in ERRα binding, we passed a sliding 
window along the genome and compared, for each consecutive window, the local IP read density with 
the whole cell extract (WCE) background read amount. All regions with a Z score bigger than 3.5 
were merged in a final total of 3225 peaks, which included binding regions in the vicinity of known 
ERRα target genes (Fig. S1A), like the pyruvate dehydrogenase lipoamide kinase isozyme 4 (Pdk4) 
and the isocitrate dehydrogenase 3 [NAD+] alpha (Idh3a) (Tiraby et al., 2011; Zhang et al., 2006). The 
enrichment of IP fragments from the ChIP-Seq experiment was validated for some of these ERRα 
target genes by semiquantitative real-time PCR (Fig. S1B). 
Most surprisingly, when we compared ERRα and PGC-1α occurrences genome-wide (Fig. 1A), we 
noticed that the majority of ERRα (~60%) peaks are actually not overlapping any PGC-1α peak, 
suggesting that the so-far believed concept of symbiotic cooperation between these two proteins is in 
fact only restricted to a small percentage of their targets (~40% for ERRα and ~18%). Some examples 
of this differential regulation are depicted in Fig. 1B. Moreover, of the 1321 ERRα peaks overlapping 
a PGC-1α site (that is, their centers are at most 200 bps apart), the vast majority are well centered on 
the closest PGC-1α peak at a distance of a couple of dozen base pairs (Fig. 1C). Noticeably, a big 
fraction of ERRα resides within 1kb from the closest RefSeq transcription start site (Fig. 1D), which 






Figure 1. ERRα and PGC-1α control the expression of distinct sets of target genes. 
(A) Venn diagram depicting the number of ChIP-Seq binding peaks for PGC-1α (blue) and for ERRα (cyan). 
(B) PGC-1α and ERRα read densities around the TSS of the genes Btbd1, Ldhb and Tusc2 obtained from the 
UCSC Genome Browser. The first plot is an example of a gene directly regulated by ERRα, but not by PGC-1α; 
the second is directly regulated by both ERRα and PGC-1α; the third is directly regulated by PGC-1α, but not by 
ERRα. 
(C) Distribution of ERRα peaks from their closest PGC-1α peaks. 





3.3.2 ERRα targets up-regulation is enhanced when also PGC-1α is present  
To integrate the results obtained from the ChIP-Seq experiment with functional data, we further 
analyzed the impact of ERRα on its downstream targets in terms of their gene expression patterns in 
differentiated muscle cells under the following conditions: (i) shGFP-transfected cells over-expressing 
GFP; (ii) shGFP-transfected cells over-expressing PGC-1α; (iii) shERRα-transfected cells over-
expressing PGC-1α and supplemented with the ERRα inverse agonist XCT-790. By comparing the 
second with the first and the third with the second condition, we sought to assess both the effect of 
PGC-1α over-expression and the response to ERRα knockdown (Fig. 2A). 
After mapping the microarray probes to known transcripts and, through these, to a reference set of 
mouse promoters (Pachkov et al., 2013), we noticed that more promoters were significantly up-
regulated (1863, corresponding to 1165 genes) than down-regulated (658, corresponding to 470 genes) 
following PGC-1α over-expression. In contrast, following ERRα knock-down, we observed the 
opposite effect: 910 promoters (corresponding to 597 genes) were significantly induced whereas 1952 
promoters (corresponding to 1205 genes) were repressed (Fig. 2B). 
By combining the expression array with ERRα and PGC-1α genomic occupancy data, we wanted to 
check whether the binding of PGC-1α to the same sites where ERRα is recruited has any remarkable 
effect on the expression of the ERRα target genes. Therefore, we used only those peaks that were 
associated to a promoter located within 1 kb from the peak center. Most interestingly, we found that 
the presence of PGC-1α at regulatory regions of ERRα targets’ determines a clear shift in the 
distribution of gene expression towards up-regulation and that the top induced genes are those hosting 
in their neighborhood both a peak for ERRα and for PGC-1α (Fig. 2C).  
As these findings suggested that, at least for some targets, PGC-1α is required to boost the expression 
level of the gene, we verified whether such a dependency can be also observed with regards to ERRα. 
Thus, based on the expression levels in the ERRα knock-down condition, we distinguished between 
ERRα-dependent (871 genes) and ERRα-independent (763 genes) PGC-1α targets. We furthermore 
used these differentially regulated genes as input for the functional annotation tool FatiGO (Al-
Shahrour et al., 2004) to stratify these in terms of the regulatory pathways involved (Fig. 2D-F).  
Surprisingly, most of the top enriched terms for induced genes were common to ERRα-dependent and 
ERRα-independent PGC-1α targets (761 and 404 genes, respectively) However, although all pathways 
had smaller (thus, more significant) p-values in ERRα-dependent targets, certain ontology terms were 











Figure 2. ERRα targets transcription levels increase upon PGC-1α recruitment.  
(A) qRT-PCR analysis of PGC-1α, ERRα and Acadm mRNA levels in response to PGC-1α over-expression 
(OV) and shERRα knock-down (KD) + XCT-790. Data are normalized to mRNA levels in GFP infected cells. 
Error bars represent ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001. 
(B) Log2 expression levels of all mouse promoters in the PGC-1α OV condition versus GFP control (left panel) 
and in the PGC-1α OV + shERRα KD + XCT-790 versus PGC-1α OV (right panel). Promoters are colored in red 
(up-regulation) when their fold change is bigger than 1.5 and in green (down-regulation) when their fold change 
is smaller than -1.5 (obtained by taking the inverse of the linear binding ratio). 
(C) Distribution of the log2 fold change for the promoters associated to an “only ERRα peak” (green) compared 
to the distribution of the log2 fold change for the promoters associated to an “overlapping ERRα and PGC-1α 
peak” (red); the overlay of the two distributions is indicated in orange. Each distribution is normalized to the 
total number of promoters within the corresponding set. 
(D-E) Distributions of all mouse promoters log2 fold change and Z score for the comparison shERRα versus 
PGC-1α over-expression. The black lines indicate the cutoffs used to define ERRα-dependent and ERRα-
independent promoters. Highlighted are the promoters significantly: (i) induced by PGC-1α OV (panel D) and 
either repressed by the ERRα KD (green) or not repressed (yellow); (ii) repressed by PGC-1α OV (panel E) and 
either induced by the ERRα KD (red) or not induced (purple). 
(F) Subset of the top significantly enriched GO and KEGG terms identified for ERRα-dependent and ERRα-
independent PGC-1α target genes, either induced or repressed (for the color code, see Fig. 2D-E). 
 
Symmetrically, also repressed PGC-1α targets show minor differences in terms of ontologies enriched 
among ERRα-dependent and ERRα-independent genes. Both groups show over-representation of 
terms related to myofibril contraction and muscle tissue development, although the ERRα-independent 
targets are also enriched in actin, calmodulin and GTP binding (Fig. 2F).  
After defining the four categories of genes depicted in Fig. 2F, we furthermore checked whether these 
targets were associated to any of the following peak groups: (i) a PGC-1α peak, (ii) an ERRα peak, 
(iii) peaks belonging to each of the two chipped proteins or (iv) no peaks. To our surprise, although 
there were more ERRα binding events in the vicinity of ERRα-dependent PGC-1α targets (99 cases), 
we observed no difference in their percentages compared to the ERRα-independent PGC-1α targets 
(13.01% and 13.12%, respectively). However, it is conceivable that some genes might be regulated by 
more distally located peaks, which cannot be identified by the limitation of our assignment of ChIP-
Seq peaks to the closest promoter within a maximum distance of 10 kb. Moreover, we noticed that > 
90% of the down-regulated targets are not associated to any peak and that the percentage of PGC-1α 
indirect targets within each one of the above mentioned four groups is always much bigger than the 
fraction of PGC-1α direct targets, supporting the hypothesis that PGC-1α-dependent gene repression is 




3.3.3 Sp1 contributes to the up-regulation of ERRα targets in muscle cells 
As a following step, we analyzed the occurrence of transcription factor DNA-binding motifs within 
the ERRα peaks. We used the software MotEvo (Arnold et al., 2012) to check which of the 190 known 
mammalian regulatory motifs downloaded from SwissRegulon (Pachkov et al., 2013) were 
significantly over-represented in our peaks compared to a set of shuffled background regions. As we 
expected, the most enriched motif, with a Z score of 123.15, was ESRRA (the motif corresponding to 
the Estrogen-related receptor alpha), even though transcription factor binding sites (TFBSs) for this 
motif were found in only ~48% of the peaks. Given the high promiscuity that exists between nuclear 
receptors consisting of different configurations of hexameric repeats (Mangelsdorf and Evans, 1995), 
it might happen that the precise identity of the nuclear receptor bound at each peak is difficult to 
deduce from DNA-binding motifs and that, like in our case, a site for ERRα could be better matched 
by the position weight matrix (PWM) of another nuclear receptor. For this reason, we clustered all 
motifs based on the similarity of their sequence logo to that of ESRRA and we could identify sites for 
these grouped motifs in ~82% of the ERRα peaks. 
In addition, to explain most of the binding site variation observed across the ERRα peaks, we applied 
the principal component analysis (PCA) to a site-count matrix N, whose elements Npm represent the 
number of predicted TFBSs for each motif m in each ERRα peak region p. Out of a total of 190, the 
first component was the most informative one, accounting for ~10% of the total variation in the dataset 
(Fig. S2A). As shown in Figure 3A, the distribution of motif projections on the first two principal 
components clearly indicate two distinct clusters of motifs that stick out from the cloud of those 
having projections close to zero. The first group, characterized by motifs with negative eigenvalues 
along the first component, includes ESRRA and other nuclear receptors which have very similar logos 
to that of the ERRα motif. This cluster reflects the most abundant sites which can be found within the 
ERRα binding regions. The second group, instead, is characterized by a set of GC-rich motifs which 
are usually found in the proximity of transcription start sites.  
The motif with the highest score along the first principal component, SP1, corresponds to the 
Specificity protein 1 (Sp1), a protein known to be often present at the promoter region of many genes 
and to be involved in several cellular processes, including cell growth, cell differentiation, chromatin 
remodeling and apoptosis. The activity of this protein can be significantly affected by post-
translational modifications, leading Sp1 to act either as an activator or as a repressor (Song et al., 
2002). We thus asked whether Sp1, in the context of ERRα binding, functions more as activator or as 
repressor on the common downstream target genes. To this purpose, we sought to combine the 
different classes of peaks (“only ERRα”, “only PGC-1α”, “overlapping ERRα and PGC-1α”) with the 
regulation of their assigned promoters (“up”, “down”, “non-changing”, “no promoter assigned”) in the 
plot shown in Figure S2B. Strikingly, whenever a site for Sp1 is present within the peak, it is more 
likely for the assigned promoter to be up-regulated, strongly suggesting that in the context of PGC-1α 
82 
Manuscript-2 
over-expression, Sp1 plays a role as an activator. This effect is enhanced when Sp1 is found in an 
ERRα peak rather than with in a PGC-1α peak.  
An additional confirmation of the fact that the SP1 motif is particularly enriched in ERRα peaks is 
shown by Figure 3B, which displays SP1 as the top scoring motif when the TFBS occurrences in 
ERRα peaks are compared to those predicted within PGC-1α peaks. This observation is further 
supported by Figure 3C, showing the decrease in terms of ranking position of SP1 when passing from 
“only ERRα peaks” (rank 2, right after ESRRA), to “overlapping peaks” (rank 14) and finally to “only 
PGC-1α peaks” (rank 33). Taken together, these results suggest not only a prevalent role of Sp1 in the 
context of ERRα binding, but also that this co-occurrence at ERRα peaks is restricted to the presence 
of ERRα itself, as Sp1 occurs less often in the “only PGC-1α peaks”. Lastly, we noticed that the ERRα 
motif ESRRA is firmly in position 1 in each of the three lists. This might suggest that other 
transcription factors with very similar binding affinity to that of ERRα could be accommodated by the 
ESRRA motif. For example, this possibility might concern the ERRα homologous proteins ERRβ – 
which is induced by PGC-1α over-expression (1.9 fold change) and repressed by the ERRα knock-










Figure 3. Sp1 is the top transcription factor partner for ERRα in skeletal muscle. 
(A) PCA analysis of the 3225 ERRα peaks. The names of the motifs with the largest projections on the first two 
principal components are indicated. Purple and light blue ellipses highlight motif clusters, as identified by PC1, 
of nuclear hormone receptor-like motifs and SP1-like motifs, respectively. 
(B) Top and bottom scoring results of motif search obtained by comparing the TFBSs predictions within the 
“only ERRα peaks” with those in the “only PGC-1α peaks”. 
(C) Top scoring motifs resulted from motif search performed on the “only ERRα peaks” (left panel), on the 
“overlapping ERRα and PGC-1α peaks” (central panel) and on the “only PGC-1α peaks” (right panel). For each 
dataset, the TFBSs occurrences were compared against binding site predictions performed on a background set 
of shuffled peaks. The motifs corresponding to ERRα and SP1 are depicted in purple and light blue. 
 
3.3.4 Modeling and validating the indirect gene regulatory effects of PGC-1α in absence of 
ERRα binding 
Provided that ERRα is the main functional partner of PGC-1α, we further investigated which other 
transcription factors might be mediating the indirect regulatory effects of PGC-1α in skeletal muscle. 
For this reason, we extended a previously introduced framework, called Motif Activity Response 
Analysis (MARA) (Suzuki et al., 2009), to incorporate the ChIP-Seq data with the gene expression 
profiles (see Methods for more details) and to model these observations in terms of the TFBSs 
occurring within promoters and of the unknown regulatory “activities” of each input motif. 
In particular, we classified promoters into four groups: (i) associated to an ERRα peak, (ii) associated 
to a PGC-1α peak, (iii) associated to both an ERRα and a PGC-1α peak (either overlapping or not), 
(iv) not associated to any peak. For the first three groups, all “direct targets” of either one or both of 
the proteins, we modeled the promoter expression using the TFBSs predicted within the binding peak, 
while for the last group of “indirect targets”, binding site predictions were made in the proximal 
promoter region, according to the usual MARA approach. For the purpose of this study, we focused on 
the indirect targets group, whose top 30 motifs are listed in Figure 4A.  
The first consideration is that ESRRA is still the top motif of the list. This might be due to the above 
mentioned possibility of having homologous proteins recognized by the same PWM or to the fact that 
some real ERRα binding sites were just below the detection threshold of our peak caller. Secondly, we 
realized that the most active motifs host several known partners of either PGC-1α or ERRα: NR5A1 
(also known as SF1), NR5A2 (also known as LHR1), NRF1, GABPA, MEF2C, RXRs and ESR1. 
Finally, since this analysis identified also several TFs as potential downstream effectors of PGC-1α, 
we decided to experimentally validate a couple of the so-far unknown ones: ZNF143 and NFYC. The 
former was chosen because, apart from the repressed IRF1,2,7 motif, it was the best scoring and 
uncharacterized motif from the list in Figure 4A. The latter was selected because it was the most 




For both these transcription factors, whose activity was predicted to increase significantly upon PGC-
1α over-expression and to decrease following ERRα knock-down (Fig. 4B), we performed an shRNA-
based knock-down in C2C12 myotubes and analyzed, through a microarray, the expression levels of 
these two candidate transcription factors and of their target genes. This experiment resulted in a strong 
reduction of the expression of the TFs (Fig. 4C), as well as the expression levels of a total of 128 
genes for ZNF143 and 73 for NFYC, which were all significantly induced by PGC-1α and repressed 
by the knock-down of the factor (for some examples, see Fig. 4C). 
 
 
Figure 4. Prediction and validation of the indirect gene regulatory effects of PGC-1α mediated 
by Nfyc and Znf143. 
(A) Top 30 active motifs in the promoters not associated to any peak, as predicted by MARA. The motifs chosen 
for validation are highlighted in bold. 
(B) Activity plots of the motifs NFY(A,B,C) and ZNF143, as predicted by MARA. 
(C) Expression levels, as measured by a microarray experiment, of Nfyc, Znf143 and 10 other genes 






ERRα has been described as an effector of PGC-1α induced regulation of gene expression in organs 
like skeletal muscle, adipose tissue or heart(Akter et al., 2008; Cho et al., 2013; Huss et al., 2002; 
Mootha et al., 2004; Schreiber et al., 2004). In skeletal muscle, PGC-1α appears to regulate all 
adaptations of this tissue to exercise (Handschin, 2010). To introduce some of these adaptations PGC-
1α coactivates ERRα to increase its transcriptional activity. When expressed in skeletal muscle cells, 
PGC-1α induces the expression of ERRα and coactivates it to regulate the expression of genes 
involved in mitochondrial biogenesis, oxidative phosphorylation and fatty acid oxidation (Huss et al., 
2004; Mootha et al., 2004; Schreiber et al., 2004). Similarly, by coactivating ERRα at the promoter of 
the PDK4 gene PGC-1α controls muscle glucose metabolism (Wende et al., 2005). The induction of 
VEGF and angiogenesis in skeletal muscle by PGC-1α involves transcriptional activity of ERRα 
(Arany et al., 2008). PGC-1α induces SIRT3 through ERRα to regulate the suppression of reactive 
oxygen species in skeletal muscle cells (Kong et al., 2010).  
However, all these studies focused on the transcription of individual genes or a set of genes. It was not 
precisely known to which extent ERRα is required for the regulation of these gene programs by PGC-
1α in skeletal muscle. The results of this study provide a global picture of the gene expression 
regulation by PGC-1α and ERRα. The co-occurrence of PGC-1α and ERRα in the promoters of genes 
which are induced by PGC-1α confirms that PGC-1α coactivates ERRα to drive the expression of 
these genes. Moreover, we have determined which subset of PGC-1α target genes is regulated by such 
direct mode of gene expression regulation by the PGC-1α/ERRα transcriptional duo. Intriguingly, 
ERRα seems to be able to bind to gene promoters and induce gene expression without being 
coactivated by PGC-1α. This is surprising, because ERRα is thought to be a rather silent and inactive 
transcription factor, which becomes active when bound and coactivated by PGC-1α (Schreiber et al., 
2003). When the crystal structure of ERRα in complex with PGC-1α was analyzed, it was shown that 
the nuclear receptor ERRα is in a transcriptionally active conformation in the absence of ligands if 
complexed by PGC-1α (Kallen et al., 2004). Instead of binding small ligands, the ligand binding 
domain of ERRα interacted with a PGC-1α peptide (Kallen et al., 2004). This and other studies led to 
the perception of ERRα as an orphan nuclear receptor which can be activated by coactivators instead 
of small molecule ligands (Gaillard et al., 2006). We show here that ERRα can bind to promoters of 
genes and regulate their expression even if not directly bound to PGC-1α. However, why ERRα is 
coactivated by PGC-1α at some gene promoters, but not at others is not clear. Because adenoviral 
vectors have been used to overexpress of PGC-1α in our experiments, we can assume that PGC-1α 
molecules are highly abundant in C2C12 cells and thus are available for ERRα binding. The high 
abundance of Sp1 motifs in ERRα peaks which do not co-occur with PGC-1α peaks offers the 
possibility that Sp1 could regulate gene expression together with ERRα. In vascular smooth muscle 
cells, Sp1 was found to bind to the promoter of Mfn2, which is a known PGC-1α target gene in 
skeletal muscle, and regulate its expression (Sorianello et al., 2012; Zorzano, 2009). Additionally, 
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ERRα can bind to the human Sp1 promoter and regulate its expression (Sumi and Ignarro, 2005). 
However, further experiments are required to show that these two transcription factors together 
regulate gene expression in skeletal muscle cells. Nevertheless, even if the interaction of ERRα would 
bind to Sp1 to regulate gene expression, it is still not clear why ERRα complexes with Sp1 at some 
promoters and with PGC-1α at other promoters. However, this might be caused by minor aberrations 
of the ERRα response elements (ERREs) between the two promoter sets. Barry and colleagues have 
found that such minor changes in the ERRα binding site can influence the conformation of ERRα at 
the binding site and therefore affect its interaction with PGC-1α (Barry et al., 2006).  
It was not surprising to find that PGC-1α can be recruited to the promoters of its target genes without 
being bound to ERRα. It was already previously shown that PGC-1α is capable of binding and 
coactivating numerous transcription factors in skeletal muscle. PGC-1α coactivates the nuclear 
respiratory factor 1 (NRF-1) in muscle cells to induce the expression of the mitochondrial transcription 
factor A (mtTFA) and thus regulate the transcription and replication of mitochondrial DNA (Wu et al., 
1999). Another nuclear respiratory factor, NRF-2, is coactivated by PGC-1α to induce the expression 
of genes involved in oxidative phosphorylation and neuromuscular junction formation (Handschin et 
al., 2007; Mootha et al., 2004). Similarly, PGC-1α regulates the activity of the myocyte enhancer 
factor 2C (MEF2C) to induce the expression of GLUT4 and thus to control the glucose uptake in 
muscle (Michael et al., 2001). Nevertheless, it was surprising to find that the motif for ERRα scored 
high when motif search was performed in PGC-1α peaks which did not co-occur with ERRα. 
However, it needs to be considered that the motif of ERRα possibly scored high only because of its 
similarity to other nuclear receptor motifs. Alternatively, PGC-1α might have been recruited to these 
promoters by ERRβ or ERRγ. In hepatic and skeletal muscle cells, it was already shown that several 
members of the ERR family of transcription factors can regulate the expression of the same PGC-1α 
target gene (Cho et al., 2013; Zhang et al., 2006). Accordingly, genome-wide studies in the heart 
found that ERRα and ERRγ share many of their target genes and thus often bind to the promoters of a 
common set of genes (Dufour et al., 2007). Moreover, the expression of two of the three members of 
the ERR family of transcription factors was induced by PGC-1α in our experiments. Therefore, in 
addition to ERRα, PGC-1α might coactivate ERRβ or ERRγ.  
The induction of some PGC-1α target genes does not require the recruitment of ERRα or of PGC-1α to 
their promoters. These indirect PGC-1α target genes might be regulated by transcription factors or 
coactivators which are themselves induced, but not coactivated by PGC-1α. One such downstream 
effector of the PGC-1α/ERRα signaling axis is Perm1, which is induced by PGC-1α and subsequently 
regulates the expression of some PGC-1α target genes (Cho et al., 2013). Our results indicate that 
transcription factors like Znf143, Nfyc or Gtf2i might be other downstream effectors of PGC-1α. 
Experiments performed in our laboratory, which involve knockdown of Znf143, Nfyc and Gtf2i 
revealed that Znf143, Gtf2i and to a lesser extent Nfyc regulated a subset of directly regulated PGC-1α 
target genes (Baresic et al., 2013). Whether these transcription factors also regulated the expression of 
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PGC-1α target genes without being coactivated by PGC-1α still remains unclear.  However, 
considering that ERRα regulates gene expression in presence and absence of PGC-1α at the target 
gene promoter, such a mode of gene expression regulation could be expected as well with Znf143, 
Gtf2i or Nfyc. 
In conclusion, this study represents a genome-wide map of the target gene occupation by the 
transcriptional network of PGC-1α and ERRα. We have identified which PGC-1α target genes in 
skeletal muscle cells are directly regulated by either ERRα or PGC-1α, by the two factors together or 
without the recruitment of any of the two factors to the target gene promoter. We predict which 
transcription factors besides ERRα might regulate the expression of PGC-1α target genes by acting 
either alone or by being coactivated by PGC-1α. In addition, we suggest Sp1 as a transcription factor, 






Cell culture and knockdown of ERRα 
The C2C12 myoblasts were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS), 100 Units/ml penicillin and 100ug/ml streptomycin. After the 
cells had reached approximately 90% confluence, the differentiation of myoblasts to myotubes was 
introduced by switching the growth medium to differentiation medium (DMEM supplemented with 
2% horse serum) for 72 hours.  
For the knockdown and inactivation of ERRα, differentiated C2C12 cells were infected with either the 
shERRα or shGFP (control) adenovirus (AV) and kept in culture for 4 days. These adenoviruses were 
a generous gift from Prof. A. Kralli from the Scripps Research Institute in La Jolla, California, USA. 
Subsequently, these cells were infected with either the flag-PGC-1α or GFP adenovirus and kept in 
culture for additional two days. The differentiation medium, which was used to infect cells, was 
supplemented with either 2µM of the ERRα inverse agonist XCT-790 (for cells previously infected 
with the shERRα AV) or with the vehicle (0.02% DMSO, for the remaining cells).  The experiments 
have been performed in biological triplicates. The RNA was isolated using TRIzol® and was 
performed according to the TRIzol® reagent RNA isolation protocol (Invitrogen). 
For the gene expression arrays, the RNAs from the following three conditions were used: shGFP AV + 
GFP AV + vehicle (0.02% DMSO); shGFP AV + flag-PGC-1α AV + vehicle (0.02% DMSO); 
shERRα AV + flag-PGC-1α AV + 2µM XCT-790.  
 
ChIP and ChIP-Seq 
The chromatin immunoprecipitation was performed according to the Agilent Mammalian ChIP-on-
chip Protocol version 10.0. For every immunoprecipitation, we used approximately 1x108 C2C12 
cells, which were differentiated to myotubes and infected with flag-PGC-1α adenovirus. For the cross-
linking, the cells were incubated in a 1% formaldehyde solution for 10 minutes. After the lysis and 
sonication but before the immunoprecipitation, 50µl of the lysate was saved for the extraction of input 
DNA. For the immunoprecipitation of ERRα, the magnetic beads (Dynabeads® Protein G, Invitrogen) 
were coated with the monoclonal anti-ERRα antibody (ERRα Rabbit Monoclonal Antibody, Clone ID: 
EPR46Y, Epitomics). The chromatin immunoprecipitation was performed overnight on a rotating 
platform at 4°C. The PGC-1α ChIP-Seq data was obtained from previous experiments and was 
performed using the monoclonal anti-flag antibodies (Monoclonal ANTI-FLAG® M2 Antibody, 
Sigma) for the immunoprecipitation (submitted but yet not published data).  
 
High-throughput sequencing 
The ERRα ChIP-Seq experiment in C2C12 cells undergoing PGC-1α over-expression was performed 
at the joint Quantitative Genomics core facility of the University of Basel and the Department of 
Biosystems Science and Engineering (D-BSSE) of the ETH Zurich in Basel. The DNA libraries for 
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ERRα and the whole cell extract (WCE) were prepared using the standard Illumina ChIP-Seq protocol, 
as described by the manufacturer. The immunoprecipitated samples were sequenced on the Illumina® 
HiSeq2000 sequencer. 
The sequenced reads underwent a quality filter which discarded all reads having Phred score >= 20, 
read length >= 25 bps and wrongly called nucleotides (Ns) per read <= 2. The reads that passed the 
filter were used as input for Bowtie version 0.12.7 (Langmead et al., 2009) and aligned to the UCSC 
mm9 mouse genome assembly. Moreover, to avoid any PCR amplification error which might have 
arisen during sample preparation, we removed redundant reads mapping to the same location with the 
same orientation and we kept only one read per position. Consequently, we obtained 2’155’507 reads 
for the IP and 84’175’472 reads for the WCE. 
 
Peak calling 
To detect regions that were significantly enriched in ERRα binding, we estimated the fraction of all 
ChIP reads fIP that fell within consecutive 200 bps sliding windows genome-wide and, in parallel, the 
fraction fWCE of reads from the whole cell extract that fell in a 2000 bps long window centered on the 
ChIP one. Using these two sets of values, we quantified the ChIP enrichment of each window as: 
𝑍 = 𝑓𝐼𝑃 −  𝑓𝑊𝐶𝐸
�𝜎2𝐼𝑃 + 𝜎2𝑊𝐶𝐸 
where 𝜎2𝐼𝑃 and 𝜎
2
𝑊𝐶𝐸 are the IP and WCE read frequency variances, given by: 
𝜎2𝐼𝑃 =  𝑓𝐼𝑃∗ (1− 𝑓𝐼𝑃)𝑁𝐼𝑃  and 𝜎2𝑊𝐶𝐸 =  𝑓𝑊𝐶𝐸 ∗ (1 − 𝑓𝑊𝐶𝐸)𝑁𝑊𝐶𝐸  
respectively. All consecutive windows having a Z-score greater than 3.5 were merged and the top 
scoring one from each window cluster was considered as the peak summit and used for further 
analyses.  
ERRα peaks were annotated to the closest Mus musculus RefSeq transcripts and defined as 
“Intergenic”, “Intronic”, “Exonic”, “Upstream of TSS” or “Downstream of TSS” in case they were 
located, respectively, farer than 10 kb from the closest transcript, within an intron, within an exon, 
between -10 and 0 kb from the nearest TSS, or between 0 and 10 kb from the closest TES. 
 
Transcription factor binding sites over-representation 
In order to account for the conservation of TFBSs across related species, we aligned the ERRα binding 
peaks to their orthologous regions from 6 mammalian species – human (hg18), opossum (monDom4), 
dog (canFam2), rhesus macaque (rheMac2), horse (equCab1) and cow (bosTau3) – using the software 
T-Coffee (Notredame et al., 2000). Using the MotEvo algorithm (Arnold et al., 2012) on these 
alignments, we predicted binding sites within our peaks for a collection of 190 mammalian regulatory 




To assess the over-representation of the predicted binding sites (i.e. those with a posterior probability 
greater than 0.1) within the ERRα peaks, we created a set of background regions by shuffling the 
columns of the multiple alignments and maintaining, at the same time, both the phylogeny and the gap 
patterns of the original aligned sequences. MotEvo was run on the shuffled alignments using the same 
settings as for the original sequences. Significant enrichment of binding sites for each motif x in the 
ERRα peaks was computed by collecting the sum 𝑛𝑥 of the posterior probabilities for its predicted 
TFBSs along ERRα peak alignments and the corresponding sum 𝑛′𝑥 in the shuffled alignments; we 
quantified the motif over-representation as: 
𝑍 =  𝑓𝑥 −  𝑓′𝑥
�𝑓𝑥 ∗
(1 −  𝑓𝑥)
𝐿𝑥
+ 𝑓′𝑥 ∗ (1 −  𝑓′𝑥)
𝐿′𝑥
 
where 𝐿𝑥 and 𝐿′𝑥 are the total lengths of the original and shuffled alignments, respectively, while 𝑓𝑥 
and 𝑓′𝑥 are given by the equations: 
𝑛𝑥 ∗  𝑙𝑥 =  𝑓𝑥 ∗  𝐿𝑥  and 𝑛′𝑥 ∗  𝑙𝑥 =  𝑓′𝑥 ∗  𝐿′𝑥 
with 𝑙𝑥 the length of motif x. 
 
Principal Component Analysis of TFBSs occurrence within peaks 
A Principal Component Analysis (PCA) was performed using the “svd” package of R programming 
language. The input data for the PCA was a p × m matrix N, composed by the total number of binding 
sites Npm predicted for each of the 3225 binding peaks p (rows) using our collection of 190 
mammalian regulatory motifs m (columns). Singular Value Decomposition (SVD) was applied to the 
mean centered matrix 𝑁�𝑝𝑚 = 𝑁𝑝𝑚 − 〈𝑁𝑚〉 using the ‘svd’ package of the statistical software ‘R’. 
 
Gene expression array analysis 
The .CEL files containing the raw probe intensities were processed using the Bioconductor package 
‘affy’ (Gentleman et al., 2004), which corrects for background and unspecific binding. After using the 
‘Mclust’ R package(R Development Core Team, 2012) to distinguish expressed from non-expressed 
probes, the intensity values were quantile normalized across all samples and mapped to the mouse 
transcripts UCSC collection. These were further associated to a comprehensive collection of mouse 
promoters that was downloaded from the SwissRegulon database (Pachkov et al., 2013). For each 
promoter, the change in  log2 expression levels (log2FC) was compared between the following 
conditions: over-expressed PGC-1α (treatment) and GFP (control); ERRα knock-down with the 
addition of XCT790 (treatment) and over-expressed PGC-1α (control). 
The significance of the expression change was assessed by a Z score, which was computed as: 




𝑛 + 𝜎2𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑛  
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where 𝑛 = 3 was the number of replicate samples, 𝐸�𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 is the mean log2 expression across the 
treatment samples, 𝐸�𝑐𝑜𝑛𝑡𝑟𝑜𝑙 is the mean log2 expression across the control samples, and 𝜎
2
𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 
and 𝜎2𝑐𝑜𝑛𝑡𝑟𝑜𝑙 are the variances of log2 expression levels across the replicates for the treatment and 
control samples, respectively. A log2FC threshold of ±0.5849625 (corresponding, in a more used 
notation, to 1.5 fold change, when taking the inverse of the linear binding ratio) and a Z score cutoff of 
±3 were used to identify significantly up-/down-regulated promoters. 
The criterion adopted to assign peaks to promoters was proximity. Each peak was assigned to its 
closest promoter (and, thus, to its associated gene symbol) whenever the distance between their central 
positions was smaller than 10 kb; otherwise, the peak was not assigned to any promoter. 
 
Ontology terms over-representation analysis 
KEGG pathways and Gene Ontology terms over-representation analysis was performed using the 
functional analysis software FatiGO (Al-Shahrour et al., 2004). As input, we used all gene IDs 
associated to the promoters that were assigned to the ERRα and PGC-1α peaks. Only ontology terms 
having an FDR-adjusted p-value <= 0.05 were considered significant. 
 
Motif activity response analysis 
The information obtained from the sequencing data and from the microarrays were integrated by 
extending MARA (Suzuki et al., 2009) in order to model the direct and indirect regulatory effects that 
ERRα and PGC-1α exert on their downstream targets.  
Using the input expression data and the computationally predicted transcription factor binding sites, 
MARA infers, for each of 190 regulatory motifs m (associated with roughly 350 mouse TFs), the 
activity Ams of the motif in each sample s when the motif occurs outside of a binding peak, and the 
activity A*ms of the motif when it occurs within a binding peak. A significant change in the motif 
activity Ams upon knock-down of ERRα and/or over-expression of PGC-1α indicates an indirect 
regulatory effect of either ERRα, PGC-1α or both of them on the motif m, whereas a change in the 
motif activity A*ms reflects a direct regulatory effect as mediated by the motif m. For each promoter p 
that was not associated with any binding peak (which we denote as “indirect target”), we modeled its 
log-expression in sample s, eps, in terms of the predicted number of TFBSs Npm that occur in the 
proximal promoter region (running from -500 to +500 relative to TSS) for each regulatory motif m. 
That is, MARA assumes the linear model: 
𝑒𝑝𝑠 = 𝑐𝑝 + ?̃?𝑠 + � 𝑁𝑝𝑚𝐴𝑚𝑠
𝑚
 
where cp is the basal expression of promoter p, ?̃?𝑠 is a sample-dependent normalization constant, and 
𝐴𝑚𝑠 is the regulatory activity of motif m in sample s, which is inferred by the model. Formally, 𝐴𝑚𝑠 
quantifies the amount by which the expression of promoter p in sample s would be reduced if a 
binding site for motif m were to be deleted from the promoter.  
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For each “direct target” promoter p that has an associated binding peak (which could be an ERRα, a 
PGC-1α or an overlapping ERRα/PGC-1α peak) within 10 kb, we modeled its expression in terms of 
the predicted TFBSs in the binding peak, i.e.: 




∗  is the number of predicted TFBSs for motif m in the peak associated with promoter p, and 
𝐴𝑚𝑠
∗  is the motif activity of regulator m in sample s when this motif occurs in the context of either 
ERRα binding, PGC-1α recruitment or both.  
Besides motif activities MARA also calculates error-bars 𝛿𝑚𝑠 for each motif m in each sample s. 
Using these, MARA calculates, for each motif m, an overall significance measure for the variation in 
motif activities across the samples analogous to a z-statistic: 
𝑍𝑚 = �1𝑆� (𝐴𝑚𝑠)2𝑚  
For each motif we calculate a z-score 𝑍𝑚 associated with its indirect activity changes, a z-score 
𝑍𝑚,𝐸𝑅𝑅𝛼∗  associated with its direct activity changes in the context of ERRα binding, a z-score 𝑍𝑚,𝑃𝐺𝐶1𝛼∗  
associated with its direct activity changes in the context of PGC-1α recruitment and a z-score 𝑍𝑚,𝐵𝑂𝑇𝐻∗  
associated with its direct activity changes in the context of both ERRα binding and PGC-1α 
recruitment. 
 
Real-time PCR  
Real-time PCR was used to validate the efficiency of the ERRα knockdown and to verify that the ChIP 
of ERRα was successful. The sequences of all primers, which were used in real-time PCRs, are 
depicted in Suppl. Table 1.  
Statistical analysis of Real-time PCR data sets. The values are presented as the mean +- SEM. A 
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3.7 Supplemental Figures and Tables 
Suppl. Figure S1. Related to Figure 1. 
(A) ERRα read densities around the TSS of the known target genes Pdk4 and Idh3a, as displayed by 
the UCSC Genome Browser. 
(B) Real-time PCR validation of the ChIP enrichment measured at the promoter of a set of ERRα 
target genes. Bars represent fold enrichment over that of the TBP intron. 
 
Suppl. Figure S2. Related to Figure 2. 
(A) Fraction of explained variance of the top 10 PCA components. 
(B) Barchart representing the different classes of peaks (“only ERRα”, “only PGC1α”, “overlapping 
ERRα and PGC1α”) together with the regulation of their associated promoters (“up”, “down”, “non-
changing”, “no promoter assigned”). Numbers shown on top of each box represent the absolute peak 
counts. 
 
















Real-time PCR primers used for ChIP validation   
gene promoter or intron forward primer reverse primer 
Tbp intron TGTGAGCTCCTTGGCTTTTT ATAGTTGCCCAGCAATCAGG 
promoter of Acadm CCTTGCCCGAGCCTAAAC GTCTGGCTGCGCCCTCT 
promoter of Atp5b CTGGAAACTTCCACCCTCACTA GAGAGGTTTTTGGCGGAACTA 
promoter of Idh3a GGACGGCGTCAAGGTCAAG  GCCTAGGTGGCCTGTCTGTG 
   Real-time PCR primers used for testing the knockdown of Esrra 
gene forward primer reverse primer 
Rn18s AGTCCCTGCCCTTTGTACACA CGATCCGAGGGCCTCACTA 
Ppargc1a TGATGTGAATGACTTGGATACAGACA GCTCATTGTTGTACTGGTTGGATATG 
Esrra ACTGCAGAGTGTGTGGATGG GCCCCCTCTTCATCTAGGAC 
Acadm AACACTTACTATGCCTCGATTGCA CCATAGCCTCCGAAAATCTGAA 
    
Suppl. Table 1. 
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4 MANUSCRIPT-3: Inhibition of cyclic nucleotide phosphodiesterase 
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Increased expression of the peroxisome proliferator-activated receptor γ coactivator 1 α (PGC-1α) in 
skeletal muscle has been associated with health benefits and was shown to ameliorate Duchenne 
muscular dystrophy, protect from sarcopenia and reduce the denervation induced atrophy of the 
skeletal muscle. Therefore, inducing a long-lasting PGC-1α mRNA expression might represent a 
therapeutic approach to treat these diseases. cAMP regulates PGC-1α expression in brown fat and the 
liver. In skeletal muscle, CREB binds to the PGC-1α promoter and the activation of β2-adrenergic 
receptor (β2-AR) signalling or protein kinase A (PKA) strongly boosts PGC-1α expression. While 
pathways which induce intracellular cAMP production induce PGC-1α expression, it is not known if 
preventing cAMP degradation has a similar effect. Cyclic nucleotide phosphodiesterases (PDEs) 
hydrolyse cAMP to AMP and therefore we hypothesised that elevating cAMP levels through PDE 
inhibition would induce PGC-1α mRNA expression. We show here that β2-AR signalling activation 
through clenbuterol leads to a transient PGC-1α mRNA and protein induction. Inhibition of PDE1 and 
PDE4 by vinpocetine and rolipram, respectively, increases the expression of the alternative exon 1 of 
PGC-1α in skeletal muscle cells but not in muscles in vivo. Surprisingly, PDE4 inhibition by rolipram 
led to higher PGC-1α protein levels suggesting that this regulation is not achieved through mRNA 





Skeletal muscle quickly adapts to exercise. Some of these changes can be beneficial for health and 
help to prevent the development of medical conditions connected to the modern lifestyle, like obesity, 
diabetes or hypertension. Thus, regular physical activity represents an effective way to reduce the risk 
of developing metabolic disorders and other medical conditions (Booth et al., 2002; Dyson, 2010; 
Henriksen, 2002). The adaptation of skeletal muscle tissue to regular endurance exercise includes 
mitochondrial biogenesis, higher capillarisation of the skeletal muscle and an increased expression of 
enzymes which are important for the anti-oxidant defence (Lira et al., 2010; Olesen et al., 2010).  
The transcriptional coactivator peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) 
appears to be the main mediator of these exercise induced changes in skeletal muscle. PGC-1α 
expression in skeletal muscle is induced by exercise training and its expression and activity are 
regulated by signalling pathways which are typically activated by contracting muscles (Akimoto et al., 
2005; Baar et al., 2002; Handschin et al., 2003; Jager et al., 2007; Pilegaard et al., 2003). When 
expressed in muscle, PGC-1α induces mitochondrial biogenesis, leads to a fibre type switch towards 
more oxidative fibres and induces angiogenesis by regulating the expression of VEGF and other 
angiogenic factors (Arany et al., 2008; Lin et al., 2002; Wu et al., 1999). The induced expression of 
PGC-1α has even been discussed in the context of mimicking exercise (Matsakas and Narkar, 2010).  
More importantly, muscle PGC-1α levels directly affect the degree of damage in different muscle 
related diseases. Transgenic overexpression of PGC-1α in skeletal muscle has been shown to 
ameliorate Duchenne muscular dystrophy, protect from sarcopenia and reduce denervation-induced 
atrophy of the skeletal muscle (Handschin et al., 2007; Sandri et al., 2006; Wenz et al., 2009). Thus, 
pharmacologically controlling muscle PGC-1α might represent an effective strategy to treat muscle 
dystrophies, sarcopenia or atrophy in bed-ridden patients. 
Because PGC-1α expression in skeletal muscle is induced by the protein kinase A activator forskolin 
and considering that the binding of the cAMP response element-binding protein (CREB) to the 
promoter of PGC-1α is required for PGC-1α induction through CamKIV in skeletal muscle 
(Handschin et al., 2003), we hypothesised that elevating cAMP levels would induce PGC-1α 
expression. This is supported by the finding that β-adrenergic receptor activation by clenbuterol 
strongly induces PGC-1α expression (Miura et al., 2007). Similarly, the induction of PGC-1α 
expression by cAMP was shown in other tissues like liver and brown fat (Herzig et al., 2001; 
Puigserver et al., 1998).  
The cyclic nucleotide phosphodiesterases (PDEs) hydrolyse cAMP to AMP and thus play an important 
role by degrading this second messenger (Omori and Kotera, 2007). By inhibiting PDEs expressed in 
skeletal muscle cells, we expect cAMP levels to increase and lead to induced PGC-1α expression. 
Mammalian PDEs are encoded by 21 genes, many of which can be alternatively spliced, are 
subdivided into 11 families and show a tissue specific distribution (Bingham et al., 2006; Omori and 
Kotera, 2007). Members of the PDE1, PDE4, PDE7 and PDE11 family are known to be expressed in 
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skeletal muscle and the inhibition of PDE4 and PDE5 in skeletal muscle was found to reduce atrophy 
or ameliorate Duchenne muscular dystrophy (Adamo et al., 2010; Bingham et al., 2006; Hinkle et al., 
2005; Omori and Kotera, 2007). There are however differences in the distribution pattern between 
species and the expression profile of some PDEs is still unknown (Omori and Kotera, 2007). This 
tissue specific distribution and the fact that dysfunctions of PDE activity have been associated to 
several diseases have led to the development of specific PDE inhibitors (Francis et al., 2011). 
Therefore, a PDE inhibitor which induces PGC-1α expression in one tissue might have no or little 
inhibitory activity in other tissues. Inhibitors of the PDE4 and PDE5 family have been suggested as 
drugs to reduce skeletal muscle atrophy or to treat Duchenne muscular dystrophy (Francis et al., 2011; 
Hinkle et al., 2005; Malik et al., 2012). 
By using unspecific PDE inhibitors like 3-isobutyl-1-methylxanthine (IBMX) we sought to determine 
the role of phosphodiesterases in the regulation of PGC-1α expression. Next we tried to identify the 
PDE family involved in this regulation and elucidate if the inhibition of that particular PDE eventually 
leads to long-lasting PGC-1α induction. The PGC-1α mRNA can also be transcribed from an 
alternative promoter and thus give rise to alternative splice variants (Miura et al., 2008). Furthermore, 
these alternative splice variants of PGC-1α appear to be preferentially induced by exercise and 
adrenergic receptor signalling (Miura et al., 2008). Therefore we measured the expression of the 
transcription of the PGC-1α which is derived from the alternative promoter (alternative exon 1) as well 
as total PGC-1α levels by measuring the expression of exon 2 of PGC-1α, as this exon is supposed to 





4.3.1 The inhibition of PDE1 and PDE4 in skeletal muscle cells increases the expression of the 
alternative exon 1 of PGC-1α in skeletal muscle cells 
To examine if cAMP signalling is involved in regulation of PGC-1α expression, C2C12 myotubes 
were treated with the protein kinase A activator forskolin or with the unspecific phosphodiesterase 
inhibitor IBMX and compared to vehicle treated cells. Both treatments lead to higher PGC-1α mRNA 
levels, however this induction was not significant (Fig. 1A). Nevertheless, there was a clear tendency 
to higher PGC-1α levels, especially when the mRNA levels of the alternative exon 1 of PGC-1α were 
compared (Fig. 1A). Considering that IBMX is a general, but not very potent inhibitor of all 
phosphodiesterase families, and in order to determine which PDE family might be involved in the 
regulation of PGC-1α expression, the myotubes were treated with specific phosphodiesterase 
inhibitors and the expression levels of PGC-1α and PGC-1β were compared. To rule out the possibility 
that intracellular cAMP is pumped out of the skeletal muscle cell instead of being degraded as reported 
by other Godinho et al, the experiment was performed in the absence and presence of the organic 
anion transport inhibitor probenecid (Godinho and Costa, 2003) (Fig. 1B, 1C). The inhibition of PDE1 
by the specific inhibitor vinpocetine led to an increased expression of the alternative exon 1 of PGC-
1α (Fig. 1B). When the cells were treated with probenecid, the PDE4 inhibitor rolipram induced the 
expression of the alternative exon 1 of PGC-1α (Fig 1C). To find out if the cAMP effector protein 
Epacs (exchange proteins directly activated by cAMP) play a role in cAMP mediated regulation of 
PGC-1α expression, we included in this study the selective Epac activator 8CPT-2Me-cAMP. The 
treatment with 8CPT-2Me-cAMP did not produce any significant change neither in the expression of 
PGC-1α nor PGC-1β. Last, there was no significant change in PGC-1β mRNA levels observed neither 
with the specific PDE inhibitors nor with IBMX treatment (Fig. 1A-1C).  
 
4.3.2 The PDE4 inhibitor rolipram moderately increases PGC-1α protein but not mRNA levels 
in skeletal muscles in vivo. 
Based on the observation from our in vitro experiments and considering that rolipram has been 
reported to reduce skeletal muscle atrophy, we decided to assess the effect of the PDE4 inhibitor 
rolipram on the expression of PGC-1α in skeletal muscle in vivo (Hinkle et al., 2005). Rolipram was 
administered by intraperitoneal injections to 10 weeks old male mice either alone or in the presence of 
the specific β2-adrenergic receptor agonist clenbuterol. β2-AR activation by clenbuterol has been 
reported to transiently induce PGC-1α expression in skeletal muscle (Miura et al., 2007). We predicted 
that the inhibition PDE4 inhibition following clenbuterol treatment might delay the cAMP hydrolysis 
and thus lead to a prolonged and eventually higher PGC-1α induction. PGC-1α, PGC-1β and Acadm 
mRNA and PGC-1α protein levels were measured 6 hours after drug administration. The PGC-1α 
mRNA levels in the tibialis anterior and gastrocnemius muscle were strongly augmented by 




Figure 1. PGC-1α but not PGC-1β expression is induced following PKA activation or PDE 
inhibition in vitro. 
(A) Differentiated primary myotubes from wild-type mice were treated with either DMSO, forskolin or IBMX 
for 3 hours. Expression of PGC-1α exon 2, PGC-1α alternative exon 1 and PGC-1β was determined by real-time 
PCR. 
(B) Differentiated C2C12 myotubes were treated with either DMSO, IBMX, forskolin, vinpocetine, EHNA, 
cilostamide, rolipram zaprinast BRL 50481, BAY 73-6691 or 8cpt-2Me-cAMP  for 3 hours. Expression of PGC-
1α exon 2, PGC-1α alternative exon 1 and PGC-1β was determined by real-time PCR. 









Figure 2. Rolipram moderately increases PGC-1α protein levels without inducing the mRNA 
expression. 
(A-D) Expression of PGC-1α exon 2, PGC-1α alternative exon 1, Acadm and PGC-1β in mouse tibialis anterior 
muscle 6 hours after administration of either PBS, clenbuterol, rolipram, clenbuterol together with rolipram or 
forskolin by intraperitoneal injections. mRNA levels were determined by real-time PCR. 
(E-H) Expression of PGC-1α exon 2, PGC-1α alternative exon 1, Acadm and PGC-1β in mouse gastrocnemius 
muscle 6 hours after administration of either PBS, clenbuterol, rolipram, clenbuterol together with rolipram or 
forskolin by intraperitoneal injections. mRNA levels were determined by real-time PCR. 
(I) PGC-1α protein levels in mouse tibialis anterior muscle determined by immunoblotting 6 hours after 
administration of either PBS, clenbuterol, rolipram, clenbuterol together with rolipram or forskolin by 
intraperitoneal injections.  
(J) Quantification of protein levels from (I) normalized to α-tubulin. 
(K) PGC-1α protein levels in mouse quadriceps muscle determined by immunoblotting 6 hours after 
administration of either PBS, clenbuterol, rolipram, clenbuterol together with rolipram or forskolin by 
intraperitoneal injections. 
(L) Quantification of protein levels from (K) normalized to α-tubulin. 
 
Rolipram treatment led only to a weak induction of PGC-1α alternative exon 1 expression in tibialis 
anterior, leaving the normal PGC-1α exon 1 levels unchanged (Fig. 2 A,B,E and F). The observed 
strong induction of PGC-1α observed with clenbuterol was not accompanied by an induction of the 
typical PGC-1α target gene Acadm (Fig 2C and G). PGC-1β expression tended to be reduced upon 
clenbuterol treatment (Fig 2 D and H). However, this suppression was not significant. Surprisingly, 
unlike the mRNA levels, the PGC-1α protein levels in tibialis anterior muscle were slightly increased 
following rolipram treatment alone or when administered together with clenbuterol (Fig. 2I and J). 
This induction could not be observed in the quadriceps muscle (Fig. 2K and L). Unexpectedly, 
forskolin did not induce PGC-1α mRNA and protein in skeletal muscle (Fig. 2). Instead, in 
gastrocnemius muscle forskolin treatment slightly suppressed PGC-1α mRNA (Fig 2E and F). 
 
4.3.3 Clenbuterol boosts both PGC-1α mRNA and protein, while PDE1 inhibition by vinpocetine 
does not alter skeletal muscle PGC-1α levels in vivo.  
Next we sought to look into the regulation of PGC-1α expression following PDE1 inhibition by 
vinpocetine. Like in the previous experiment, vinpocetine was administered by intraperitoneal 
injections into 11 weeks old male mice either alone or in the presence of clenbuterol. Similarly, we 
expected a prolonged PGC-1α induction by clenbuterol when the hydrolysis of cAMP is inhibited by 
vinpocetine. To examine this, PGC-1α mRNA and protein levels were measured 6 hours and 24 hours 
after the drug administration. Aminophylline, a nonselective PDE inhibitor, was included in this 
experiment because it was shown to restore muscle structure in a zebrafish model of Duchenne 
muscular dystrophy (Kawahara et al., 2011). In tibialis anterior muscle, clenbuterol strongly induced 
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PGC-1α mRNA expression, while it suppressed PGC-1β expression 6 hours after drug administration 
(Fig. 3A, B and C). This suppression was probably a compensation for the induction of PGC-1α. The 
induction of PGC-1α was transient, because 24 hours after drug administration all induction was gone 




Figure 3. Clenbuterol boosts both PGC-1α mRNA and protein, while PDE1 inhibition by 
vinpocetine does not alter skeletal muscle PGC-1α levels in vivo. 
(A-C) Expression of PGC-1α exon 2, PGC-1α alternative exon 1 and PGC-1β in mouse tibialis anterior muscle 
6 hours after administration of either DMSO, clenbuterol, vinpocetine, clenbuterol together with vinpocetine or 
aminophylline by intraperitoneal injections. mRNA levels were determined by real-time PCR. 
(D-F) Same like (A-C) but 24 hours after drug administration. 
(G-H) PGC-1α protein levels in mouse tibialis anterior muscle determined by immunoblotting 6 hours (G) or 24 
hours (H) after administration of either DMSO, clenbuterol, vinpocetine, clenbuterol together with vinpocetine 




Vinpocetine treatment alone did not have any effect on PGC-1α or PGC-1β expression neither after 6 
hours, nor after 24 hours. When administered together with clenbuterol, vinpocetine seemed to further 
increase the clenbuterol induced PGC-1α expression and diminish the clenbuterol induced suppression 
of PGC-1β 6 hours after drug administration, suggesting that it might enhance the beneficial effects of 
clenbuterol treatment (Fig. 3A, B and C). Unfortunately, this difference was not significant and 
similarly to the clenbuterol treatment, 24 hours after administration all PGC-1α mRNA induction was 
lost (Fig. 3A, B, C, D, E and F). The nonselective PDE inhibitor aminophylline did not alter PGC-1α 
expression in the tibialis anterior muscle 6 hours after drug administration, but unexpectedly, it 
moderately raised the expression of PGC-1β at this time point (Fig. 3A, B and C). Like with other 
treatments, this effect was lost 24 hours after drug administration (Fig. 3D, E and F). When it comes to 
PGC-1α protein levels, only clenbuterol treatment provoked a strong induction, but like the PGC-1α 
mRNA the PGC-1α protein levels returned to normal levels 24 hours after drug administration (Fig. 
3G and H).  
 
4.3.4 Clenbuterol and aminophylline treatments provoked moderate and transient changes in 
liver and kidney and caused no changes in the white adipose tissue. 
Next we examined if the β-adrenergic receptor stimulation by clenbuterol or the inhibition of PDEs by 
vinpocetine and aminophylline caused any changes in PGC-1α and PGC-1β expression in organs other 
than skeletal muscle like liver, kidney and fat. In liver, PGC-1α is known to be regulated by cAMP 
and to induce gluconeogenesis while exercise and adrenaline induce PGC-1α expression in white 
adipose tissue (Sutherland et al., 2009; Yoon et al., 2001). The regulation of PGC-1α and its role in 
kidney are not known. Thus we measured the levels of PGC-1α and PGC-1β in these tissues 6 and 24 
hours following clenbuterol, vinpocetine and aminophylline treatment. First, vinpocetine treatment 
alone did not cause any changes in the expression of these genes. Only when combined with 
clenbuterol, vinpocetine led to a weak but significant induction of PGC-1α expression in the liver, six 
hours after administration (Fig. 4). In liver, clenbuterol induced PGC-1α expression 6 hours after 
administration while not changing PGC-1β. This induction was significantly lower when clenbuterol 
was administered together with vinopocetine (Fig. 4A). Interestingly, while aminophylline moderately 
raised PGC-1β mRNA levels in muscle, it lowered PGC-1β levels in the liver (Fig. 4A). However 24 h 
after drug administration the effects of all treatments were lost, confirming the transient nature of these 
changes (Fig. 4B). In kidney clenbuterol treatment alone or in combination reduced both PGC-1α and 
PGC-1β gene expression. This suppression was equal when clenbuterol was administered alone or in 
combination with vinpocetine and was lost after 24 hours (Fig. 4C and D). In the white adipose tissue 
neither of the drugs showed any effect at the time points we measured the gene expression (Fig. 4E 




Figure 4. Clenbuterol and aminophylline treatments provoked moderate and transient changes 
in liver and kidney and caused no changes in the white adipose tissue. 
(A-B) Expression of PGC-1α exon 2, PGC-1α alternative exon 1, and PGC-1β in liver 6 hours (A) or 24 hours 
(B) after administration of either DMSO, clenbuterol, vinpocetine, clenbuterol together with vinpocetine or 
aminophylline by intraperitoneal injections. mRNA levels were determined by real-time PCR. 
(C-D) Expression of PGC-1α exon 2, PGC-1α alternative exon 1, and PGC-1β in kidney 6 hours (C) or 24 hours 
(D) after administration of either DMSO, clenbuterol, vinpocetine, clenbuterol together with vinpocetine or 
aminophylline by intraperitoneal injections. mRNA levels were determined by real-time PCR. 
(E-F) Expression of PGC-1α exon 2, PGC-1α alternative exon 1, and PGC-1β in visceral white adipose tissue 6 
hours (E) or 24 hours (F) after administration of either DMSO, clenbuterol, vinpocetine, clenbuterol together 







The main goal of this study was to test if by intervening in cAMP signalling through inhibition of 
PDEs we can induce the expression of PGC-1α or PGC-1β in skeletal muscle and if so to determine 
which PDE family is involved in this regulation. In this study we show that the activation of β2-
adrenergic receptor signalling transiently induces PGC-1α expression in skeletal muscle (Fig. 2 and 3). 
Furthermore, using forskolin in skeletal muscle cells to activate the protein kinase A, an effector 
protein of cAMP which is downstream of β2-adrenergic receptor activation, we observed a strong 
tendency towards increased PGC-1α levels (Fig. 1). Forskolin administration in vivo did not change 
PGC-1α or PGC-1β levels (Fig. 2). This might be due to different regulation in skeletal muscle tissue 
compared to isolated skeletal muscle cells, however it is also possible that forskolin administered by 
intraperitoneal injection was insufficiently concentrated, did not reach skeletal muscle tissue or simply 
that we measured at a wrong time point. Nevertheless, these observations strongly suggest that 
elevated cAMP levels indeed regulate PGC-1α expression. Similar results have already been shown by 
other groups, thus confirming the role of cAMP in PGC-1α regulation (Miura et al., 2008; Miura et al., 
2007; Pearen et al., 2008). PDE inhibition by the nonselective PDE inhibitor IBMX in skeletal muscle 
cells led to a tendency towards increased PGC-1α, which is comparable to forskolin treatment (Fig. 
1A). However, when selective PDE inhibitors were used, only a weak induction of PGC-1α with 
vinpocetine and rolipram was observed (Fig 1B). This cannot be explained by export of cAMP out of 
the cells as suggested by Godinho & Costa because when the same experiment was performed in cells 
treated with probenecid, PGC-1α induction by PDE inhibition was still very modest (Fig 1C)(Godinho 
and Costa, 2003).  
When applied in vivo, rolipram lead to a very modest induction of the alternative exon 1 of PGC-1α, 
but did not further increase the PGC-1α expression when administered together with clenbuterol (Fig. 
2). The PGC-1α protein levels were significantly higher following rolipram treatment in the tibialis 
anterior muscle but not in the quadriceps muscle, meaning that this induction is probably regulated 
through another pathway than direct induction of PGC-1α mRNA expression, supposedly by PGC-1α 
protein stabilization (Fig. 2I, J, K and L). This regulation might explain the already published 
inhibition of skeletal muscle atrophy by rolipram (Hinkle et al., 2005). Vinpocetine administration 
alone had no influence on PGC-1α expression in skeletal muscle but tends to further increase the 
clenbuterol-induced PGC-1α expression (Fig. 3A and B). It also led to a weaker compensatory PGC-
1β suppression compared to clenbuterol treatment alone (Fig. 3C). Last, liver PGC-1α levels were 
significantly less induced following clenbuterol and vinpocetine treatment compared to clenbuterol 
treatment alone (Fig. 4A). Thus the role of vinpocetine in PGC-1α regulation should be further 
studied.  
Once generated in the cell, cAMP can only be eliminated by hydrolysis or eventually by export out of 
the cell (Godinho and Costa, 2003). Thus, we expected that PDE inhibition should prolong the 
transient PGC-1α induction by clenbuterol. This was not the case in our study, because all effects of 
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clenbuterol were gone after 24 hours despite the PDE inhibition. Possible explanations are that cAMP 
is hydrolysed by PDE families which are insensitive to IBMX or rolipram like PDE8 or PDE7. 
Moreover, the binding affinity of the catalytic site of PDE4 for rolipram depends on conformational 
changes of the enzyme (Omori and Kotera, 2007). Another explanation is that in vivo, cAMP is indeed 
exported to the extracellular space. Additionally, compartmentalised cAMP signalling might play a 
role for the regulation of PGC-1α expression and thus global intracellular changes of cAMP 
concentration would not affect the regulation of PGC-1α expression or the activation of other cAMP 
effector proteins like Epacs (Houslay, 2010). Last, the expression profiles of PDEs are not identical in 
mice and humans, thus it is worth studying the effect of PDE inhibition in human skeletal muscle cells 
(Bingham et al., 2006; Omori and Kotera, 2007).  
An identification of a PDE which regulates PGC-1α expression might represent a first step towards the 
development of a drug for the treatment of many medical conditions for which PGC-1α expression 
shows therapeutic effects. PDEs are important drug targets for the treatment of numerous diseases like 
asthma, depression or erectile dysfunction, thus many specific PDE inhibitors have already been 
developed (Omori and Kotera, 2007). Interestingly, in our study clenbuterol treatment suppressed 
PGC-1α and PGC-1β expression in kidney (Fig. 4C). The role of these coactivators in this tissue is not 
yet known but PDE inhibitors or agonists might be used to study it. PGC-1α is expressed in kidney 
and if PGC-1α and PGC-1β turn out to regulate important processes in this organ, PDEs might also 






Cell culture and treatments 
C2C12 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% 
fetal bovine serum (FBS), 100 Units/ml penicillin and 100ug/ml streptomycin. To obtain myotubes, 
the C2C12 myoblasts were allowed to reach 90% confluence and the medium was changed to DMEM 
supplemented with 2% horse serum (differentiation medium) for 72 hours. 8cpt-2Me-cAMP was 
purchased from Tocris bioscience. All drugs other drugs were purchased from Sigma Aldrich. The 
drugs were dissolved in DMSO and used in following concentrations: IBMX (3-Isobutyl-1-
methylxanthin) 100µM, forskolin 100µM, vinpocetine 140µM, EHNA hydrochloride 20µM, 
cilostamide 5µM, rolipram 20µM, zaprinast 10µM, BRL 50481 5µM, BAY 73-6691 5µM, 8CPT-
2Me-cAMP 22µM, probenecid 100µM. These concentrations correspond to approximately 10-20 fold 
IC50 (EC50 for 8CPT-2Me-cAMP and forskolin) concentrations. 
Primary skeletal muscle cells were isolated from 6 weeks old wild-type C57BL/6J mice as described 
previously (Megeney et al., 1996). The myoblasts were grown in Ham’s/F-10 medium supplemented 
with 20% FBS (Hyclone, heat inactivated at 56 degrees for 30 min), 1x Pen/Strep, 2.5 ng/mL bFGF 
(Invitrogen). For differentiation the cells were shifted to DMEM with 5% horse serum for 72 hours. 
 
Real-time PCR and target gene validation 
The sequences of the primers used in real-time PCR experiments are depicted Table 1 below. The 
values are presented as the mean +/- SEM. Student’s t test was performed and a p-value < 0.05 was 
considered as significant. (*p<0.05, **p<0.01, ***p<0.001).  
   Real-time PCR primers used  
gene forward primer reverse primer 
Rn18s AGTCCCTGCCCTTTGTACACA CGATCCGAGGGCCTCACTA 
Tbp GGCCTCTCAGAAGCATCACTA GCCAAGCCCTGAGCATAA 
Ppargc1a exon2 TGGGCACATCACCACTACAC TCTGGCTATGCAGTTCAGCC 
Ppargc1a altern. exon1 TCTGCGCTGGAGTCAGTTAC CCGCCTCCTTTTCCTCTCAT 
Ppargc1b TTCGAAGGCTTTGCAAGGAAG TTCGGGGTCCTCACTGGTTT 
Acadm AGTGGATCCGCCAGCTACTC ATGGGAATGTCTCTGCCAAA 
   Table 1. Real-time primer sequences.  
 
Experimental animals and drug administration 
Clenbuterol, rolipram and forskolin treatment: 
Following drugs were dissolved in PBS and administered by intraperitoneal injections to 10 weeks old 
wild-type C57BL/6J mice: PBS as vehicle, clenbuterol 1mg/kg b.w., rolipram 5mg/kg b.w., a 
combination of clenbuterol and rolipram 1mg/kg and 5mg/kg b.w. respectively and forskolin 0.7mg/kg 
b.w. All mice were sacrificed 6h after drug administration. Gastrocnemius, tibialis anterior and 
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quadriceps muscles were collected and RNA and protein were isolated. RNA was reverse transcribed 
and transcript levels were measured by real-time PCR. Protein levels of PGC-1α and α-tubulin were 
measured by immunoblotting using following antibodies: anti-PGC-1 from Millipore (Chemicon) and 
anti-α-tubulin (11H10) from Cell Signaling. 
Clenbuterol, vinpocetine and aminophylline treatment: 
Following drugs were dissolved in DMSO and administered by intraperitoneal injections to 11 weeks 
old wild-type C57BL/6J mice: DMSO as vehicle, clenbuterol 1mg/kg b.w., vinpocetine 10mg/kg b.w., 
a combination of clenbuterol and vinpocetine 1mg/kg and 10mg/kg b.w. respectively and 
aminophylline hydrate 20mg/kg. First group of mice was sacrificed 6h and a second group 24hafter 
drug administration. Tibialis anterior muscle, liver, kidney and visceral fat were collected and frozen. 
RNA and protein were isolated and the RNA was reversed transcribed and used for quantification by 
real-time PCR. Protein levels of PGC-1α and α-tubulin were measured by immunoblotting using 
following antibodies: anti-PGC-1α mouse (4C1.3) from Millipore (Calbiochem) and anti-α-tubulin 
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5 FINAL DISCUSSION 
5.1 Summary of major findings 
-Identification of all interactions of PGC-1α with the genome and how it regulates gene expression: 
The data sets, which are generated in this thesis, represent a collection of all interactions of PGC-1α or 
ERRα with the genome in cultured skeletal muscle cells. The peaks were assigned to adjacent genes to 
understand why PGC-1α is recruited to these locations in the genome and how it regulates gene 
expression.  The data from expression arrays was included in the analysis and revealed that the genes 
involved in cellular respiration, electron transport chain or metabolic pathways in general were up-
regulated, which was also expected (Manuscript 1, Figure 1) (Handschin and Spiegelman, 2006; 
Mootha et al., 2004). While it was known that PGC-1α regulates metabolic gene expression, the 
precise mechanism underlying this regulation was not known. Published papers on PGC-1α induction 
of gene expression mostly focused on direct regulation of gene expression, where PGC-1α binds a 
transcription factor in the promoter of the induced gene (Michael et al., 2001; Mootha et al., 2004; 
Puigserver et al., 2003; Puigserver et al., 1998). Surprisingly, the induction of gene expression by 
PGC-1α was not only directly by binding to transcription factors in promoters, but also indirectly, 
without the need for PGC-1α to be present at the promoters of some induced genes.  (Manuscript 1, 
Figure 1). Actually, almost two thirds of all up-regulated genes were indirectly induced by PGC-1α. 
Therefore PGC-1α induces gene expression by both direct and indirect regulation of gene expression. 
The expression of inflammatory genes was repressed by PGC-1α (Manuscript 1, Figure 1). This was to 
some extent expected because previous work suggested a role for PGC-1α in regulating inflammatory 
genes. This is also confirmed by work of colleagues from our lab (Eisele et al., 2013; Handschin and 
Spiegelman, 2008). This suppression was almost exclusively indirectly because it did not require the 
recruitment of PGC-1α to the promoters of suppressed genes. This indicates that PGC-1α does not act 
as a corepressor in skeletal muscle cells. How this suppression is accomplished is not clear yet, but it 
might be by inducing transcription factors involved in immunosuppression. Alternatively, it might by 
attenuating the activity of pro-inflammatory transcription factors like NF-κB as suggested by our 
MARA results. 
-ERRα, as the major transcriptional binding partner for PGC-1α, can regulate gene expression in 
presence or absence of PGC-1α 
De novo motif search and the comparison of DNA sequences in peaks to known transcription factor 
motifs identified ERRα as the major transcriptional partner and mediator of PGC-1α induced 
regulation of gene expression (Manuscript 1, Figure 3). Unexpectedly, the evaluation of the ERRα 
ChIP-Sequencing data demonstrated that ERRα can be transcriptionally active and regulate gene 
expression with and without PGC-1α. Why PGC-1α coactivates ERRα at some targets, but not at 
others is not clear. However, it might explain how PGC-1α indirectly regulates gene expression, 
because PGC-1α also induces the expression of ERRα (Mootha et al., 2004). Moreover, the abundance 
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of the motif for the transcription factor specificity protein 1 (Sp1) is very high in ERRα peaks, 
especially in a subset of ERRα peaks. This subset is represented by peaks which are adjacent to ERRα 
target genes, which do not require direct coactivation by PGC-1α for the induction of their expression. 
This raises the possibility that SP-1 and ERRα might cooperatively regulate the expression of some 
ERRα target genes. 
Several other transcription factors cooperate with PGC-1α in skeletal muscle cells: 
In addition to ERRα, PGC-1α seems to regulate many other transcription factors, as revealed by the 
principal component analysis (PCA) and motif search in DNA fragments, which are derived from peak 
sequences (Manuscript 1, Figure 3). By combining motifs, which are found in peak sequences, with 
expression array data, we predicted which subset of PGC-1α target genes is regulated by a particular 
transcription factor. The knockdown of the predicted transcription factors Fos, Jun, Atf3, Gtf2i, 
Zfp143 and Nfe2l2 but not Nfyc led to a diminished or absent induction of many of their predicted 
target genes (Manuscript 1, Figure 4). This strongly indicates that these predicted transcription factors 
indeed cooperate with PGC-1α in skeletal muscle cells and regulate gene expression. It is likely that 
other transcription factors, which were predicted by the motif search, also are transcriptional partners 
for PGC-1α.  
PGC-1α regulates the response to hypoxia possibly by coactivating the AP-1 transcription factor 
complex:   
The transcription factors Fos, Jun and Atf3, which in our experiments have been found to be involved 
in the expression of a subset of PGC-1α target genes, are all subunits of the activator protein 1 (AP-1) 
transcription factor complex (Shaulian, 2010; Shaulian and Karin, 2002; Vesely et al., 2009). The gene 
ontology analysis of directly regulated PGC-1α target genes with AP-1 motif in the peak revealed that 
these genes are involved in the regulation of the cellular response to hypoxia and the mTOR signaling 
pathway (Manuscript1, Figure 5). PGC-1α was previously found to be inducible by hypoxia and 
subsequently coactivate ERRα to regulate the expression of VEGF and angiogenesis (Arany et al., 
2008). Our results propose a possible coactivation of the AP-1 complex by PGC-1α to control the 
expression of other hypoxia induced genes.  
PDE1 and PDE4 inhibition does not lead to increased PGC-1α mRNA levels in skeletal muscle:  
Because the activation of PKA by forskolin or inhibition of PDE1 or PDE4 by specific PDE inhibitors 
increased PGC-1α mRNA levels in cultured skeletal muscle cells, we assumed that modulating cAMP 
levels by PDE inhibition might have a similar effect in vivo (Manuscript 3). The activation of β2-AR 
signaling transiently increased the PGC-1α mRNA levels in murine skeletal muscles. However, neither 
the inhibition of PDE1 by vinpocetine nor PDE4 by rolipram had any effect on PGC-1α expression.  
These PDE inhibitors neither induced the expression of PGC-1α when administered alone, nor did 
they prolong the transient induction of PGC-1α when administered together with the β2-AR signaling 
activator clenbuterol. These findings can be interpreted as evidence that PDE1 and PDE4 are not 
regulating PGC-1α expression in muscle in vivo, but cannot exclude the involvement of cAMP and 
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other PDEs in the regulation of PDE expression. Members of the PDE7 or PDE11 family are highly 
expressed in skeletal muscle and hydrolyze cAMP (Bender and Beavo, 2006; Omori and Kotera, 
2007). Similarly, members of cAMP hydrolyzing PDE families PDE2, PDE3, PDE8 and PDE10 do 
not show high expression in skeletal muscle but might still be involved in regulation of PGC-1α 
expression due to the possibility of compartmentalized signaling (Francis et al., 2011). Therefore, 
because cAMP signaling induces PGC-1α expression in different tissues including skeletal muscle, we 
can assume that PDE inhibition would delay the degradation of the second messenger and thus shape 
PGC-1α expression (General Introduction, Chapters 1.3 and 1.4). However, whether this is true and 
which PDE family would be in this case responsible for the hydrolysis of cAMP to lower its levels 
subsequent to an induction, still needs to be identified. Last, a difference in the species specific PDE 





The data obtained from our ChIP-Seq experiments can be considered as a snapshot of all interactions 
of PGC-1α with the genome in a typical skeletal muscle cell. The peaks represent the localization of 
all PGC-1α recruitments to chromatin across the entire genome. In general, the binding of a 
transcription factor to DNA should not be considered as a binary event, where only the state „bound“ 
and „not bound“ can occur. The nature of transcription factor binding is rather equilibrium of binding 
and dissociation from DNA and the signal strength represents the strength of interaction with the 
genome at a particular location (Furey, 2012). In theory, a strong signal can arise from a strong 
interaction in a small number of cells or a weaker interaction but in a larger share of cells. The 
chromatin from many millions of cells, typically 1x108 cells for each immunoprecipitation, is used as 
starting material. Therefore, ChIP-Seq data does not only consist of sharp peaks and background 
noise, but also of binding events, which are more of continuous nature. This poses a difficulty at 
setting a cut-off for the peak-calling. Also, the number of peaks increases with the sequencing depth, 
meaning that the more reads we obtain from sequencing experiments, the more peaks will be identified 
in the data set (Park, 2009). This should be considered when interpreting the number of peaks in our 
data sets. 
There is no standard procedure to study such big data sets. Once the reads are mapped and the peak 
calling is done, there are different ways to continue with the downstream analysis. Researchers can 
focus on individual genes in these data sets and study the role of PGC-1α in the regulation of these 
particular genes. Alternatively, they can use different informatics tools to analyze all binding events 
together. Because the aim of this thesis was to study the regulation of gene expression by PGC-1α 
globally, we applied the latter approach to be able to draw general conclusions on PGC-1α 
transcriptional activity. This is now the first time that the recruitment of PGC-1α to DNA was studied 
in skeletal muscle cells on a genome-wide scale.  
The genomic location of PGC-1α peaks alone does not tell much about how PGC-1α acts to control 
transcription. The PGC-1α peaks were assigned to genes in their proximity and the expression of these 
genes was measured by expression arrays. This allowed us to investigate to which genes or gene 
regulatory sequences PGC-1α tends to be recruited to and if this recruitment is functional, in terms of 
gene expression changes. The finding that 14% of all peaks are upstream of promoters combined with 
the fact that the peaks are symmetrically distributed around the promoter leads to the conclusion that 
around 28% of all peaks are around the transcription start site (TSS) (Manuscript 1, Figure 1). This 
clearly reflects the direct participation of PGC-1α in gene transcription. This is in agreement with the 
finding from Charos and colleagues, who reported that around 38% of PGC-1α peaks are found around 
the TSS in HepG2 cells (Charos et al., 2012). This value is higher than the one which is observed in 
our experiments.  However, this higher value is observed when 1886 PGC-1α peaks (FDR=1%) were 
considered for the analysis. It can be expected that this value would drop if the 9366 PGC-1α peaks 
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(FDR=5%) were taken into calculation. Also, the mode of action of PGC-1α in hepatic cells might be 
different than the one observed in skeletal muscle cells.  
Intriguingly, almost half of the PGC-1α peaks in our experiment are located in intergenic regions, 
which is unexpected, considering that PGC-1α is a transcriptional coactivator (Manuscript 1, Figure 
1). It is very well possible that PGC-1α interacts with enhancers or other remote regulatory sequences 
which can be located 50kb or more away from the TSS. However, this probably is not the only reason 
and does not account for all intergenic peaks. Some peaks might be located on genes but still 
considered as peaks in intergenic regions due to the assignment of peaks to genes. Peaks which are 
more than 10 kilobases (kb) away from a TSS are considered as peaks in intergenic regions. This cut-
off was set to avoid a false assignment of a peak to distant genes. However, eukaryotic genes harbor 
introns and a typical gene like Ppargc1a itself spans over 100kb. The mouse dystrophin gene Dmd 
covers more than 2’200 kb (2,2 megabases)! Therefore, it is very likely that many peaks in our 
experiments are located on genes but are considered as lying in intergenic regions. However, this is 
inevitable in our gene assignment. There are no 100% error-free methods to assign genes to peaks, and 
every method is a trade-off between reducing the assignment to false genes and introducing such 
artifacts. Nevertheless, it is possible that PGC-1α actually binds to distant genomic locations. In this 
case, the purpose of these interaction events cannot be explained yet. 
While it was expected to find that PGC-1α induces the expression of genes which are involved in 
metabolism, it was not known how the expression of these genes is precisely regulated (Manuscript 1, 
Figure 1) (Mootha et al., 2004). So far, published work on PGC-1α induced gene expression mostly 
describes a direct mode of regulation, where PGC-1α binds a transcription factor in the promoter of 
the induced gene (Michael et al., 2001; Mootha et al., 2004; Puigserver et al., 2003; Puigserver et al., 
1998). It was not known if this is the major way how PGC-1α induces gene expression. We were 
surprised to find that in addition to directly inducing gene expression, PGC-1α induced two thirds of 
its target genes indirectly, without being present at the promoters of these target genes. Therefore, we 
can assume that PGC-1α does not coactivate the transcription factors which transcribe these indirectly 
regulated PGC-1α target genes. However, it is possible that PGC-1α induces the expression of 
transcription factors, which than in turn transcribe genes in absence of PGC-1α.  
In contrast, almost all down-regulated genes are suppressed in an indirect manner, without the need for 
PGC-1α to be present at the transcription site. The promoters of only 36 out of 727 suppressed genes 
are occupied by PGC-1α. This is less than 5% of all down-regulated genes. This strongly indicates that 
PGC-1α primarily acts as a coactivator and does not directly corepress transcription in skeletal muscle 
cells. Consequently, the suppression of inflammatory genes by PGC-1α appears to be indirect 
(Manuscript 1, Figure 1). Therefore, it is likely that PGC-1α induces the expression of a transcription 
regulator which suppresses the expression of inflammatory or immune response genes. Alternatively, 
it is possible that the direct suppression of target genes by PGC-1α occurs immediately after PGC-1α 
itself is induced. In that case, PGC-1α would be recruited to DNA to suppress gene expression and 
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then quickly dissociate from the DNA. Because our ChIP experiment is performed 48h after C2C12 
cells were treated with PGC-1α coding adenovirus, this early association of PGC-1α with DNA cannot 
be detected. With the present data, we cannot provide an answer if the latter mode of gene suppression 
by PGC-1α is true or not, but it is not very likely. 
Together these findings identify PGC-1α as a coregulator, which operates in a direct and indirect way 
to induce the expression of mainly metabolic genes. The suppression of genes involved in immune 
response and apoptosis by PGC-1α appears to be almost exclusively indirect. In contrast to our mode 
of PGC-1α mediated regulation of gene expression, Charos and colleagues observed that PGC-1α and 
its transcriptional partners associated with both up-regulated and down-regulated genes in hepatic cells 
(Charos et al., 2012). Moreover, they report that the association of PGC-1α and ERRα is even higher 
with down-regulated genes (Figure 6).  
This would suggest that PGC-1α and the transcription factors which are bound to it directly repress 
gene expression. It cannot be excluded that the mode of action of PGC-1α differs between skeletal 
muscle and liver cells, but it still would be surprising to identify ERRα and HNF4α as a strong 
repressors of gene expression. 
 
 
Figure 1. Correlation of transcription regulator binding and gene expression in HepG2 cells 
following forskolin treatment. Figure taken from (Charos et al., 2012). 
 
As described in the introduction to this thesis, PGC-1α does not directly bind DNA but rather acts as a 
master regulator by coordinating the activity of numerous transcription factors. Therefore, we 
expected to find more than one transcription factor to interact with PGC-1α. Nevertheless, it was still 
surprising to find that more than 139 transcription factor motifs were overrepresented in PGC-1α 
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peaks (139 Motifs with a Z-score≥2.0). It is not very likely that all these transcription factors really are 
coactivated by PGC-1α. Some of the transcription factors from these motifs are not even expressed in 
our skeletal muscle cells. Therefore, several constraints have been used to exclude such transcription 
factors and obtain a list of likely transcriptional partners for PGC-1α (Manuscript 1, Figure 3).  The 
resulting list contained 15 motifs and some of the transcription factors from these motifs were knocked 
down to validate their involvement in the regulation of PGC-1α target genes (Manuscript 1, Figures 4 
and 5). This predicts that in skeletal muscle cells, PGC-1α might be regulating the activity of many 
transcription factors. Moreover, considering that the performed motif search did not contain motifs for 
all transcription factors which can be found in the mouse genome, this list might even be longer. The 
human genome encodes around 2000 transcription factors and a similar number of transcription 
factors can be expected in the mouse genome (Lodish et al., 2012; Vaquerizas et al., 2009). Therefore, 
such a prediction, based on motif search also has its limitations, especially if we consider that some 
transcription factors bind to similar consensus motifs. This can theoretically lead to detection of false 
negatives and false positives. Motifs for transcription factors which are not coactivated by PGC-1α but 
recognize a similar motif like one of true PGC-1α partners might be overrepresented in the motif 
search. These motifs would score high only because their similarity to a real binding partner for PGC-
1α. This might be the case for the many members of the nuclear receptors superfamily, which due to 
their evolutionary conserved structure often bind to similar consensus sites (Mangelsdorf et al., 1995). 
On the other hand, the fact that some transcription factors recognize similar DNA sequences also 
could lead to detection of false negatives. The orphan nuclear receptors estrogen-related receptor β and 
γ (ERRβ and ERRγ) both recognize similar DNA elements like ERRα and eventually might regulate 
gene transcription together with PGC-1α in our experiments (Tremblay and Giguere, 2007). However, 
these transcription factors cannot be identified as binding partners for PGC-1α by the motif search 
alone, because they recognize same DNA elements.  
Because of these limitations of the motif search, there were uncertainties whether our predictions for 
putative transcription partners for PGC-1α are reliable or not. ERRα was already previously described 
as an important binding partner for PGC-1α and all our results indicated that ERRα is the major 
effector of PGC-1α mediated regulation of gene expression (Mootha et al., 2004; Schreiber et al., 
2004). The results from motif activity response analysis (MARA), principal component analysis 
(PCA) and MotEvo all identified ERRα as the top scoring transcription factor motif. Many of the 
remaining predicted transcription factors have never been shown to cooperatively regulate gene 
expression with PGC-1α. In order to have a biological validation of our predictions, we knocked down 
seven of the predicted transcription factors while overexpressing PGC-1α, namely Fos, Jun, Atf3, 
Gtf2i, Nfe2l2, Nfyc and Zfp143. If these transcription factors really regulate the expression of PGC-1α 
target genes, we should observe a decreased induction of the PGC-1α target genes, which have a PGC-
1α peak with the motif for the corresponding transcription factor in their promoter. The finding that 
the knockdown of all these transcription factors, except for Nfyc, reduced the induction of these 
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predicted target genes, confirmed that our predictions indeed seem to be true (Manuscript 1, Figure 4). 
However, to prove that these transcription factors really are coactivated by PGC-1α, we would need to 
show their physical interaction with PGC-1α, possibly by performing co-immunoprecipitation 
experiments.  
Similarly, the knockdown of ERRα in the presence of the inverse agonist XCT790 confirmed that 
ERRα is a transcription factor which mediates induction of gene expression by PGC-1α. Similarly, the 
ChIP-Sequencing of ERRα showed that ERRα and PGC-1α often colocalized in the promoters of their 
common target genes. The surprising observation that PGC-1α does not coactivate ERRα on all of its 
target genes provides an explanation how PGC-1α might indirectly regulate gene expression. PGC-1α 
induces the expression of ERRα itself, whereupon ERRα induces the expression of its target genes in 
the presence and in absence of PGC-1α. The MARA results from PGC-1α ChIP-Seq experiments 
already suggested such a mode of gene expression regulation by PGC-1α and ERRα, because ERRα 
activity was equally active in the promoters of primary and secondary genes (Manuscript 1, Figure 2). 
Previous work on cooperative regulation of gene expression by ERRα and PGC-1α often identified 
ERRα as an effector of PGC-1α but it was not revealed if ERRα also induced PGC-1α target genes 
without being coactivated by PGC-1α. We do not know why ERRα is not coactivated by PGC-1α on 
all of its target genes. The observation that the motif for the transcription factor specificity protein 1 
(Sp1) is found more frequently in the ERRα peaks if they do not co-occur with PGC-1α tempts us to 
speculate. It can be carefully speculated that Sp1 might interact with ERRα, possibly forming a 
heterodimer and making PGC-1α dispensable for ERRα. This putative interaction however requires 
further investigation. It is important to note that PGC-1α can induce transcription factors which can 
also be active without being coactivated by PGC-1α. Therefore, it is very likely that this is not only 
true for ERRα. Furthermore, it is theoretically possible that PGC-1α induces the expression of some 
transcription factors but does not coactivate them at all. This would explain how PGC-1α indirectly 
regulates gene expression. Interestingly, when the ERRα ChIP-Seq data was explored by PCA to 
analyze the variance in the data the motif for Sp1 was identified in one component. The other 
component contained the motifs for ERRα and other nuclear receptors (Manuscript 2, Figure3). This 
again indicates that Sp1 might in a yet unknown way be involved in the regulation of gene expression 
by ERRα.  
While the role for ERRα as an important mediator of PGC-1α mediated induction of metabolic genes 
is well established, it is not known which biological programs are regulated by PGC-1α and its 
predicted transcriptional binding partners. We have a biological validation that Fos, Jun, Atf3, Gtf2i, 
Nfe2l2 and Zfp143 are required for the induction of a subset of PGC-1α target genes. We also have 
found that Fos, Jun and Atf3, which are all possible components of the Activator protein 1 (AP-1) 
transcription complex, together with PGC-1α directly regulate the expression of 47 PGC-1α target 
genes (Manuscript 1, Figure 5) (Vesely et al., 2009). These genes are involved in response to hypoxia 
and mTOR (mammalian target of rapamycin) signaling pathways (Manuscript 1, Figure 5). Whether 
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this is true in skeletal muscle needs to be shown through in vivo experiments. However, it needs to be 
considered that AP-1 was shown to be involved in many biological processes like apoptosis, 
differentiation or growth (Vesely et al., 2009). In fact, Jun and Fos belong to the top 5 most cited 
transcription factors at all (Vaquerizas et al., 2009). AP-1 can be composed of different subunits and 
therefore either favor or suppress a biological process depending of which subunits AP-1 is composed. 
AP-1 has been found to have pro-apoptotic functions, but differently composed AP-1 can regulate cell 
survival (Hess et al., 2004). Interestingly, AP-1 has been described as a sensor of environmental 
processes, which subsequent to sensing induces changes in gene transcription. In the introduction of 
this thesis, this feature was attributed to PGC-1α (Wagner, 2001). Moreover, AP-1 can be induced by 
oxidative stress, and an overexpression of PGC-1α in muscle cells in our experiments clearly 
represents such a situation (Reuter et al., 2010). The fact that AP-1 can be regulated by cytokines 
raises the question whether in our PGC-1α ChIP-Seq experiments AP-1 suppresses the expression of 
immune response genes which is observed following PGC-1α overexpression (Manuskript1 Figure1) 
(Hess et al., 2004). Therefore, considering the current knowledge about AP-1, the possibility that AP-1 
and PGC-1α cooperatively regulate gene expression is legitimate and not against all expectations. 
However, the complex biology of AP-1 calls for a profound investigation of the two transcription 
regulators.  
Another protein which is regulated by oxidative stress is Nfe2l2, which was also found to regulate the 
expression of a subset of PGC-1α target genes in our experiments (Manuscript 1, Figure 4) (Reuter et 
al., 2010). Nfe2l2 is the key regulator of antioxidant genes and under normal circumstances, Nfe2l2 is 
bound by Keap1 which targets the protein for degradation (Kensler et al., 2007; Stepkowski and 
Kruszewski, 2011). Following oxidative stress, Keap1 is dissociated from Nfe2l2 rendering a 
transcriptionally active protein, which translocates to the nucleus and binds to DNA sequences called 
antioxidant response elements (AREs) in the promoters of antioxidant response genes to induce their 
expression (Stepkowski and Kruszewski, 2011). Therefore, the Nfe2l2 mRNA does not necessarily 
need to be induced in oxidative stress situations. In our PGC-1α ChIP-Seq experiments, the expression 
of Nfe2l2 is not induced, but this does not mean that Nfe2l2 is not active in cells overexpressing PGC-
1α. Unfortunately, Nfe2l2 is also known as Nrf2 and therefore can be mistaken for Nuclear respiratory 
factor 2 (Nrf2 also known as GABPA-GA binding protein transcription factor alpha). The confusion is 
even greater because GABPA is coactivated by PGC-1α and for Nfe2l2 it has been speculated that it 
might form a regulatory loop with PGC-1α because the PGC-1α promoter contains ARE sequences 
(Baldelli et al., 2013). Because Nfe2l2 regulates antioxidant response and PGC-1α has been found to 
help the cell to deal with reactive oxygen species, it seems likely that PGC-1α indeed coactivates 
Nfe2l2 (St-Pierre et al., 2006).  
Interestingly, AP-1 has been reported to control the response to oxidative stress through Nfe2l2 
thereby connecting the two pathways to regulate oxidative stress response (Vaz et al., 2012). Indeed 
both Nfe2l2 and AP-1 regulate the expression of sulfiredoxin, an important antioxidant enzyme 
127 
Final Discussion 
(Soriano et al., 2009). Sulfiredoxin is required in oxidative stress when other antioxidant enzymes 
(peroxiredoxins) become hyperoxidated and inactive. Sulfiredoxin reverses this hyperoxidation and 
thus reactivates the peroxiredoxins (Soriano et al., 2009). It is peculiar that even though the expression 
of sulfiredoxin 1 (Srxn1) is induced by PGC-1α overexpression in our ChIP-Seq experiments, neither 
the knockdown of Nfe2l2 nor of the AP-1 components (Fos, Jun and Atf3) reduced the induction of 
Srxn1 by PGC-1α (Manuscript 1, Figure 4). The significance of the possible coactivation of Zfp143 
and Gtf2i still needs to be further investigated.  
Because the knockdown of Nfyc did not reduce the induction of the predicted PGC-1α target genes, 
one could argue that Nfyc is not coactivated by PGC-1α and that this prediction was wrong. However, 
this is not necessarily true. The Nfyc gene codes for the NF-YC subunit of the trimeric transcriptional 
complex NF-Y, which consists of the three subunits NF-YA, NF-YB and NF-YC (Dolfini et al., 
2012). For the biological validation of our predictions in ChIP-Seq experiments, we have chosen to 
knock down Nfyc because the expression of this gene is strongly induced by PGC-1α. If the 
intracellular concentration of Nfyc is much higher than the concentration of Nfya or Nfyb, then the 
knockdown of Nfyc does not necessarily have to reduce the transcription of the entire NF-Y complex. 
A recent study investigated the binding of NF-Y to DNA in different cell lines and surprisingly found 
that around half of the NF-Y binding events were in DNA repeat regions (Fleming et al., 2013). 
Unlike common transcription factors, NF-Y was apparently able to bind to inactive or polycomb-
repressed chromatin (Fleming et al., 2013). Because around half of PGC-1α peaks in our experiments 
is located in intergenic regions, it is possible that NF-Y recruits PGC-1α to these sites (Manuscript 1, 
Figure 1). To test this hypothesis, we would need to perform additional experiments. This could 
possibly be tested by combining ChIP with knockdown of Nfyc and followed by real-time PCR 
amplification of selected intergenic regions. Nevertheless, even if we assume that Nfyc was wrongly 
predicted as a mediator of PGC-1α gene expression regulation, it would be only one false positive 
prediction out of seven. Therefore, we can rely on our predictions and assume that for the most part 





We have extensively studied how PGC-1α controls gene expression on a genome-wide scale and 
identified a set of transcription factors which are its potential binding partners and together with PGC-
1α comprise a complex transcriptional network. However, the experiments were performed in cultured 
muscle cells, which have a low basal PGC-1α expression level. To have robust PGC-1α levels, we had 
to introduce tagged PGC-1α artificially by using adenoviral vectors. This was necessary because 
successful ChIP-Seq studies require well detectable levels of the protein of interest, many cells as 
starting material and a ChIP-grade antibody with as little as possible unspecific binding. If these 
requirements are not met, it gets even harder to distinguish the signal from noise or real binding events 
from unspecific binding. While the ChIP-Seq approach with cultured cells certainly has its advantages, 
it also clearly has some drawbacks. Biological processes like fiber type switch, angiogenesis, the 
development of neuromuscular junctions or generally adaptations to exercise, which are controlled by 
PGC-1α in a living muscle, cannot be studied in culture (Handschin, 2010). In vivo studies could not 
be performed because of the lack of good, ChIP-grade PGC-1α antibodies. Such studies would allow 
investigating the activity of PGC-1α before, during and after exercise, in different models of 
dystrophies, atrophies and other muscle disorders. Of course, in vivo studies would also facilitate it to 
study the role of skeletal muscle PGC-1α in systemic disorders like type II diabetes where the muscle, 
liver, pancreas, fat and other tissues interact. In addition, by precipitating endogenous PGC-1α it 
would be possible to study the protein at physiological levels and to include the different splice variant 
of PGC-1α in the study. Therefore, one of the next steps should be to perform ChIP-Seq studies of 
PGC-1α in a living muscle. Because obtaining a very good antibody is not a simple task, it should be 
considered to tag endogenous PGC-1α. For this purpose, one could decide to use a knock-in method 
like for example the endogenous tagging method described by Zhang and colleagues, which uses 
adeno-associated viruses to efficiently introduce the recombinant DNA into cells (Zhang et al., 2008).  
Now that the PGC-1α ChIP-Seq is established, different posttranslational modifications of the PGC-1α 
protein might be introduced. This would allow detecting changes in PGC-1α recruitment to chromatin 
before and after the posttranslational modification was introduced. By analyzing the transcription 
factor motifs in the PGC-1α peaks it could be discovered which set of transcription factors is 
coactivated by PGC-1α after each posttranslational modification. If a gene ontology analysis is applied 
to genes adjacent to peaks, it would be possible to detect which biological pathways are regulated by 
PGC-1α following each posttranslational modification. In addition, the genome-wide occupation 
studies could be performed when PGC-1α is in presence of the inhibitory proteins p160MBP and 
RIP140. Thereby it would be possible to detect to which extent the function of PGC-1α as a 
coactivator is attenuated. Does PGC-1α become completely inactive when the inhibitory proteins are 
expressed or does it still coactivate a subset of its transcriptional partners?  
With the PGC-1α and ERRα ChIP-Seq experiments we have generated large amounts of data. 
Although we have run different tools to analyze the data, the analysis is not complete. Not all 
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information has been extracted from this data at is very likely the future approaches and new tools will 
extract more information from this data and new knowledge about PGC-1α will be won. In future, the 
genomic annotations and gene ontology databases will be further updated, thereby allowing 
identification of new biological pathways which are not detectable now. Conversely, researchers could 
try to work in the opposite direction and create their own gene ontology groups. In other words, to 
search PGC-1α regulated genes and select these genes which carry out some known PGC-1α 
biological functions. For example, to extract PGC-1α regulated genes which are involved in ROS 
defense and search the adjacent peaks to identify which transcription might be involved in the PGC-
1α-mediated regulation of ROS defense. Do these peaks harbor antioxidant response elements and if 
so, is the expression of the adjacent genes regulated by Nf2l2 or AP-1? PGC-1α has already previously 
been discussed as an inducer of hypoxia genes like VEGF in a pathway which did not involve the 
hypoxia inducible factor (HIF) (Arany et al., 2008). Does this regulation mainly depend on the 
transcriptional activity of the PGC-1α/ERRα tandem or are possibly other transcription factors 
involved (Shoag and Arany, 2010)?  
Of course, it will be even more important to test the predictions that are made in this thesis for their 
biological significance. For example, do PGC-1α and AP-1 regulate response to hypoxia and mTOR 
signaling pathway, like it is predicted from our cell culture experiments (Manuscript 1, Figure 5)?  
Similarly, it would be interesting to know how PGC-1α suppresses gene expression. It is evident, that 
this suppression is almost exclusively indirect, and therefore does not require that PGC-1α is 
physically present at the site of transcription (Manuscript 1, Figure 1). The suppressed genes include 
such genes which are involved in immune response and apoptosis (Manuscript 1, Figure 1). 
Interestingly, both Nfe2l2 and AP-1 have been shown to regulate cell survival following 
environmental stress situations (Hess et al., 2004; Kensler et al., 2007; Stepkowski and Kruszewski, 
2011). Are these transcription factors responsible for the PGC-1α-mediated suppression of genes 
involved in apoptosis? Alternatively, does the small heterodimer partner (SHP) suppress the 
expression of these genes? SHP is a nuclear receptor which lacks a DNA binding domain and is 
known to directly bind to other nuclear receptors and inhibit their activity (Zhang et al., 2011). 
Interestingly, Nr0b2, the gene which codes for SHP, is barely expressed in cultured skeletal muscle 
cells treated with the control adenovirus, and becomes the most strongly induced gene when the cells 
are treated with the PGC-1α adenovirus. Thus it is possible that SHP is responsible for the suppression 
of gene expression by PGC-1α. In addition, the role of SHP might be to serve as an inhibitor of PGC-
1α activity, thereby forming a negative feedback loop.   
Nfe2l2 has recently been found to be required for mitochondrial biogenesis and suppression of pro-
inflammatory genes in the lungs of mice, which are suffering from pneumonia (Athale et al., 2012). In 
the alveolar region of wild type mice the expression of mitochondrial biogenesis genes including 
PGC-1α was strongly induced by pneumonia. Interestingly, this induction was absent in Nfe2l2 knock-
out mice (Athale et al., 2012). Although these experiments have been performed in lung tissue, it still 
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shows two important functions of Nfe2l2. First, it is able to suppress pro-inflammatory genes and 
might also be mediate the suppression of immune response genes by PGC-1α. Second, in lung tissue 
Nfe2l2 seems to be upstream of PGC-1α and possibly regulate its expression. This could also be true 
in our experiments in skeletal muscle cells. Nfe2l2 is released from Keap1 in environmental stress 
conditions and therefore might be available even before the transcription of PGC-1α is up-regulated. 
Possibly, it could even activate the PGC-1α protein or induce its expression. In this case Nfe2l2 would 
not only be coactivated by PGC-1α but might also regulate the abundance of active PGC-1α in the 
cell.  
It is hard to explain why the half of all PGC-1α peaks is located in intergenic regions. One possible 
explanation is that is associated to enhancer regions, but it cannot be excluded that PGC-1α also has 
functions, which are beyond direct regulation of gene transcription. One possible way to investigate 
this would be to compare PGC-1α peaks to genome-wide histone modification studies or RNA 
polymerase II occupation. This might provide an explanation why PGC-1α occupies these distant 
locations. 
Last, once the in vivo ChIP-Seq is established, it would be interesting to investigate the regulation of 
transcription by PGC-1α on a genome-wide scale in other tissues like liver, brain, heart or kidney. We 
would thereby discover which functions of PGC-1α are ubiquitous and which are tissue-specific. 
Additionally, the roles of the two remaining members of the PGC-1 family, PGC-1β and PRC, could 
be studied by ChIP-Seq.  
In summary, this work has created large amounts of data and several predictions have been made. 
Therefore, these results can serve as a starting point for several projects in the future and will 
hopefully lead to the discovery not only of new facettes of regulation of transcription by PGC-1α but 
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